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Following homozygosity mapping and locus re-sequencing we show that homeodomain mutations 
in the evolutionary conserved transcription factor IRX5 cause Hamamy syndrome (HMMS); a 
recessive congenital disorder affecting face, eye, ear, brain, blood, heart, bone and germ cell 
development.  
We illustrate through in vivo modeling in Xenopus embryos that IRX5 modulates the migration of 
stem cell populations in branchial arches and gonads through the repression of Sdf1.  
Moreover, encompassing discrete clinical features with known human craniofacial syndromes, we 
demonstrate that IRX5 controls dorso-ventral eye patterning and midface expansion by direct 
activation of Bmp4 expression that antagonizes Shh signaling.  
Finally, we find that protein partners GATA3 and TRPS1 modulate IRX5 transcriptional activity 
of downstream genes which are essential for craniofacial development.  
A picture emerges whereby IRX proteins integrate combinatorial transcriptional inputs to regulate 
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Chapter 1 Introduction 
While the 20th century is marked by a decline in infant mortality from malnutrition and 
infectious diseases, mortality arising from birth defects is unchanged (Howson, 2000). Birth 
defects, defined as physical, mental, or biochemical abnormalities that are present at birth, are the 
leading cause of death for millions of infants and children each year. Worldwide, about 6% of all 
births are reported with major defects with the highest rate in middle- and low- income countries 
(March of Dimes, 2006). It is the leading cause of infant mortality in developed countries such as 
in Europe where 24 per 1000 births were recorded for the period of 2003-2007 (Dolk et al., 
2010). In 20% of the most severe cases, abnormal embryogenesis causes fetal deaths or stillbirths. 
For affected children who survive, structural and functional abnormalities cause lifelong mental 
and physical disabilities and considerable burden to families. Half of the structural defects are 
observed in limbs, such as digit deformities, in the heart, with missing or misshaped valves, and 
in the spinal cord resulting in malformations such as spina bifida. One third of all congenital 
syndromes affect craniofacial morphogenesis with clefting of lips or palate being the most 
common clinical manifestation (March of Dimes report, 2006). 
The origin of birth defects can be categorized into three main groups. Birth defects can be caused 
by in utero exposure to teratogenic agents, such as infectious diseases, toxins and drugs (10%). 
One example of drug-induced birth defect is Thalidomide, a medicine prescribed to pregnant 
mothers to ease their morning sickness, which resulted in children born with seal like limbs 
(Knobloch et al., 2007). Chromosomal abnormalities can also lead to congenital disorders, such 
as Down syndrome caused by chromosome 21 trisomy (6%). Finally, 8% of the defects at birth 
can be classified as monogenic, that is caused by a single gene defect, which is usually inherited 
(Christianson et al., 2008, The March of Dimes Global report on birth defects). Many examples 
of congenital malformations have been correlated with alteration of a single gene, as for instance 
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SHH which causes holoprosencephaly with cyclopia (Belloni et al., 1996). It is also accepted that 
multi-factorial influences such as genetic background combined with environmental factors can 
also compromise embryonic development. For instance, altered NOTCH signaling in combination 
with embryonic hypoxia has been shown to lead to congenital scoliosis (Sparrow et al., 2012). 
Even though a great number of disease-causing genes have been uncovered, the etiology of 50% 
of all birth defects remains unknown. Furthermore, unknown congenital disorders are regularly 
reported. Many of these may be caused by orphan autosomal recessive or dominant mutations in a 
single gene, or submicroscopic deletion or uniparental disomy. Studies have shown that in a 
population with a high rate of consanguinity, there is a significant increase in the prevalence of 
genetic congenital disorders like mental disorders, heart diseases and hearing deficit (Bener et al., 
2007; Hamamy et al., 2007a). Homozygosity mapping of rare recessive syndromes occurring in 
inbred families has proven to be a powerful tool to uncover new genes involved in human 
embryonic development (Lander and Botstein, 1987; Reversade et al., 2009; Tian et al., 2010). 
Consanguineous marriage is a common practice in 20% of the world’s population (Modell and 
Darr, 2002), and genetic analysis of affected inbred families from such populations is expected to 
reduce the number of rare Mendelian disorders with unknown etiology. The knowledge gained 
from these studies allows genetic counselling to be offered to affected families and permits the 
development of potential therapeutic drugs or procedures that may revert or alleviate the 
deleterious effects of mutations. 
In line with this approach, I undertook to solve a new recessive syndrome first reported in 2007 
by Prof. Hanan Hamamy (Hamamy et al., 2007b). This disorder, causing hereditary birth defects, 
was diagnosed in three patients born to double first cousin parents in Jordan. The three siblings, 
two boys and one girl, share an unusual array of phenotypes consisting of bone fragility, anemia, 
heart defects and a constellation of craniofacial dysmorphisms. The unusually marked 
hypertelorism/telecanthus, myopia, malformed ears and deafness combined with osteopenia 
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suggested that this syndrome was novel, distinct from other disorders such as frontonasal 
dysplasia, craniofrontonasal syndrome and Teebi syndrome which all display hyperteloric 
features (Grutzner and Gorlin, 1988; Sedano et al., 1970) but not bone fragility. 
The craniofacial defects characterized in this new syndrome suggest that the responsible gene 
may be required for proper development of cranial neural crest cells (NCCs) since these 
progenitor cells are known to drive the formation of almost all the cranial and facial structures 
(Trainor, 2005). NCCs also participate in the development of cardinal sensory axes present in the 
head including eyes, ears, nose and mouth, as well secondary organs such as dental, lacrimal, 
salivary and thyroid apparatus (Hall, 2008), tissues which are affected to varying degrees in this 
syndrome. Numerous studies showed that craniofacial malformations do arise through intrinsic 
NCC defects or primary defects in surrounding tissues with which the NCCs interact. Although 
molecular mechanisms have been elucidated, it is vital to investigate the genetic and 
embryological pathways that control patterning of NCC-derived structures to better understand 
the etiology of birth defects. Investigating the genetic defect leading to Hamamy syndrome 
(HMMS) should help to further understand craniofacial morphogenesis in humans and bring 
insights into the diversity of head patterning in the context of evolution. 
After a brief introduction on craniofacial morphogenesis, this chapter will provide an overview of 
the key molecules and known pathways that control and regulate the induction and migration of 
the cranial NCCs during normal face and brain development in animal models and humans. To 
end with, craniofacial dysmorphisms and other clinical manifestations of the Jordanian patients 




1. Craniofacial morphogenesis is driven by cranial Neural Crest Cells (NCCs) 
Craniofacial morphogenesis is driven by the precise interactions and orchestration of signaling 
molecules, responding cells and in the context of fast developing tissues. Multiple germ layers 
such as the surface ectoderm, pharyngeal mesoderm, neural crest cells and endoderm contribute 
to the formation of specialized tissues which give rise to the central and peripheral nervous 
system, the musculature, the skeleton and connective tissues of the face and head (Noden and 
Trainor, 2005). 
In humans, facial development occurs mainly between the 4th and 10th weeks of gestation 
(Hinrichsen, 1985). A month after fertilization, four main folding appear at the cephalic end of 
the embryo (Fig. 1a-c), these are: 
- the frontonasal prominence (FNP) which gives rise to the forehead, nose, nostrils, palate and 
philtrum. 
- the maxillary process of the first branchial arch (BA) which gives rise to the upper jaw and 
most of the upper lip. The nasolacrimal apparatus is formed when the FNP and maxillary 
process fuse. 
- the mandibular process of the first BA which gives rise to the lower jaw, chin, lower lip and 
part of the middle ear. Nodules present between the first and the second BAs form the 
external ears. 
- the other branchial arches (BA2, BA3 and BA4) which contribute to formation of structures 
in the lower part of the head, throat, neck and internal organs such as the thymus and thyroid 
glands. 
All these processes are populated by specialized cranial NCCs that are considered as the main 




Figure 1: Human face development from week 4 to week 10 
(a) Frontal view of the cephalic end of human embryo at four weeks of development. Frontonasal 
prominence, maxillary process and mandibular process are highlighted in red, yellow and blue respectively. 
Frontal plan (right panel) showing branchial arch (BA) structure. Each BA is composed of four germ 
layers: endoderm, mesoderm, ectoderm and neural crest cells. (b,c) Frontal view of the cephalic end of 
human embryo at 6 and 10 weeks of development respectively. Adapted from a powerpoint presentation 




2. Where do NCCs come from and what are they? 
Initially described in the chick embryo by Wilhelm His in 1868 as a novel layer of cells which 
participates in skeletogenesis (His, 1868), this specific mesenchymal population was next named 
the neural crest by Arthur Milnes Marshall based on its position close to the “crest” of the neural 
tube (Fig. 2a) (Marshall, 1879). 
The NCCs are a transient pool of progenitor cells that are unique to vertebrates. They are 
multipotent since they can self-renew and differentiate in many different cell types and tissues. 
The NCCs arise from a region called the neural plate border, between the neural plate 
(neuroectoderm) and ectoderm (non-neural ectoderm) (Fig. 2a). After induction by secreted 
signals such as WNTs, BMPs and FGFs, the cephalic NCCs delaminate from the dorsal 
neuroepithelium and migrate dorso-laterally to different regions of the developing face (Fig. 2b) 
where they form a wide range of derivatives including (Gross and Hanken, 2005; Hall, 2008; 
Helms et al., 2005; Minoux and Rijli, 2010): 
- cephalic peripheral nervous system: glial cells (Schawnn cells), cranial nerves, ganglia, 
cranial sensory neurons (Fig. 2c) 
- skeletal system: dermis, connective tissues, bones and cartilages of most craniofacial skeleton 
such as jaw and skull (chondroblasts, chondrocytes, osteoblasts, osteocytes) (Fig. 2d) 
- teeth, dentine (odontoblasts) and ossicles of the middle ears (Fig. 2e,f) 
- cornea, sclera, ciliary and attachment muscles of the eyes 
- connective tissues and vascular elements essential for the function of glands such as the 
thymus, thyroid (calcitonin-producing cells, parafollicular cells), parathyroid, lacrimal and 




Figure 2: Cranial Neural Crest Cells (NCCs) and their derivatives 
(a) Schematic representation of NCC formation at neurulation. NCCs are first induced in the neural plate 
border. At closure of the neural fold, NCCs delaminate from the dorsal neural tube and migrate between 
ectoderm and mesoderm. (b) Migrating NCCs (shown in green) in a mouse embryo E9.5 (Dr. Amanda 
Barlow, Trainor lab). (c) Distribution of the cranial nerves in a human head. Nerves receiving neuronal 
contribution from the NCCs are in color, nerves receiving no NCC contribution appear in gray. (d) Human 
head showing the global repartition of NCC- and mesoderm-derived bones and cartilages. Only the main 
NCC-derived facial elements are labeled. (e) NCCs form the three ossicles of the middle ear. (f) 
Contribution of the NCCs to various parts of the teeth. Adapted from Theveneau and Mayor (2011). 
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Neural crest cells which derive from the trunk neural tube give rise to other tissues and cell types 
such as:  
- sympathetic, parasympathetic and peripheral nervous systems (spinal ganglia, Schwann cells, 
Rohon-Beard cells, Merkel cells, sensory, adrenergic and cholinergic neurons) 
- adipose tissues, dermis (fibroblasts), peripheral pigment cells (melanocytes) 
- adrenal glands (chromaffin cells) 
- smooth and striated muscles (smooth myoblasts, myosatellite cells) 
- cardiac septa, valves, aortic arches, and blood vessels 
The formidable diversity of tissues in which the NCCs can afford to differentiate has led to the 
concept that these cells, which are unique to vertebrates, represent a "fourth embryonic germ 
layer” along side with the canonical endoderm, mesoderm and ectoderm lineages (Hall, 2000). 
3. What induces delamination of NCCs? 
Morphological and cellular events induce NCC delamination which resembles an epithelial-to-
mesenchymal transition (EMT). When neuroepithelium cells emigrate from the neural plate 
border, they undergo EMT involving quick changes in: 
- cell-cell adhesion (via inhibition of N-cadherin) (Nakagawa and Takeichi, 1998; Taneyhill, 
2008) 
- cell-extracellular matrix interaction (collagens, integrins, laminins) (Delannet et al., 1994; 
Perris and Perissinotto, 2000) 
- cell shape (actin cytoskeleton), cell protusion and polarity  (Ahlstrom and Erickson, 2009)  
- activation of locomotory machinery such as Rho GTPases, Rac1 and Cdc42 (Carmona-
Fontaine et al., 2008; Matthews et al., 2008; Ridley et al., 2003). 
At the gastrula stage, EMT of NCCs is regulated by a balance of several embryonic signaling 
pathways including WNT, BMP, NOTCH and FGF which induce formation of neural crest 
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precursors (Garcia-Castro et al., 2002; Glavic et al., 2004b; Mayor et al., 1997). In mouse, 
chicken, zebrafish and Xenopus, these precursor cells express a characteristic set of transcription 
factors (also called neural crest gene regulatory network) such as Pax3/7, Snail2/Slug, Sox9/10, 
AP-2, FoxD3, c-Myc and Twist, which control NCC formation and proliferation. Their role in 
NCC development was validated through functional assays and mutant animal models showing 
craniofacial malformations (Southard-Smith et al., 1998; Tremblay et al., 1995). Recently, these 
transcription factors have been also shown to be expressed in pre-migratory NCCs in humans 
(Betters et al., 2010). 
Even though all vertebrates seem to use the same signals for neural crest formation, the hierarchy, 
intensity and timing may differ slightly between different model organisms, leading to different 
patterns of emigration. For instance, cranial NCCs start to delaminate when complete fusion of 
the neural tube takes place in chicken (Thiery et al., 1982) whereas NCCs emigrate from the 
neural fold when it is wide open in Xenopus, mouse and human embryos (Nichols, 1987; 
O'Rahilly and Muller, 2007; Sadaghiani and Thiebaud, 1987). 
To conclude, each of these intrinsic and extrinsic factors is important for induction, EMT and 
segregation of the NCCs from the neural tube, and prepares them for their migration through 
different embryonic tissues. 
4. Where do NCCs go and what controls their migration? 
After delamination, NCCs undergo segmental and directional migration in four individual 
streams. NCCs from the di- and mesencephalon populate the frontonasal prominence and regions 
around the eyes; from the posterior mesencephalon, rhombomeres 1 and 2 fill the first BA1 (Fig. 
3a, S1); from rhombomere 4 fill the second BA2 (Fig. 3a, S2); from rhombomeres 6 and 7 
colonize indifferently the third and fourth BAs (Fig. 3a, S3). 
10 
 
In the avian hindbrain, pre-migratory NCCs undergo apoptosis in rhombomeres 3 and 5, 
generating NCC-free regions (Ellies et al., 2002). Compared to trunk NCCs that show apparent 
differences in migratory timing and trajectories between species, the cephalic NCCs show little 
variation (Collazo et al., 1993; Erickson and Weston, 1983; Raible et al., 1992).  
NCC migration does not only depend on intrinsic genetic programs, on their communication with 
each other, but also on their exposure to rapidly-changing environment among neural ectoderm, 
paraxial mesoderm, pharyngeal endoderm and superficial ectoderm (Fig. 1a). 
To begin with, the NCC environment expresses regulators that control their motility and direction 
by generating permissive and restricted areas (Theveneau and Mayor, 2012). Depending on the 
species, a combination of membrane-anchored Ephrin ligands and their Eph receptors regulate 
cell movements mostly by altering cell-cell contacts. They contribute to the maintenance of NCC-
free regions (Fig. 3a) (Mellott and Burke, 2008; Smith et al., 1997). As Ephrin/Eph signaling 
molecules, the NCCs that express Neuropilins/Plexins (Nrp1/2) receptors are repelled by 
Semaphorin ligands present in NCC-free regions, inhibiting early migration of the NCCs (Fig. 3a) 
(Koestner et al., 2008; Yu and Moens, 2005). At later stages, the repulsion is not as clear since 
NCCs populate branchial arches where Semaphorins are also expressed (Gammill et al., 2007). 
Erb4 receptor/Neuregulin 1 ligand is another negative regulator complex which was shown to 
maintain rhombomere 3 free of NCCs in mouse and chick (Fig. 3a) (Golding et al., 2004). 
Besides negative regulators, other factors are known to promote motility of NCCs such as VEGF, 
PDGF and FGF factors, which create permissive environment and attract NCCs especially in the 
second BA (McLennan et al., 2010; Trokovic et al., 2003). The stromal cell-derived factor 1 gene 
(SDF1, also known as CXCL12) codes for a chemokine also present in the developing head. This 
secreted protein directs migration of NCC-expressing CXCR4, a cognate receptor for SDF1, into 
the pharyngeal arches and around the eyes (Olesnicky Killian et al., 2009; Theveneau et al., 
2010). Overexpression of Sdf1 or Cxcr4 in zebrafish embryos leads to ectopic NCC migration 
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over the eye vesicles resulting in craniofacial defects (Olesnicky Killian et al., 2009). Soluble 
gradients of SDF1 also chemo-attract various populations of migratory cells such as the 
gastrulating mesoderm (Fukui et al., 2007), germ cells (Molyneaux et al., 2003; Staton et al., 
2011), muscle progenitor cells (Vasyutina et al., 2005), hematopoietic stem cells (Wang et al., 
2010) as well cancer cells (Dewan et al., 2006; Kucia et al., 2005a; Kucia et al., 2005b). In vitro 
experiments have shown that local sources of SDF1 are sufficient to attract CXCR4 expressing 
cells (Theveneau et al., 2010). Cooperative regulation of endothelial cell movements by EphB 
and SDF1 was also documented in cultured cells (Salvucci et al., 2006). 
To conclude, both negative and positive regulators have been shown to control streaming of 
NCCs from neural tube to the four BAs during craniofacial development of many different 
vertebrate species including Xenopus (Fig. 3b). Migration mechanisms in Xenopus embryos 
follow the same trend as in mammals; therefore frog is a valid animal model to study NCC 
development (Fig. 3b) (DeSimone et al., 2005). Moreover, the “ex utero” development of frog 
embryos allows easy genetic manipulation such as loss and gain-of-function assays and classical 
cut-and-paste grafting experiments. 
Mechanisms that stop NCC migration are still unclear, but a few candidates have been proposed 
such as Semaphorin 3A (Kawasaki et al., 2002), BMP4 and SHH which drive multipotent NCCs 












Figure 3: NCC segmental and directional migration in mammal and amphibian embryos 
(a) NCC migration in a representative mammalian embryo. The yellow arrows represent the patterns of 
NCC migration from specific region of the brain into the frontonasal prominence (FNP) and the four 
branchial arches (BA1-4). The NCCs migrate in three individual streams: S1, S2 and S3. Di-: diencephalon, 
Mes-: mesencephalon, r1: rhombomere 1. Some of the molecular mechanisms involved in the migration of 
NCCs are shown, such as Ephrin B2/EphA4/EphB1, Nrp1-2/Sema3f and Erbb4. Adapted from Minoux and 
Rijli (2010). (b) Restricted migration of NCCs at different stages of Xenopus development. Purple: first 
branchial arch (BA1) or mandibular crest segment. Green: second BA2 or hyoid crest segment. Red: third 
BA3 or anterior branchial crest segment. Blue: fourth BA4 or posterior branchial crest segment. Black: 





5. Molecular cues that control NCC differentiation during craniofacial morphogenesis 
Specific transcription factors are expressed by subpopulation of NCCs establishing their identity 
and driving their proliferation and differentiation. For instance, the homeobox (Hox) genes 
provide spatial identity of NCCs along the antero-posterior axis of the BAs (Fig. 4a) (Gendron-
Maguire et al., 1993; Rijli et al., 1993). While the NCCs of the first BA do not express Hox 
genes, Hoxa2/b2/a3/b3/d3/d4 are found in subsequent BAs. Ectopic expression of Hox genes in 
the most anterior neural fold of avian embryos inhibited facial skeleton development (Creuzet et 
al., 2005a). It is the distal-less homeobox (Dlx) genes which provide intra-arch polarity along 
dorso-ventral axis of BAs (Fig. 4b) (Depew et al., 2005). Dlx1/2 regulate upper jaw development 
while Dlx5/6 confer lower jaw fate. Some of the DLX5/6 downstream genes have been identified, 
among which many have been reported to cause craniofacial defects in mouse when mutated 
(Jeong et al., 2008). 
Besides intrinsic genetic program, environmental signals also influence NCC transcriptional 
activity to achieve craniofacial patterning. As previously referred, secreted proteins such as SHH, 
BMPs and FGFs are important during induction and delamination of NCCs. Concentration 
gradients of these morphogens are also involved in NCC differentiation by regulating 
transcription of specific downstream genes (Fig. 4c). Head patterning driven by these signaling 
pathways resembles that of the neural tube and limb buds (Balaskas et al., 2012; Niswander and 
Martin, 1993).  
Depletion of SHH signaling in zebrafish, chick, mouse and human induce defects in NCC 
survival, proliferation and patterning causing severe head abnormalities (Ahlgren and Bronner-
Fraser, 1999; Chen et al., 2001; Chiang et al., 1996; Hu and Helms, 1999). Shh present in the 
foregut endoderm is important for patterning the skeletal structures that are generated from BA1 
(Couly et al., 2002) while SHH signaling arising from the ventral brain promotes formation of 
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anterior neurocranium and upper jaw cartilage (Eberhart et al., 2006). Moreover, Shh expressed in 
the frontonasal ectoderm, together with Fgf8, regulate the growth and dorso-ventral polarity of 
the upper face that contribute for instance to the morphological diversity of beak shape among 
bird species (Fig. 4c) (Hu and Marcucio, 2009; Hu et al., 2003). 
BMP signaling pathway is also involved in the formation of a variety of craniofacial elements 
including the NCCs and facial primordia, but also skeleton, tooth, lip and palate (Nie et al., 2006). 
Bmp4 overexpression in dorsal neural tube explants stimulated production of NCCs. Conversely, 
the addition of the BMP4 inhibitor, Noggin, prevented NCC migration (Kalcheim and Burstyn-
Cohen, 2005; Sela-Donenfeld and Kalcheim, 1999). Dysregulation of Bmp4 expression in the 
facial ectoderm or in mesenchyme of the frontonasal process of finch embryos gave different 
beak shapes and lengths (Abzhanov et al., 2004). As established for SHH, face patterning is also 
driven by different type of tissues secreting BMP4 (Fig. 4c). 
Finally, FGF signaling from the pharyngeal endoderm is also important for normal arch and 
cartilage development during craniofacial skeletal patterning (Crump et al., 2004; Piotrowski and 
Nusslein-Volhard, 2000). Reducing FGF8 or increasing BMP4 by nucleic acid electroporation in 
the chick anterior neural ridge resulted in smaller head and brain, whereas inhibition of BMP4 
caused huge brain development (Creuzet, 2009). 
All together, these morphogens interact and regulate specific downstream genes which contribute 
to form variety of head sizes and shapes among vertebrate species. Modulation in their expression 
cause cascades of events that produce broad craniofacial diversity or defects. Besides shaping the 
head skeleton, these signals are also known to control morphogenesis and patterning of sense 










Figure 4: NCC intrinsic transcriptional programs and environmental signals that control vertebrate 
head development 
(a) The homeobox (Hox) code provides spatial identity to NCCs colonizing the four branchial arches 
(BA1-4) along the antero-posterior axis. Each BA is represented by a different color (see Key) representing 
its specific Hox expression code. (b) The Dlx code provides spatial identity to NCCs along the dorso-
ventral axis of BAs. (c) Environmental signals involved in craniofacial morphogenesis. Induction (black 
arrow) or repression (flat arrow end) of genes by BMP4 or FGF8 or SHH are indicated. Some differences 
might exist in different species. md, mandibular process of BA1; mx, maxillary process of BA1. NCCs, 
neural crest cells. Adapted from Minoux and Rijli (2010). 
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6. Eye and ear morphogenesis is contingent on NCCs 
Vertebrate eye development starts with evagination on both sides of the diencephalon giving rise 
to lateral eye vesicles which extend toward the overlying surface ectoderm (Fig. 5a). Contact and 
signal exchange between the neuroepithelium and the ectoderm induces lens placode formation 
and pre-patterning of the retina (Fig. 5b). The lens placode and distal optic vesicle invaginate to 
form a bi-layered optic cup. The cells of the outer layer produce melanin pigment and ultimately 
become the retinal pigment epithelium (RPE) (Fig. 5c,d). The cells of the inner layer generate a 
variety of glia, ganglion cells, light- and color-sensitive photoreceptor neurons (rods and cones) 
and bipolar interneurons. These cells with many other specialized neurons constitute the neural 
retina (NR). The more proximal portion of the optic vesicle differentiates into the optic stalk (or 
optic nerve) composed of ganglion cells whose axons send electrical impulses to the brain (Fig. 
5c,d) (Fuhrmann, 2010). 
 
 
Figure 5: Schematic representation of vertebrate eye development 
(a-b) Formation of the optic vesicle (OV) by evagination of the diencephalon. (c-d) Formation of the optic 
cup by invagination of the lens placode (LP) and optic vesicle. C: Cornea; L: lens; LV: lens vesicle; MS: 
mesenchyme; NR: neural retina; ON: optic nerve; OS: optic stalk; RPE: retinal pigment epithelium; S: 




Like head development, proximo-distal and dorso-ventral patterning of the eye depends on 
intrinsic signals, cell-cell contact and extracellular signaling molecules that promote optic vesicle 
interaction with the extra ocular mesenchyme (mesoderm, neural crest cells) and the surface 
ectoderm. 
Many studies have shown that two antagonist morphogens, namely BMP4 and SHH, specify 
dorso-ventral polarity of the eye vesicles from early stage of development (Zhao et al., 2010). Shh 
expression at the embryonic midline, together with retinoic acid and Fgfs, control specification of 
the ventral retina and expansion of the optic stalk, and indirectly antagonize Bmp4 which is 
strictly expressed in the dorsal retina (Lupo et al., 2005). Other reports showed that BMP 
signaling is inhibited by antagonists such as Ventroptin (Chordin-like 1) expressed in the ventral 
part of the eye (Sakuta et al., 2001). Besides dorso-ventral patterning of the eye, the separation of 
the single eye field into two bilateral regions depends on the secretion of SHH from the 
prechordal plate. Mutations of Shh cause dysregulation of multiple downstream genes expressed 
in the anterior tip of the neural plate such as Pax6, Six3 and Rx1 (Halder et al., 1995), resulting in 
cyclopia in the most severe cases (Chiang et al., 1996; Li et al., 1997; Roessler et al., 1996). 
Bmp4 seems to cooperate also with Pax6 and Bmp7 during lens placode induction, retinal and 
optic nerve development (Furuta and Hogan, 1998; Wawersik et al., 1999).  
Besides opposite morphogens, a few studies have shed light that Iroquois (Irx) transcription 
factors also play a role during eye development in metazoans from Drosophila to mouse (Cheng 
et al., 2005; McNeill et al., 1997). In fruitfly eye, Iroquois genes (Iro-C) organized the dorso-
ventral patterning of the eye imaginal discs (Dominguez and de Celis, 1998; McNeill et al., 
1997). Although all six Irx genes were expressed in mouse developing retina (Bosse et al., 2000), 
only Irx5 was shown to be required for the development of cone bipolar neurons (Cheng et al., 
2005). Studies on frog Irx genes mainly focused on their role for neural patterning (Rodriguez-
Seguel et al., 2009) and only Irx5 was shown to be transcribed in Xenopus retina (Garriock et al., 
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2001). Irx genes were also expressed in zebrafish embryonic eyes, and Irx1a/Irx2a regulated 
Hedgehog waves during retinogenesis (Cheng et al., 2006; Choy et al., 2010).  
In addition, cephalic NCCs and their derivatives also contribute to the morphogenesis of the 
ocular and periocular apparatus (Creuzet et al., 2005b). Sema3A/Npn-1 signaling complex, which 
was shown to control migration of NCCs in branchial aches, also seems to play an essential role 
in coordinating periocular neural crest migration that is vital for proper ocular development 
(Lwigale and Bronner-Fraser, 2009). 
To end with, molecular and cellular resemblances are observed between optic and otic 
morphogenesis. Development and patterning of the inner ear start by the appearance of bilateral 
otic placodes near rhombomeres 5 and 6. These ectodermal thickenings then invaginate and pinch 
off from the ectoderm or cavitate to form otocysts. At this stage, asymmetric gene expression can 
be observed in the otic vesicles, giving rise to elaborate ear morphology with clear polarity in all 
three axes (Fekete and Wu, 2002). Dorso-ventral patterning with the formation of a NCC-derived 
sound-detecting cochlea emerges as a ventral protrusion of the otocyst and is regulated by 
opposite gradients of SHH (Riccomagno et al., 2002) and WNT (Riccomagno et al., 2005) 
signaling pathways. BMPs and FGFs play also main roles in inner ear morphogenesis (Ohyama et 
al., 2010; Schimmang, 2007). 
To conclude, SHH, BMPs and other signaling activities emanating from neural plate and adjacent 
non-neural tissues are required for ectodermal thickening forming distinct sensory placodes, 




7. Genetic etiology of human syndromes with craniofacial abnormalities 
In the preceding sections were introduced some of the essential genes expressed by the four germ 
layers that pattern individually or synergistically pharyngeal arches and frontonasal prominence. 
Gene depletion analysis in different animal models, together with in vitro experiments, showed 
that these genes are involved directly or indirectly in pathways that control NCC induction, 
delamination, migration and differentiation. We should therefore consider that each of these 
genes discussed above are potential candidates for birth defects in humans. 
For many well-known syndromes with craniofacial abnormalities, causative genes have been 
found and functional analysis has allowed us to get a better understanding of the underlying 
mechanisms behind disease pathogenesis. Finding phenotypic resemblances between Hamamy 
syndrome and known genetic disorders should help us to formulate hypotheses as to which 
signaling pathways may be altered in HMMS. To illustrate this point, below are examples of 
human syndromes sharing craniofacial dysmorphisms with the HMMS (Fig. 6a): 
- Craniofrontonasal syndrome (CFNS; MIM304110) displays hypertelorism, brachycephaly, 
downslanting palpebral fissures, broad nose, high arched palate, pectus excavatum and 
diaphragmatic hernia (Fig. 6b). Mutations in the EFNB1 gene (Twigg et al., 2004; Wieland et 
al., 2004), as well in OPHN1, YIPF6, STARD8 and PJA1 were shown to cause CFNS 
(Wieland et al., 2007). 
- Oculodentodigital Dysplasia (ODDD; MIM164200-257850) caused by mutations in GJA1 
(also known as CX43) display severe telecanthus together with nasal, dental, limb 
dysmorphisms and un-synchronized heart contraction (Fig. 6c) (Paznekas et al., 2003; 
Richardson et al., 2006). 
- ALX4 gene, associated with the WNT signaling pathway, causes severe hypertelorism or 
frontonasal dysplasia when mutated (Fig. 6d) (Kayserili et al., 2009). 
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- Change in the SHH signaling pathway causes variability in facial midline expansion, such as 
hypertelorism seen in patients with Donnai-Barrow syndrome (DBS; MIM222448) caused by 
mutations in LRP2 (Fig. 6e) (Kantarci et al., 2007), or conversely holoprosencephaly 
(MIM600725) which is linked to SHH depletion (Fig. 6f) (Belloni et al., 1996; Roessler et al., 
1996). 
- Eye patterning defects accompanied with mild craniofacial defects were also diagnosed in 
patients carrying BMP4 mutations (Fig. 6g) (Reis et al., 2011). 
- The ear anomalies and dysplasia of the lacrimal-salivary apparatus in HMMS resemble 
Lacrimoauriculodentodigital disorder (LADD; MIM149730) caused by FGF signaling 
impairment (Fig. 6h) (Rohmann et al., 2006). 
- Finally, sparse bilateral eyebrows, flat philtrum, thin upper lip, high arched palate, mild 
micrognathia and teeth anomalies (Fig. 6i) were diagnosed in patients with 
Trichorhinophalangeal type 1 syndrome (TRPS1; MIM190350) carrying mutations in the 
TRPS1 gene (Momeni et al., 2000). 
We can therefore anticipate that the gene responsible for HMMS may contribute to NCC 
patterning by direct or indirect interaction with one or several of these genes which regulate 








Figure 6: Human syndromes with craniofacial anomalies for which the genetic etiology has been 
uncovered 
(a-i) Full face photograph of patients showing specific craniofacial dysmorphisms. Gene and syndrome 
names are indicated under each picture. Adapted from Hamamy (2007) (a), Twigg (2004) (b), Richardson 
(2006) (c), Kayserili (2009) (d), Kantarci (2007) (e), Roessler (1996) (f), Reis (1999) (g), Rohmann (2006) 
(h), Momeni (2000) (i). 
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8. Clinical manifestations of patients diagnosed with HMMS 
Two brothers (patients 1 and 2) who belonged to a Jordanian family displayed abnormal heart, 
blood and bone ontogeny as well as defective craniofacial morphogenesis including severe 
hypertelorism, myopia, malformed ears and deafness (Hamamy et al., 2007b). Since Hamamy’s 
paper (2007), another child was born in this family with similar birth defects (patient 3). The 
unaffected parents were double first cousins born to first cousin maternal and paternal 
grandparents (Fig. 7a). Besides the 3 affected siblings, family history was unremarkable for 
hypertelorism or bone fragility. 
In more details, the three probands shared a unique set of craniofacial defects including 
craniosynostosis, brachycephaly, midface prominence, severe telecanthus, sparse lateral 
eyebrows, severe myopia, broad nasal bridge with pointed nasal tips and anteverted nostrils, 
smooth and long philtrum, large mouth with downturned corners and thin upper lip, high arched 
palate, protruding and malformed ears, sensorineural hearing impairment, mild mental retardation 




Figure 7: Craniofacial anomalies in three Jordanian probands with Hamamy syndrome (HMMS) 
(a) Pedigree of the inbred family from Jordan. Males and females are represented by squares and circles 
respectively. Filled black symbols signify affected individuals (1-3). Crossed symbols indicate individual 
deceased. (b-d) Full face pictures of affected patients at different ages, with common craniofacial 
dysmorphisms including midface prominence, sparse lateral eyebrows, severe telecanthus, anteverted 
nostrils, pointed nasal tip, flat philtrum, thin upper vermillion border and protruding ears. Participants gave 




Beside craniofacial anomalies, severe bone fragility was observed in HMMS patients (Hamamy 
et al., 2007b). At age of 8 and 9 years old, the two Jordanian brothers were diagnosed with 
osteopenia. Dexa scan (Dual Energy X-ray Absorptiometry), used for measuring bone mineral 
density of the hip and lumbar spine (Fig. 8a,b), revealed osteopenia with high risk of osteoporosis 
that may explain the repeated long bone fractures reported in both patients (Fig. 8c). Supportive 
osteotomies were undertaken to prevent further bone fractures.  
Loss of lamina dura, which is a thin hard layer of bone that lines the socket of a tooth, was also 
diagnosed in HMMS probands, accompanied with teeth malocclusion, thin enamel and 
hypodontia.  
Other skeletal survey documented hip dysplasia, expansion of the medullary space resulting of 
widening of the hand bones (Fig. 8d). Digits malformations were also observed such as ectopic 
finger creases (Fig. 8e), long fingers, short index (Fig. 8f) and thumb deviation (Fig. 8g). 
For the last four years, additional anomalies have been ascertained in the Jordanian HMMS 
patients such as lacrimal-salivary apparatus hypoplasia, microcytic hypochromic anemia, heart 
intraventricular conduction delay and low gonadal activity. Two Turkish brothers, born to a first 
degree cousin marriage, have been also diagnosed with similar symptoms as the Jordanian 








Figure 8: Bone fragility and digit anomalies in HMMS patients 
(a,b) Dexa scan (Dual Energy X-ray Absorptiometry) of the lumbar spine and hip reveals low Z-score and 
low bone mineral density (BMD) for two patients (1 and 2). (c) Femora radiograph of patient 2 showing 
multiple fractures and corrective osteotomy. (d) Hand X-ray of patient 1 reveals expansion of the 
medullary space resulting in widening of the hand metacarpal bones and phalanges (black arrow). The bone 
test results and radiographs were provided by Prof. Hamamy, Jordan University Hospital (2004). (e,f) Palm 
images of patients 1 and 2 show ectopic finger creases (red arrowheads), long fingers with short index 





9. Objectives and significance of this study 
As outlined in this introduction, birth defects with craniofacial anomalies are often caused by 
genetic errors. Since the origin of more than half of the congenital syndromes remains unclear, it 
is worthwhile to study families displaying rare and unique symptoms such as Hamamy syndrome 
(Hamamy et al., 2007b). This new recessive disease presents with distinct craniofacial defects 
together with bone, blood, heart and gonad anomalies. Besides FISH and karyotype analysis, 
which did not show any chromosomal anomalies or subtelomeric rearrangements, no further 
analysis has been carried out. 
The pedigree of the Jordanian family showed that only the last generation of males and female 
were affected by Hamamy syndrome suggesting a genetic etiology with an autosomal recessive 
mode of inheritance. Therefore the first aim of this study was to find the defective gene that 
causes HMMS and to investigate its function in the context of normal embryonic development 
and disease state.  
Our first task was to delineate the causative allele by homozygosity mapping using high density 
single nucleotide polymorphism (SNP) arrays (to avoid a second step of fine mapping), followed 
by either candidate gene approach or high throughput re-sequencing of all mapped genes. We 
then aimed to analyze the influence of the genomic mutations on the corresponding protein 
synthesis, function and stability by comparing it to its wild type form, using patient’s cells and 
newly raised antibodies. 
Our second objective was to use animal models such as Xenopus laevis to carefully examine the 
expression pattern of the responsible gene during embryogenesis and to attempt to phenocopy the 
human disease by carrying out knock-down (KD) experiments using translation blocking 
morpholinos. We anticipated that disease modeling would document the potentially defective 
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migration of the neural crest cells in the developing embryo, and further help us understand the 
role played by this gene during craniofacial development. 
Finally, by contrasting the gene expression profiles between knock-down and control embryos, I 
ought to identify specific genes whose expression or inhibition might be dependent on the HMMS 
gene. The identity of these downstream genes may in turn help us decipher what developmental 
pathways were dysregulated in HMMS. Concurrently, I also explored potential protein partners 
using biochemistry tools and a yeast two-hybrid system hoping to find interacting proteins that 
could modulate the activity of the HMMS protein.  
Overall, our objective was to reach a mechanistic model that could in part explain the 
pathogenesis of HMMS in the context of craniofacial morphogenesis. This thesis, I hoped, would 
provide a clearer picture of the molecular and cellular mechanisms that patterns the skull, face, 
eyes, ears and jaws of vertebrates and shed light on the importance of this new gene in the 
ontogeny of other organs including bone, heart and gonads that were also affected in HMMS 
patients. Ultimately, I believed that discovering the gene causing HMMS would perhaps be 
instrumental for the development of better treatments or prevention of common ailments such as 




Chapter 2 Materials and Methods 
1. Patients and clinical assessment 
The Jordanian index cases were initially diagnosed at the Pediatrics Department in the Jordan 
University Hospital by Prof. Hanan Hamamy (Hamamy et al., 2007b). The affected children in 
the Turkish family were clinically evaluated at the Medical Genetics Department, Istanbul 
Medical Faculty by Prof. Hülya Kayserili. For the last four years, patients from both families 
have borne further clinical examinations such as ultrasound scanning, electrocardiogram (ECG), 
ophthalmic examination, electroretinography (ERG), magnetic resonance imaging (MRI) and 
dacryoscintillography in order to ascertain new congenital defects or postnatal symptoms 
associated to this syndrome. After approval by the local ethics commission, each participant gave 
their consent to publish photographs and to use their sample for diagnosis and subsequent 
research. 
2. Sample collection and genomic DNA extraction 
Genomic DNAs (gDNAs) were extracted from saliva samples collected in OragenTM DNA self-
collection kit (DNA Genotek) using a Puregene DNA Purification Kit (Gentra Systems). After 
incubation of Oragen kits containing saliva at 50°C overnight, 1 ml of saliva was transferred in a 
2 ml eppendorf tube. 250 µl of Puregene Cell Lysis Solution (Gentra, cat# 158906) was added in 
each tube and vortexed vigorously (max speed). Then, 500 µl of Protein Precipitation Solution 
(Gentra, cat# 158910) was added into the center of each sample and vortexed vigorously (max 
speed) to precipitate proteins. Samples were centrifuged at 13000 rpm, 2 min, and the clear 
supernatants were carefully collected into new tubes while the tight dark pellets were discarded 
(850 µl/tube). Then, 600 µl of isopropanol (100%) was added and tubes were rotated gently 50 
times to precipitate DNA. After centrifugation at 13000 rpm, 2 min, 600 µl of 70% ethanol was 
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added to each DNA pellet. Finally, after short centrifugation, DNA pellets were resuspended into 
30 to 50 µl of DNA Hydration Solution (Gentra, cat# 158914) or other standard buffer such as TE 
buffer or H2O. Samples were incubated at 65°C for 1 hour or overnight at room temperature for 
complete resuspension. The purity and quality of the extracted gDNAs were assessed by 
calculating the 260/280nm absorbance ratio (NanoDrop spectrophotometer) and run on a 1% 
agarose gel. Double stranded DNA was quantified using Quant-iT™ PicoGreen ® dsDNA 
(Invitrogen) (Singer et al., 1997) and kept at -20°C (or -80°C for long storage). 
3. Genotyping and homozygosity mapping 
Array-based genotyping of Jordanian samples was performed on an Illumina BeadStation 
platform using Infinium HD Human 1M-Duo BeadChips (Illumina Inc. California, USA). 
Experiments were processed at the Genome Institute of Singapore following manufacturer’s 
instruction. Genotype data were generated using Illumina BeadStudio Software. Call rates were 
above 99%, gender and relationship were confirmed.  
Mapping was performed by searching for shared regions that were homozygous and identical-by-
descent (IBD) in the 3 affected individuals using custom programs written in the Mathematica 
(Wofram Research, Inc.) data analysis software. The confidence criteria to identify IBD blocks 
were a minimum of 3 cM and a SNP density over the 5th percentile. Centimorgan distances 
between SNPs were determined from the HapMap Phase II recombination rate map. Candidate 
regions were further refined by exclusion of common homozygous segments with any unaffected 
family member.  
Homozygosity mapping of the Turkish family was performed using SNP genotyping data of the 
affected boy and unaffected parents and sibling generated from Affymetrix GeneChip Human 
Mapping NspI 250K Arrays. Visual Genome Studio (VIGENOS) program (Hemosoft Inc, 
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Ankara) developed at the Gene Mapping Laboratory facility of Hacettepe University Medical 
Faculty allowed genome-wide haplotyping of SNP data (Kayserili et al., 2009). 
4. Genomic loci capture 
Experiments and analysis were processed at the University of California, Los Angeles (UCLA) 
following manufacturer’s instruction. 
4.1. Custom sequence capture array preparation 
Samples were performed using the Illumina Library Generation Protocol version 2.3 (Fig. 9). 
4 µg of good quality genomic DNA were diluted with elution buffer to a final volume of 150 µl 
and then randomly fragmented by sonication. After PCR purification using QIAquick PCR 
Purification Kit, samples were eluted in 30 µl. T4 and Klenow DNA polymerases were used to 
repair 3’ and 5’ overhangs and generate blunt ends for all the double stranded DNA fragments. 
After purification and elution in 32 µl, single ‘A’ base was added to the 3’ end of the templates 
using Klenow exo- (3’ to 5’ exo minus). After purification using QIAquick MinElute PCR 
Purification Kit, samples were eluted in 10 µl. Adaptors, supplied by Solexa, were ligated to the 
fragments using 2000 U of T4 DNA ligase with T4 DNA ligase buffer. After 15 min of 
incubation at room temperature, samples were purified using QIAquick PCR Purification Kit and 
eluted in 30 µl. Templates were run on a 2% agarose gel and fragments with a size-range of 150-
200 bp were extracted using QIAGEN Gel Extraction Kit. Fragments with the right adaptors pairs 
ligated were amplified by PCR using primers complementary to the adaptors and Phusion DNA 
Polymerase (Finnzymes Oy). To generate enough DNA to hybridize on the capture array, 4 tubes 
of PCR amplification were run resulting in a yield ~4 µg of purified DNA.  
Amplified and purified products were diluted in EB for a final volume of 158 µl, and mixed with 
50 µg of Human Cot-1 DNA, 52 µl of Agilent 10X Blocking Agent and 260 µl of Agilent 2X 
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Hybridization Buffer according to the Agilent CGH 244K Array Protocol. This hybridization mix 
was incubated at 95°C for 3 min and 37°C for 30 min. 490 µl of the hybridization mix was added 
to the array and hybridized in the Agilent Hybridization oven for 40 hours at 65°C. Unbound 
DNA fragments were washed following Agilent procedure A protocol. The second wash was 
extended to 5 min to increase stringency.  
After washing, the array was stripped by incubation at 95°C for 10 min with 1.09X Titanium Taq 
PCR Buffer. After collection of the solution, 46 µl was taken and added with 1 µl of dNTPs (10 
mM each), 1 µl of Titanium Taq and 1 µl of each Solexa primers. 15 cycles of PCR were 
performed and purified using QIAquick PCR Purification Kit. Samples were eluted in 30 µl of 
EB. The amplified and purified products were diluted to 10 nM, the working concentration for 




Figure 9: Sequence capture array re-sequencing in 5 steps: 
1. Genomic DNA sample is fragmented 
2. Sample is hybridized to a custom sequence capture array 
3. Unbound fragments are removed 
4. The target-enriched pool is eluted & amplified 




4.2. High-throughput re-sequencing and analysis 
Each enriched sample was loaded on one lane of the Solexa Flowcell at a final concentration of 2 
pm and sequenced by Illumina Genome Analyzer (GAII) using standard manufacturer’s protocol. 
The image data was processed by the provided GA Pipeline (Firecrest version 1.3.4 and Bustard 
version 1.3.4) and all sequences were aligned to the human reference genome (University of 
California, Santa Cruz, build 18, http://genome.ucsc.edu/) by Blat-like Fast Accurate Search Tool 
(BFAST, https://secure.genome.ucla.edu/index.php/BFAST/). Variants were called using 
SAMtools pileup tool (SAMtools, http://samtools.sourceforge.net/) and the variants submitted to 
an internal database for further filtration and annotation. Mismatches were filtered to identify 
variants seen 10 or more times, where the variant called homozygous, and did not overlap with a 
known dbSNP129 entry mismatch. Non-synonymous mutations were identified using additional 
SeqWare tools and the "knownGene" gene model from the UCSC hg18. The open source 
SeqWare project which provides a LIMS tool for tracking samples (SeqWare LIMS) and a 
pipeline for sequence analysis (SeqWare Pipeline, http://seqware.sourceforge.net/) was used 
throughout this work (O'Connor et al., 2010). 
Positional candidate genes were obtained from the GenBank (http://www.ncbi.nlm.nih.gov 
/mapview/) and Ensembl (http:// www.ensembl.org/) databases. Flanking primers for each exon 
were manually designed and direct Sanger re-sequencing was performed with the BigDye 
Terminator cycle sequencing kit (Applied Biosystems). 
5. In vitro / in vivo luciferase assays 
5.1. Transient cell transfections 
10T1/2 (clonal mouse embryo C3H/10T1/2) and MS5 (murine stromal) cell lines were co-
transfected with luciferase reporters (rKcnd2, hBMP4, hSDF1, hGCMB) and expressing vectors 
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(mouse wild type Irx5, Irx5A150P, Irx5N166K, Irx5∆HD, Irx5S36D/S63D) at 60-70% confluency using 
Fugene HD (Roche, cat# 11814443001) in 24-well plate. However, 293T (human embryonic 
kidney HEK293T) were transfected using Lipofectamine 2000 reagent (Invitrogen, cat# 11668-
019). After 48 hours of incubation, cells were lysed using freshly made 1X Passive Lysis Buffer 
(PLB). After 10 min of incubation at room temperature with shaking, cells were detached by 
pipetting up/down, and the lysates were transferred in 1.5 ml eppendorf tubes. Vigorous vortexing 
and overnight storage at -80ºC allowed complete cell lysis.  
For luciferase assays carried out in vivo, 55 pg of Firefly and 3 pg of Renilla constructs were 
mixed in water or in pure morpholino oligo, and injected at the 2- to 4-cell stage Xenopus 
embryos. Five embryos were lysed in 100 µl of 1X PLB at stage 25. Luciferase activities were 
read and analyzed in the same way as described below. 
5.2. Luciferase reporter assays 
Firefly (Photinus pyralis) and Renilla luciferase assays were carried on cell lysates using Dual-
Luciferase® Reporter Assay (Promega, cat#E1910 or E1960). Typically, the “experimental” 
reporter (firefly) was correlated with the effect of specific experimental conditions, while the 
activity of the co-transfected “control” reporter (Renilla) provided an internal control that served 
as the baseline response. Normalizing the activity of the experimental reporter to that of the 
internal control minimized experimental variability caused by differences in cell viability, 
transfection/cell lysis/assay efficiencies and differences in pipetting.  
Lysates were centrifuged at 13000 rpm, 1 min, and 20 µl of the supernatant was transferred in a 
96-well white flat bottom opaque plate (Greiner bio-one, cat# 655075). After addition of enzyme 
substrates, activities were measured using SpectraMax and Softmax Pro 5.3 (Luminescence: 
1000; Assay Plate Type: 96-well standard opaque; Wells to read selected). 
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6. Western blot analysis 
Embryos or transfected cells were lysed in RIPA buffer (50 mM Tris HCl pH 7.4; 1% NP-40 
(Igepal CA-630); 0.5% Na-Deoxycholate; 150 mM NaCl) supplemented with protease inhibitor 
cocktails (Complete EDTA free, Roche, cat# 12245300). Extracted proteins were diluted in 1X 
reducing Loading Buffer (1 X Stacking gel buffer; 4% SDS; 20%  Glycerol; 10 mg Bromophenol 
blue; 1.65 g DTT; ddH20 to 50 ml),  and separated by electrophoresis on SDS (Sodium Dodecyl 
Sulfate) polyacrylamide gels with reducing DTT (DiThioThreitol), followed by transfer on PVDF 
membrane.  
The following antibodies were used for probing western blots: mouse monoclonal anti-IRX5 
(Sigma, cat# WH0010265M1), mouse monoclonal anti-ACTIN (Chemicon, cat# Mab1501R), 
rabbit polyclonal anti-β-CATENIN (Sigma, cat# C2206) and mouse monoclonal anti-Protein C 
(Roche, cat# 11814508001). To block protein ubiquitin-dependent degradation, 10 µM of 
Lactacystin (Sigma, cat# L6785) or MG132 (Calbiochem, cat# 474790) were added to cultured 
cells overnight. 
7. Whole mount embryo in situ hybridization (WISH) 
7.1. In vitro fertilization of Xenopus laevis eggs 
This protocol describes the in vitro fertilization of Xenopus eggs, to obtain large amount of 
synchronous and de-jellied embryos ready for microinjection and experimental manipulation. 
Xenopus laevis pigmented and albinos female’s breeders with a big belly and a red cloaca were 
injected with 800 units (800 μl) of Human Chorionic Gonadotropin (Sigma, cat# CG10-IVL) into 
the dorsal lymph sacs, near the lateral line sense organs. Frogs were kept at room temperature 
(23⁰C) until they started to lay about 9-10 hours later. After ovulation, frogs need to rest at least 3 
months before being induced again.  
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In the morning, the females were transferred in 1X High Salt Barth’s solution (10X High Salt 
Barth’s Solution: 1.095 M NaCl; 10 mM KCl; 24 mM NaHCO3; 8 mM MgSO4.7H2O; 100 mM 
Hepes; 3.4 mM Ca(NO3)2.4H2O; 4 mM CaCl2.2H20 pH7.7; up to 4000 ml nanopure H2O), and 
eggs started to be collected after 1-2 hours using a pipetman (25 ml pipet) at very slow speed. 
Delicately, eggs were collected into a 100 mm glass Petri dish (1/3 the surface of the plate). In the 
same time, testes were excised and kept at 4⁰C in 1.5 ml eppendorf tube. 1X High Salt Barth was 
drawn off using a Pasteur pipet and kimwipes to suck up as much buffer as possible. 1 ml of 
Steinberg’s solution (10X Steinberg’s Solution: 581 mM NaCl; 6.7 mM KCl; 3.3. mM 
Ca(NO3)2.4H2O; 8 mM MgSO4.7H2O;  0.01 % Kanamycin; 50 mM Tris Base pH 7.45; up to 
1000 ml nanopure H2O) was added to the testes which were then minced with scissors in the 
tube. 5 to 10 drops of this testes solution were added onto the eggs and incubated at room 
temperature for 5 min (covered). 0.1X Barth (10X Barth’s Solution: 889 mM NaCl;  10 mM KCl; 
24 mM NaHCO3; 100 mM Hepes; 8 mM MgSO4.7H2O; 3.3 mM Ca(NO3)2.4H2O; 4.1 mM 
CaCl2.2H2O pH7.6 ;  up to 500 ml nanopure H2O) was then added carefully in order to 
submerge any floating eggs and allow sperm enter the eggs. After 20 min of incubation at room 
temperature, water was decanted and water excess was removed with Pasteur pipet. Fresh 
Cysteine Solution (800 ml with 0.1X Barth’s; 20 g L-Cysteine Hydrochloride Monohydrate 
(Sigma, cat# C7880-500G) pH 7.8; up to 1000 ml nanopure H2O) was added and incubated for 8 
min at room temperature to allow the complete removal of the jelly surrounding the eggs. Cystein 
Solution was decanted; fresh solution was added to the eggs and incubated for 3 min. Then, eggs 
were washed at least 6 times with 0.1X Barth solution. The embryos were finally cultured in 0.1X 
Barth in plastic Petri dishes lined with a 1% agarose solution cushion. 
Note that when solutions were diluted to 1X, 1 ml of 5 % Ampicillin (Sigma, cat# A9518) was 
added per liter. 
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7.2. Microinjection of morpholino oligos and DNAs in Xenopus embryos 
The Irx5 morpholino oligo (Rodriguez-Seguel et al., 2009) (Irx5 MO) and Sdf1 morpholino oligo 
(Theveneau et al., 2010) (Sdf1 MO) synthesized by Gene Tools, LLC (Oregon) were resuspended 
in sterile water to a concentration of 1 mM. At the 2- to 4-cell stage, the Irx5 MO was injected 
pure (123 ng per embryo) and Sdf1 MO at 25 ng per embryo. For rescue experiments, 80 pg of 
non-linearized pCS2+ plasmids encoding either wild type murine Irx5 (mIrx5), or mutant A150P 
mIrx5, or mutant N166K mIrx5 were co-injected with the Irx5 MO. Morpholino sequences are 
given in Appendix 1. 
When embryos reached the desired stage of development, they were fixed in 1X MEMFA (10 ml 
of 10X MEM (100mM MOPS (pH 7.4); 2mM EGTA; 1mM MgSO4; pH 7.4, filtered) + 10 ml of 
Formaldehyde + 80 ml dH2O) at least 2 hours at room temperature (or overnight at 4°C). Then, 
they were dehydrated through methanol series (24%, 50%, 75%, and 100%) in 1X PBS, which 
lasted 5 min each. 
7.3. Synthesis of antisense RNA probe 
20 µg of plasmids containing cDNA of interest were digested with 60 U of suitable restriction 
enzyme for linearization (60 µl total reaction). Digestion was purified using a PCR purification 
kit (Qiagen, cat# 28106). 2 µg of the linearized plasmids were transcribed using 40 U of the 
suitable RNA polymerase (either T3 RNA Polymerase (Roche, cat# 1031163), or T7 (cat# 
881767), or SP6 (cat# 810274)) and 4 µl of 10X DIG (Digoxigenin) RNA Labeling Mix (Roche, 
cat# 1277073) (40 µl total reaction). After 3 hours of incubation at 37⁰C, sample was treated with 
2 µl of DNaseI for 20 min at 37⁰C to get rid of the DNA plasmid. The unincorporated, free 
nucleotides were removed by adding 100 µl of isopropanol (100%) + 10 µl of LiCl (in ice). After 
mixing, RNA was precipitated at least for 2 hours at -80°C. Then, sample was spun down at 4°C, 
max speed for 30 min. The pellet was rinsed with 400 µl ethanol 70% in ice and spun down at 
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4°C, max speed for 10 min. After complete ethanol removal, RNA probe was resuspended in 30 
µl of RNAse free water. RNA yield was quantified with NanoDrop spectrophotometer and 
quality was checked on agarose gel. 
7.4. Xenopus whole mount in situ hybridization (WISH) 
Except proteinase K treatment, all the steps were performed in ice and in RNAse free conditions. 
First, embryos were rehydrated through a methanol series (75%, 50%, 25%) in 1X PBS 0.1% 
Tween-20 (PBSw) (10X PBS: 80 g NaCl; 2 g KCl; 14.4 g Na2HPO4;  2.4 g KH2PO4; up to 1000 
ml ddH2O, pH 7.4, 0.1% DEPC) which lasted 5 min. After 3 washes in 1X PBSw, 5 min each, 
embryos were treated for 8 minutes with 10 μg/ml Proteinase K (Gibco, cat# 25530-049) in 
PBSw at room temperature. Digestion was stopped with 2 mg/ml of glycine in PBSw. After 3 
washes in 1X PBSw, 5 min each, embryos were re-fixed in fresh 4% paraformaldehyde / 0.2% 
glutaraldehyde in PBSw for 15 min. After a fast wash with PBSw, embryos were washed 3 times 
with PBSw, 5 minutes each, followed by a 3 min wash with 1 ml of 50% PBSw / 50% 
Hybridization Solution (HS) (10 g Boehringer Block; 500 ml Formamide; 250 ml 20x SSC, heat 
at 65ºC for 1 hour. Add 120 ml DEPC treated water; 100 ml Torula RNA (10 mg/ml in filtered 
water); 2 ml Heparin (50 mg/ml in 1X SSC); 5 ml 20% Tween-20; 10 ml 10% CHAPS; 10 ml 0.5 
M EDTA). Then, embryos were again washed in HS (100%) for 3 min and pre-hybridized in 400 
µl of HS for 3 hours at 65ºC. 2 µg of RNA probes were denatured in 100 μl of HS at 95ºC for 5 
min, and added to each embryo for overnight hybridization at 70ºC. 
On the second day, probes were removed and replaced with 800 μl of HS for 5 min at 70ºC. 
400μl of 2X SSC (pH4.5) (20X SSC: 175.3 g NaCl; 88.2 g Sodium Citrate; up to 1000 ml ddH2O 
DEPC treated) was added to each vial and incubated 5 min at 70ºC. This step was repeated 2 
times (final volume = 800 μl + 400 μl + 400 μl + 400 μl = 2000 μl). The mix was removed and 
embryos were washed 2 times with 2X SSC (pH7) / 0.1% CHAPS at 70ºC for 30 min, 2 times in 
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MAB (100 mM Maleic Acid; 150 mM NaCl pH 7.5) at room temperature for 10 min, 2 times in 
MAB at 70ºC for 30 min, 2 times in PBS at room temperature for 10 min, and finally 1 time in 
PBSw at room temperature for 5 min. Then, embryos were incubated in 1ml Antibody Buffer 
(10% heat inactivated goat serum; 10% Boehringer blocking stock solution (Roche, cat# 
1096176); 80% PBSw. Heat at 70°C for 10 min, vortex, cool on ice and filter) at 4ºC, rocking, for 
2 hours. In the same time, the antibody Anti-Dig-Alkaline Phosphatase (Roche, cat# 1093274; 
diluted at 1:5000 from a stock of 150 units/200 µl) was pre-blocked in Antibody Buffer at 4ºC, 
rocking. After 2 hours, the Antibody Buffer was replaced with 1.5 ml of pre-blocked antibody 
and incubated at 4ºC, overnight, rocking. 
On the third day, embryos were quickly washed with 0.1% BSA (Bovine Serum Albumin) in 
PBSw, followed by 5 washes in 0.1% BSA in PBSw at room temperature, 1 hour each, rocking. 
Then, embryos were washed 2 times in PBSw at room temperature for 30 min, 2 times in AP1 
Buffer (0.1 M NaCl; 0.1 M Tris pH 9.5; 50 mM MgCl2) for 10 min each. AP1 Buffer was 
replaced with 1 ml BM Purple (Roche, cat# 1442074) and tubes were covered with aluminium 
foil and incubated at 4ºC with rocking until desired staining was reached (overnight).  
Staining reaction was stopped by washing 2 times in Stop Solution (100 mM Tris pH 7.4; 1 mM 
EDTA) for 15 min each and embryos were dehydrated through a methanol series (25%, 50%, 
75% and 100%), which lasted 5 min each. To remove pigmentation or excess background, 
embryos could be bleached with 3 ml of fresh bleaching solution (2/3 Methanol 100%; 1/3 
Hydroxyde Peroxyde 31.5%, Calbiochem, cat# 386790). 
A stereomicroscope M205 FA equipped with an ICD camera (Leica) was used to capture images 




8. Co-immunoprecipitation (co-IP) 
Co-IP technique is used to analyze protein interactions and the procedure is usually composed of 
4 main steps: i) An antibody specific to the protein of interest is added to a cell lysate; ii) Immune 
complex “antibody-protein” is precipitated using protein-G or protein-A sepharose beads which 
bind most antibodies; iii) Proteins that do not bind to the beads are removed by washes; iv) Co-
immunoprecipitated proteins are identified by western blot analysis. 
All our co-IP experiments were processed with anti-Protein C Affinity Matrix (Roche, cat# 
11815024001). These agarose beads are coupled to the antibody anti-Protein C (anti-PC, Roche, 
cat# 11814516001) that recognize the epitope EDQVDPRLIDGK, also called PC-Tag. 
8.1. Preparation of cell lysates 
To obtain the crude mixture that serve as the source of bait-protein complexes, 293T cells were 
transfected with pCS2+ plasmids coding for proteins of interest, fused or not to affinity PC-Tag. 
By using the same antibody anti-PC, different PC-Tagged bait proteins could be 
immunoprecipitated without ordering specific antibodies. After 48 hours of cell growth, cells 
were harvested and proteins were extracted using a lysis RIPA buffer (50 mM Tris HCl pH 7.5; 
150 mM NaCl; 0.1% NP-40 (Igepal CA-630); 0.05% Na-Deoxycholate) that contains 1mM 
CaCl2 (Ca2+ allows high affinity binding of antibody to PC epitope) and complete Protease 
Inhibitor Cocktail tablets (EDTA free, Roche, cat# 12245300). 
8.2. Immunoprecipitation 
The PC-Tagged bait proteins were isolated from the lysates by precipitation to the anti-PC beads. 
Before immunoprecipitation, 30 µl of affinity PC-beads (60 µl of slurry) were washed 3 times in 
1 ml of lysis RIPA buffer and mixed by rotation. Each wash lasted 5 min in ice, and beads were 
spun down at 4000 rpm. Depending on the amount of protein extracted, 150 µl to 400 µl of PC-
40 
 
tagged bait protein was immunoprecipitated to 30 µl of PC-beads in 1.5 ml eppendorf tube 
(Axygen, MAXYMum Recovery, cat# MCT-150-L-C) for 4 hours at 4°C, rotating. After 
centrifugation at 3000 rpm, 1 min, the PC-beads were washed 3 times in 1 ml of lysis RIPA 
buffer and mixed by rotation. Each wash lasted 5 min in ice, and beads were spun down at 4000 
rpm.  
8.3. Co-immunoprecipitation and protein elution 
On each immunoprecipitated complex was added 150 µl of target protein which was expected to 
bind. After a rotating incubation at 4°C overnight, the co-immunoprecipitated complexes were 
centrifuged at 4°C, 3000 rpm, 1 min and washed 1 time in 1 ml of lysis RIPA buffer. Unspecific 
proteins were eluted from the beads by 3 washes with high salt wash buffer (20 mM Tris HCl pH 
7.5; 0.5 M to 1 M NaCl; 1 mM CaCl2). Each wash lasted 5 min in ice, and beads were spun down 
at 4000 rpm. The purified bait complexes were denatured and dissociated from the PC-beads by 
addition of 200 µl of 2X reducing Loading Buffer (1 X Stacking gel buffer; 4% SDS; 20% 
Glycerol; 10 mg Bromophenol blue; 1.65 g DTT; ddH20 to 50 ml). For complete protein-bead 
dissociation, complexes were boiled at 95°C for 10 min and vortexed. Beads were spun down at 
4000 rpm for 1 min and the supernatants were carefully recovered. The presence of target protein 
in the bait complex was determined by western blot. 
To assess whether the interaction observed between PC-bait protein and a target protein was 
specific, negative controls were included. For instance, cells were transfected with non-
expressing plasmids (e.g. pCS2+ empty) and lysates were concurrently immunoprecipitated. 
9. Chromatin immunoprecipitation (ChIP) on Xenopus laevis embryos 
ChIP was used to isolate DNA fragments associated with IRX5 protein in vivo. The procedure of 
ChIP involved 5 main steps described in the following paragraphs. 
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9.1. Stabilization and fragmentation of protein-DNA complexes 
Xenopus embryos were collected at stage 25 of development, when the transcription factor IRX5 
was highly expressed. The protein-DNA complexes were stabilized by using crosslinking reagent 
and crosslinked chromatin was fragmented to small sizes (< 1000 bp) by sonication, 
Formaldehyde is most commonly used to crosslink proteins to DNA for ChIP. Therefore, 30-35 
embryos (stage 25) were fixed in 1% formaldehyde/PBS (3 ml) during 25 min. Morpholino-
injected embryos being smaller, 20% more were fixed. The crosslinking time could be adjusted 
from 15 to 45 min.  
Crosslinking was quenched by a 10 min wash in 0.125 M Glycine/PBS, followed by 3 washes in 
PBS. After removing excess of PBS, embryos could be either frozen at -80°C (3 months) or 
processed for ChIP immediately. If the fixed samples were frozen, they were thawed 15 min in 
ice.  
Fixed embryos were resuspended in 600 µl of lysis RIPA buffer (50 mM Tris HCl pH 7.4; 1% 
NP-40 (Igepal CA-630); 0.25% Na-Deoxycholate; 150 mM NaCl; 1 mM EDTA; 0.1% SDS) + 
DTT (0.5mM) + Protease inhibitor cocktail (Complete EDTA free, Roche, cat# 12245300) to 
isolate nuclei and extract the proteins. Embryos were homogenized first with a pestle 2 times, 30 
sec and incubated 10 min in ice. After centrifugation at 4°C, 14000 rpm, 10 min, the supernatant 
was discarded and the edge of the tube wiped to remove lipids. Nuclear proteins were extracted 
by addition of 650 µl of RIPA buffer. Pellets were homogenized with a pestle 40 sec and kept in 
ice. 
Lysates were transferred in 2 ml eppendorf tubes and sonication was processed in ice at 4°C. 
Using a sonicater with a standard tip, extracts were sonicated for 20 sec, 15 times, with amplitude 
of 16%. In between pulses, samples were sat on ice for 59 sec. Sonicated products were 
centrifuged at 4°C, 14000 rpm, 10 min, and the supernatants, which contain now the chromatin 
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extracts, were transferred into pre-chilled eppendorf tubes and kept in ice. To quantify and verify 
the size of the sheared DNA (300 to 1000 bp), 20 µl of chromatin extract was digested with 
proteinase K (65°C overnight) and ran on 1% agarose gel.  
While previous steps were processed, protein-G sepharose beads (Rec-Protein G-sepharose 4B, 
Zymed Laboratories, Invitrogen, cat# 10-1243) were washed and blocked. Depending on the 
antibody tested, other type of beads may be used (Dynabeads Protein G, Invitrogen, cat# 
100.03D). In 15 ml conical tubes, the protein-G sepharose beads were washed 2 times in 10 ml of 
PBS and 1 time in 10 ml of 3% BSA/PBS. Each wash lasted 10 min in ice, and spun down at 4°C, 
1000 rpm for 3 min. After wash, the beads were blocked by addition of 0.15 mg/ml of sonicated 
salmon sperm DNA (10mg/ml) (Deoxyribonucleic acid, single stranded from salmon testes, 
Sigma, cat# D7656) in 10 ml of 3% BSA/PBS, for at least 2 hours at 4°C, rocking. The blocked 
beads were washed 3 times in 10 ml RIPA. Each wash lasted 10 min in ice and spun down at 4°C, 
1000 rpm for 3 min. 
9.2. Immunoprecipitation of crosslinked chromatin  
Before immunoprecipitation, the chromatin extract was pre-cleared by adding 100 µl of blocked 
beads per 600 µl of chromatin extract, and incubated for 2 hours at 4°C, rotating. After 
centrifugation at 3000 rpm, 1 min, the “clear” chromatin was transferred to new pre-chilled tubes 
(without beads). Each immunoprecipitation was prepared in individual eppendorf tube 
containing: 250 µl of chromatin extract + 250 µl RIPA buffer (containing DTT + Protease 
inhibitor cocktail) + 2.5 to 5 µg of the primary antibody against the protein of interest. As a 
negative control, immunoprecipitation was also prepared with 2.5 to 5 µg of IgG. The reactions 
were incubated overnight at 4°C, rotating.  
For input, 10% of non-immunoprecipitated chromatin extract (= 25 µl) was kept in 275 µl of TES 
buffer (50 mM Tris HCl pH 8; 10 mM EDTA; 1% SDS) at -80°C. 
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9.3. Purification of crosslinked chromatin 
The immunocomplexes “DNA-protein-antibody” were centrifuged at 4°C, 14000 rpm for 5 min, 
and transferred in pre-chilled tubes. Each immunocomplex was precipitated with 100 µl of fresh 
pre-blocked beads at 4°C for 4 hours, rotating. 
The precipitated immunocomplexes were washed in different buffers at 4°C as follows: 2 times 
with 1 ml TSEI (20 mM Tris HCl pH 8; 1% Triton X-100; 150 mM NaCl; 2 mM EDTA; 0.1% 
SDS), 2 times with 1 ml TSEII (20 mM Tris HCl pH 8; 1% Triton X-100; 500 mM NaCl; 2 mM 
EDTA; 0.1% SDS), 2 times with 1 ml TSEIII (10 mM Tris HCl pH 8; 1% NP-40 (Igepal CA-
630); 1% Na-Deoxycholate; 1mM EDTA; 0.25 M LiCl), and finally 2 times with 1 ml TE (10 
mM Tris HCl pH 8; 1 mM EDTA). Each wash was done at 4°C, with 10 minutes incubation, 
rotating. Samples were spun down at 1000 rpm, 1 min.  
After the series of washes, beads were eluted with 150 µl of TES (50 mM Tris HCl pH 8; 10 mM 
EDTA; 1% SDS) and incubated for 15 min at 65°C, vortex at 900 rpm. After centrifugation at 
14000 rpm, 1 min, the eluate was transferred in a new tube, and the elution was repeated a second 
time. The 150 µl was pooled with the previous 150 µl eluate (total 300 µl).  
Finally, the eluate and input samples were incubated with 8 µl Proteinase K (20 mg/ml) overnight 
at 65°C in the oven to reverse crosslink and digest proteins. 
9.4. DNA extraction and purification 
Immunoprecipitated DNAs were RNase-treated, extracted, precipitated and finally re-suspended 
in water.  
To dilute SDS, 300 µl of TE was added to each de-crosslinked sample (total 600 µl) and RNase 
treatment (with 0.2 µg/ml RNaseA) was incubated at 37°C, 2 hours. DNAs were extracted with 
600 µl phenol/chloroform/isoamyl alcohol. Each sample was vortexed vigorously and centrifuged 
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at room temperature, 14000 rpm for 3 min. The upper, aqueous phase was transferred to a clean 
tube. A second extraction could be performed if the aqueous phase was still cloudy, by addition 
of 600 µl of chloroform. To precipitate DNAs, 20 µl of 5 M NaCl was added to each sample with 
1 ml of 100% ethanol. After mixing by inversion, samples were incubated at -80°C for 30 min. 
Samples were centrifuged at 4°C, 14000 rpm, 15 min, and pellets were washed with 1 ml 70% 
ethanol. After mixing by inversion, samples were centrifuged at 4°C, 14000 rpm, 5 min, and 
ChIP DNA samples were resuspended in 50 µl of water. 
9.5. Quantitative PCR of ChIP DNA samples 
1 µl of ChIP DNA sample was mixed with 5 µl SYBR Green (Fast Start Universal SYBR Green 
Master, Roche, cat# 04913850001), 2 µl PCR primer pool (2.5 pmol/µl per primer) and 2 µl H2O 
(10 µl total reaction). Reactions were run in triplicate and samples were amplified using the 
standard SYBR Green program with an initial melt stage at 95°C for 10 min, followed by at least 
40 cycles of 95°C for 20sec, 60°C for 30 sec and 72°C for 1 min. The run was finished by a melt 
curve from 95°C to 60°C to ensure PCR product purity. 
10. Yeast two-hybrid system 
The CytoTrap system uses the yeast S. cerevisiae mutant strain cdc25H which is temperature-
sensitive; the cells can grow at 25°C, but not at 37°C unless rescued with a protein-protein 
interaction. The human homolog of Cdc25 is hSOS gene, encoding a guanyl nucleotide exchange 
factor that binds RAS. Expression of hSOS and its subsequent localization to the plasma 
membrane occurs through the interaction of two-hybrid proteins and allows the cdc25H yeast 
strain to grow at 37°C by activating the yeast Ras-signaling pathway (Fig. 10). 
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The products used were: CytoTrap™ XR Library Construction Kit (Agilent, cat# 200444); 
CytoTrap™ Vector Kit, containing pSos bait vector and pMyr vector (Agilent, cat# 217438); 
cdc25H yeast strain (Agilent, cat# 217437).  
 
 
Figure 10: Yeast two-hybrid system workflow summarized in 8 steps 
46 
 
10.1. cDNA library screening 
10.1.1. Choice of the cDNA library (cloned in pMyr plasmid) 
To find protein partners of IRX5 during embryogenesis, the mouse embryo cDNA library 
(Agilent, cat# 975316) prepared from 40-pooled embryos at E9.5 was used. At this stage of 
development IRX5 is highly expressed in different embryonic tissues such as brain, spinal cord, 
branchial arches and limb buds. Mouse cDNAs (about 1.1 kb length) were cloned in the pMyr 
vector encoding target proteins with a myristylation membrane localization signal (Myr) in 5’. 
The GAL1 promoter, driving expression of the Myr-target fusion proteins, was induced by adding 
galactose to the growth medium (Fig. 11). 
10.1.2. Cloning of mIrx5 (the bait) in pSos plasmid 
mIrx5 gene was cloned in the pSos vector encoding a fusion protein of human hSOS in 5’ and the 
IRX5 bait protein. The ADH1 promoter, driving expression of the hSOS-bait fusion protein, was 
constitutively active (Fig. 11). 
 
Figure 11: pMyr and pSos vector maps 
pMyr contains DNA encoding the myristylation membrane localization signal (Myr) followed by Multiple 
Cloning Site (MCS), the pUC and 2μ origins for replication in E. coli and yeast, respectively. It also carries 
the yeast biosynthetic gene URA3, for selection of yeast transformants based on nutritional requirements, 
and the chloramphenicol-resistance gene (Cam) for selection in E. coli. pSos contains DNA encoding the 
human hSOS followed by MCS, the pUC and 2μ origins. It also carries the yeast biosynthetic gene LEU2, 
for selection of yeast transformants based on nutritional requirements, and the ampicilin-resistance gene 
(Amp) for selection in E. coli.  
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First, mIrx5 was amplified by PCR (Appendix 1), then digested with SalI / MulI restriction 
enzymes and finally inserted in pSos vector by ligation, in the same reading frame as the hSOS 
protein. Sequencing was performed to verify that mIrx5 was in frame with hSOS, and that no 
mutations which could affect stability or binding of the hSOS-bait protein were randomly 
included. After transfection of 293T cells with pSos-mIrx5 vector, protein level of mIRX5 was 
high enough to be detected by western blot using the anti-mIRX5 antibody (Sigma, cat# 
WH0010265M1), validating our cloning. 
Co-transformation of the yeast mutant strain cdc25H with both vectors (pMyr and pSos) should 
allow physical interaction between Myr-target proteins that are anchored in the yeast membrane 
and hSOS-mIRX5. The hSOS protein being recruited to the membrane, the activation of the Ras-
signaling pathway allows the mutant strain to grow at 37°C. 
10.1.3. Competent yeast cell preparation 
Yeast cells (stored in glycerol at -80˚C) were streak on a rich YPDA medium plate (28 g of YPD 
Agar with adenine hemisulfate (Clontech, cat# 630465); 400 ml dH2O) and incubated overnight 
at 24˚C. Because the temperature-sensitive growth phenotype of the mutated yeast strain could be 
reverted over time, yeast cells were also incubated on YPDA plate at 37ºC. No cell growth was 
observed, suggesting that the yeast strain did not contain revertants. 
The day after, cells were resuspended in 40 ml of liquid rich YPDA medium (20 g of YPDA 
medium with adenine hemisulfate (Clontech, cat# 630464); 400 ml dH2O) and incubated 3 to 4 
hours at 24˚C (shaking) until OD595 = 0.5. After splitting the cells in two falcon tubes, they were 
spun down at 600 g, 5 min. The pellets were gently washed with 20 ml of water, and spun down 
at 600 g, 5 min. The pellets were resuspended in 1 ml of water and cells were transferred into 2 
ml eppendorf tubes. After spin down at 600 g, 5 min, cells were washed with 1 ml of LiAc/TE 
(100 μl 10X LiAc; 100μl 10X TE; 800 μl dH2O) and the two tubes were pooled into one tube. 
After spin down at 600 g, 5 min, pellet was resuspended in LiAc/TE.  
48 
 
10.1.4. LiAc co-transformation of yeast S. cerevisiae with pMyr and pSos 
5 µg pSos-mIrx5 + 10 µg of cDNA library + 2 µl of DNA carrier (2 min at 100ºC) was added to 
100 µl of competent yeast cells. After 10 min of incubation at room temperature, 240 μl of 
PEG/LiAc/TE (192 µl PEG; 24 µl LiAc; 24 µl TE) were added and gently mixed. After 45 min of 
incubation, 43 µl of DMSO was added to the cells and kept at 42°C, 5 min.  After spin down at 
600 g, 5 min, cells were washed with 1 ml of water. After spin down at 600 g, 5 min, cells were 
resuspended in 150 µl of water and plated on 15 cm agar glucose plate (18.7 g  min SD agar 
Glucose (Clontech, cat# 430412); 400 μl Histidin (20 mg/ml); 0.26 g -His-Leu-Ura DO 
supplement (Clontech, cat# 630423); 400 ml dH2O). The inverted plates were incubated under 
non-selective conditions at 24°C to control that transformation was successful. After 2 days of 
growth, the screening plates were replica plated onto galactose plate (21.6 g min SD agar 
Base/Gal/Ra (Clontech, cat# 430421); 400 μl Histidin (20 mg/ml); 0.26 g -His-Leu-Ura DO 
supplement; 400 ml dH2O) and incubated at 37°C for 4-5 days until colonies were visible. Clones 
that exhibit galactose-dependent growth at 37°C were picked up and resuspended in 0.5 ml of TE 
for pMyr plasmid extraction. 
10.2. Isolation of pMyr-target cDNA plasmids from yeast cells 
From each positive interaction clone selected, pMyr yeast plasmids were extracted from yeast 
cells. After recovering yeast cells in 0.5 ml of TE, cells were spun down at 4˚C, 600 g, 5 min. 
Pellets were resuspended in 100 μl of Buffer I + 2 μl Lyticase (Sigma, cat# L2524) + 1 μl β-
mercaptoethanol, and incubated for 3-4 hours at 37˚C. Cell lysates were spun down at room 
temperature, 600 g, 5 min, and pellets were resuspended in 100 μl of Buffer II + 10 μl SDS (10%) 
+ 2 μl Proteinase K (20mg/ml). After 30 min of incubation at 65˚C, tubes were placed 10 min in 
ice, and 10 μl of NaAc (3M) was added. Tubes were kept on ice for 30 min. Cell debris were 
spun down at 4˚C, max speed, 15 min, and supernatant containing DNAs was collected for each 
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tube. An equal volume of isopropanol was added, and precipitated DNAs were spun down at 
room temperature, max speed, 10 min. Pellets were washed with 70% ethanol and spun down at 
room temperature, max speed, 10 min. Finally, dry pellets were dissolved in 10 μl of dH2O.  
In order to identify the candidate cDNA cloned into pMyr, plasmids were amplified using 
bacteria transformation and selection with chloramphenicol. Therefore, 2 µl of resuspended 
DNAs were used for XL Blue E.coli electroporation (50 µl). Transformed bacteria were plated on 
LB-chloramphenicol (170 µg) agar plates, and incubated at 37˚C overnight.  
Growing clones were collected. pMyr plasmids were extracted after mini-prep., and sequenced to 
identify the cDNA cloned. 
10.3. Verification of interaction between mIRX5 and each candidate target 
To verify the specificity of the interaction between the bait and target proteins, the isolated pMyr 
plasmids were used to co-transform cdc25H cells with either the original bait (pSos-mIrx5) or 
irrelevant bait such as empty vector pSos (pSos-empty). The co-transformed yeasts were 
therefore assayed for their ability to grow at 37°C on galactose agar plates. 
Preparation and transformation of the yeast competent cells were performed in the same way as it 
was previously described in previous paragraph. 
The yeast cells were co-transformed only with 500 ng pSos-mIrx5 + 500 ng of candidate pMyr 
plasmid. As a negative control, empty pSos was concurrently transformed with each candidate 
pMyr. Each transformation was first plated on agar glucose plates incubated at room temperature 
(22-25°C) until colonies were visible (4-6 days). At this temperature, the mutated yeast strain 
should grow, and expression of the pMyr fusion protein should be repressed by the presence of 
glucose in the medium. The transformants that grew on agar glucose plates were patched on 4 
different plates: 1) glucose at 25ºC, 2) glucose at 37ºC, 3) galactose at 25ºC, 4) galactose at 37ºC. 
All of them were incubated for a minimum of 4 days. The growth phenotype of the co-
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transformants was evaluated, and only the clones transformed with pSos-mIrx5 which were 
present in galactose plate at 37ºC were selected as positive candidates. 
 
 Glucose Galactose 
Yeast transformation 1) 25ºC 2) 37ºC 3) 25ºC 4) 37ºC 
pSos-mIrx5 
+ pMyr putative candidate + - + + 
pSos-empty 
+ pMyr putative candidate + - + - 
 
 
11. Statistical analysis  
Statistical tests used are described in the individual figure legends. Excel software was used for 
calculations and graphing. The significance of pairwise comparisons was always determined by 




Chapter 3 Results and discussion  
This chapter, divided in 5 main parts, describes published and unpublished data. 
1. Genetic etiology of Hamamy syndrome (HMMS) 
Hamamy syndrome encompassed a wide range of clinical features that were also found in other 
dysmorphic syndromes. Telecanthus seen in HMMS recalled Craniofrontonasal, Donnai Barrow 
and Oculodentodigital Dysplasia syndromes caused by EFNB1 (Wieland et al., 2004), LRP2 
(Kantarci et al., 2007) and GJA1 (Paznekas et al., 2003) respectively. The ear anomalies and 
dysplasia of the lacrimal-salivary apparatus in HMMS patients were reminiscent of impaired 
FGF10 signaling which was disrupted in Lacrimoauriculodentodigital syndrome (Rohmann et al., 
2006). We also found discrete clinical features overlapping with Trichorhinophalangeal Type 1 
Syndrome (Ludecke et al., 2001) and Hypoparathyroidism Sensorineural Deafness and Renal 
Disease (HDR; MIM131320), caused by mutations in TRPS1 (Momeni et al., 2000) and GATA3 
(Van Esch et al., 2000) respectively. Prof. Hamamy also referred to similarity with other 
syndromes in her paper (Hamamy et al., 2007b) which reads: “Additional rare syndromes to be 
considered nosologically include Naguib-Richieri-Costa syndrome [Richieri-Costa et al., 1989; 
Teebi, 1992], Baraitser-Winter syndrome [Rossi et al., 2003], Lenz-Majewski hyperostotic 
dwarfism [Majewski, 2000], and a small number of chromosomal syndromes”. However, none of 
these aforementioned disorders had craniofacial dysmorphisms, myopia, and deafness, together 
with osteopenia and bone fragility, which supported our hypothesis that HMMS was a novel 






1.1. Comprehensive clinical description of HMMS diagnosed in five probands 
1.1.1. Symptom description of HMMS in 3 Jordanian siblings 
In recognition to Prof. Hamamy clinical insights and extensive contribution in human genetics, 
we named this disorder as Hamamy syndrome or HMMS. This syndrome was recently referenced 
in the Online Mendelian Inheritance in Man (OMIM) catalog with the accession number 611174. 
Besides cranio-fronto-nasal anomalies and severe bone fragility described in Chapter 1 and 
illustrated in figures 7 and 8 respectively, hypoplasia of the lacrimal-salivary apparatus was 
ascertained. During eye examination, Dr. Osama Ababneh observed the absence of lacrimal 
punctum and epiphora in all Jordanian patients (Fig. 12a). Further tests were therefore requested 
to examine the lacrimal drainage system. Dacryoscintillography (DSG) showed tears flowing 
over both cheeks in patient 2 (Fig. 12b). Scan of technetium pertechnetate in patient 2 also 
showed a decreased activity in the sub-mandibular and parotid glands compared to thyroid glands 
(Fig. 12c). On the contrary, normal distribution of technetium in nasal mucosa, salivary and 
thyroid glands were observed in patient 1 (Fig. 12c). MRI scans illustrated that both lacrimal sacs 
and parotid glands were present (Fig. 12d,e) but lacrimal glands were absent (Fig. 12f). 
Therefore, malfunction of the lacrimal-salivary apparatus may be caused by either hypoplasia of 








Figure 12: Dysplasia of the lacrimal-salivary apparatus observed in HMMS patients 
(a) Eye picture of a HMMS patient illustrating agenesis of lacrimal punctuae (red arrowhead). (b) 
Dacryoscintillography (DSG) in patient 2 shows tear flowing over left lateral cheek (red arrowhead). (c) 
Scan of technetium pertechnetate shows normal distribution of technetium in nasal mucosa (nm), salivary 
glands (sg), thyroid gland (tg) in patient 1 compared to patient 2 who shows decreased activity in nasal 
ducts, submandibular and parotid glands. (d-f) Patient 2 coronal MRI T2 sequence shows both lacrimal 
sacs (not seen on DSG) with left sac dilated (d, red arrowhead), symmetrical and normal size parotid glands 
(e, red arrowheads) and absence of both lacrimal glands (f, red arrowheads). DSG and MRI were performed 







1.1.2. A second family from Turkey diagnosed with the same disorder 
A year after Prof. Hamamy’s publication (Hamamy et al., 2007b), two Turkish brothers, born to a 
first degree cousin marriage (Fig. 13a), were diagnosed by Prof. Kayserili (Medical Genetics 
Department, Istanbul University, Turkey) with similar symptoms as the Jordanian propositi. They 
also displayed severe telecanthus, sparse lateral eyebrows, severe myopia, broad nasal bridge 
with pointed nasal tips and anteverted nostrils, smooth and long philtrum, large mouth with 
downturned corners and thin upper lip, high arched palate, protruding and malformed ears (Fig. 
13b,c). They were mentally retarded and displayed sensorineural hearing impairment. As 
Jordanian cases, they had multiple long bone fractures caused by bone fragility, loss of lamina 
dura and digit malformations (Fig. 13d,e). Naso-lacrimal anomalies and heart defects were also 





Figure 13: Craniofacial anomalies and bone fragility in Turkish probands with HMMS 
(a) Pedigree of the inbred family from Turkey. Males and females are represented by squares and circles 
respectively. Filled black symbols signify affected individuals (4,5). Crossed symbols indicate individual 
deceased. Small black circle means miscarriage (sex unspecified). SB, stillborn (b,c) Full face pictures of 
affected patients at different ages, with common craniofacial dysmorphisms including midface prominence, 
sparse lateral eyebrows, severe telecanthus, anteverted nostrils, pointed nasal tip, flat philtrum, thin upper 
vermillion border and protruding ears. (d) Femora radiograph of patient 5 showing multiple fractures and 
corrective osteotomy. (e) Image of patient 5’s hands reveals tapering fingers and syndactyly (green 
arrowhead). The pedigree, pictures and X-ray were provided by Prof. Kayserili. Participants gave consent 




Some inter-familial phenotypic variations were however observed as, for instance, 
craniosynostosis which was seen in the Jordanian family but not in the Turkish proband. 
Moreover, long bone fragility of the Turkish patient may be due to osteosclerosis rather than 
osteopenia as his bone age and bone parameters were in normal limits (Z score was 2.5 at the age 
of 2 and 4.5 at the age of 5) compared to that of the Jordanian probands. 
Although a few clinical discrepancies were noted between these two families, they did not appear 
significant as phenoytpic variability was also observed within a pedigree. For instance, in the 
Turkish family, patient 4 had total AV canal whereas his brother (patient 5) only displayed 
intraventricular conduction delay. Parotid glands did not function in patient 1 but seemed to work 
in patient 2 of the Jordanian family.  
To conclude, inter- and intra-phenotypic variations being a well-documented and accepted 
phenomenon for dysmorphic syndromes, we hypothesized that both families shared the same 
syndrome which bears a wide range of clinical symptoms detailed in Table 1.  
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Gender M M F M M
Patient number (refer to pedigrees) 1 2 3 4 5
Craniofacial dysmorphisms
Craniosynostosis + + + - - 
Brachycephaly + + + + + 
Bulging midface + + + - - 
Laterally sparse eyebrow s + + + + + + 
Severe telecanthus / hypertelorism + + + + + 
Severe progressive myopia + + - n.d. + 
Absence / dysfunction of nasolacrimal structures + + + n.d. + 
Dysfunction of parotid glands - + n.d. n.d. - 
Broad nasal bridge / pointed nasal tips / anteverted nostrils + + + + + 
High arched palate + + + + + + 
Smooth / long philtrum + + + + + + 
Thin upper vermillion border / w ide mouth + + + + + + 
Loss of lamina dura + + n.d. n.d. + 
Thin enamel / enamel hypoplasia + + n.d. n.d. + + 
Worn out teeth / malocclusion / hypodontia n.d. n.d. n.d. n.d. + + 
Low -set / ear abnormalities + + + + + + 
Bilateral preauricular tags - - - - + 
Sensori neural hearing impairment + + + n.d. + +
Mild micrognathia + + + - - +
Low  posterior hair line / extra frontal hair w horl + + + + + 
Bone / skeletal abnormalities
Generalized osteopenia + + + n.d. - + 
Long bone fractures + + + n.d. + 
Hip dysplasia + + + n.d. + + 
Pectus excavatum - + n.d. n.d. -
Pterygium colli / slopping shoulder + + + + -
Syndactyly / tapering f ingers / long toes / 5th f inger clinodactyly - - - + +
Thumb deviation / ectopic f inger creases / long f ingers / short index + + + n.d. +
Heart defects 
Tiny patent ductus arteriosus + - - n.d. -
Mild mitral regurgitation - + - n.d. -
Atrial septal defect - - + n.d. -
Intraventricular conduction delay + + + n.d. +
Total A-V canal - - - + -
Other clinical manifestations
Inguinal hernia + + - + +
Hypoparathyroidism - - n.d. n.d. + +
Cryptorchidism and absence of gonad activity + + n.d. + +
Microcytic hypochromic anemia + + + n.d. +
Sw allow ing diff iculties n.d. n.d. n.d. n.d. +
Moderate psychomotor retardation + + + n.d. + +







Table 1: Detailed description of clinical manifestations in five HMMS patients and overlapping 
phenotypes with TRPS1 and HDR syndromes 
n.d., not determined; +, affirmative; -, negative; M, Male; F, Female 
58 
 
1.2. Mapping and locus re-sequencing indentify responsible gene for HMMS 
1.2.1. Genotyping and homozygosity mapping of the Jordanian family 
Karyotype and FISH (Fluorescent In Situ Hybridization) analysis performed on the Jordanian 
samples ruled out chromosomal anomaly or subtelomeric rearrangements (Hamamy et al., 
2007b). All cases, males and female, were born to consanguineous unaffected parents making 
autosomal recessive inheritance the most likely mode of transmission. Homozygosity mapping 
was therefore the most powerful method to find the causative allele for this disease. 
After informed consent, saliva samples from 17 family members of the Jordanian family (Fig. 7a) 
were collected with Oragene DNA self-collection kits comprising: 
- four children (patients 1, 2, 3 and their unaffected sister sample 2’). 
- father and mother (samples 5’ and 12) 
- six siblings of the father (samples 6 to 11) 
- two siblings of the mother (samples 13 and 14) 
- three grand-parents (samples 15, 16 and 17). 
Genomic DNA (gDNA) was extracted from each saliva sample using Puregene DNA Purification 
Kit (Gentra Systems). Purity and quality of each gDNA were examined and found to be suitable 
for genotyping processing. 
With the exception of the three grand-parents, all gDNA samples were genotyped on the Illumina 
Infinium HD Human 1M-Duo BeadChips at the Genome Institute of Singapore. Genotypes were 
called using Illumina BeadStudio software. The final call rate was superior to 98% for each 




Deletion or supernumerary copies of a gene may contribute to the etiology of this new syndrome. 
To test this, Dr. Barry Merriman (Geffen School of Medicine, University of California, Los 
Angeles) examined the density of Mendelian genotype errors throughout the genome and 
analyzed the signal intensity of each SNP probe present in the Illumina Infinium array. No 
deletion bigger than 10 SNPs or 30 kb was detected and no Copy Number Variation (CNV) was 
found to segregate with the disease. 
Autozygosity mapping identified many large homozygous regions found on autosomal 
chromosomes, confirming consanguinity (Fig. 14a), as well as shared identical regions (Fig. 14b). 
Candidate homozygous regions common with any unaffected family member were excluded. As 
a result, four candidate Identical-By-Descent (IBD) regions were delineated as being identical 
and homozygous in all three affected Jordanian individuals and heterozygous in unaffected 
parents, sister, uncles and aunts (Fig. 14c).  
The 4 IBD loci totaling 23 Mb or 37 cM containing 157 genes (Appendix 2) were as follow: 
- 16q12.2-q21   (~9.2 Mb) 
- 16p13.2-p13.12  (~3.5 Mb) 
- 7p15.1-p14.1  (~8.2 Mb) 
- 18q23   (~2.2 Mb) 
HMMS could be caused either by point mutation or deletion or insertion or duplication in the 
coding region of one of these 157 genes, or in regulatory sequences present within these 4 loci. 





Figure 14: Homozygosity mapping of the 3 Jordanian patients identifies 4 IBD regions 
(a) Homozygous blocks were found across all the autosomal chromosomes. Their position on each 
chromosome (from 1 to 22) is represented on the “x” axis while their size is given in centimorgan (cM) on 
the “y” axis. Are highlighted in red all the homozygous regions found on chromosome 16 (Chr. 16). (b) 
From the 3 pair-wise comparisons, identical regions were also found across all the autosomal 
chromosomes. Are highlighted in red all the identical regions found on Chr. 16. (c) Only 4 loci are 
homozygous and identical in all three affected individuals. Are highlighted in red the two IBD blocks found 
on Chr. 16. Mapping graphs were generated by Dr. Merriman (2009). 
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1.2.2. A total of 157 genes are re-sequenced by capture array 
All the exonic and regulatory regions of the 157 genes (Appendix 2) mapped in the Jordanian 
family were pulled-down on a custom Agilent 244K array since the mapping results of the 
Turkish kindred were unknown at this time. A DNA library from patient 1 was prepared and 
hybridized to the array. After washing, elution and amplification, the sample was sequenced using 
high-throughput Illumina Solexa platform.  
While sequencing of the 157 genes was being completed, homozygosity mapping of the Turkish 
family was released (Appendix 3). Sample collection of the affected boy (patient 5), unaffected 
parents and sibling, gDNA extraction and genotyping were processed by the Gene Mapping 
Laboratory of Hacettepe University Medical Faculty in Turkey. Assuming a common etiology in 
both families, the two sets of mapping data were cross referenced. A single common denominator 
of 9.2 Mb was delineated on chromosome 16q12.2-q21, between genomic coordinates 52,812,847 
and 61,978,673 and comprising 73 candidate genes.  
This common IBD region contained about 730 targeted contigs (encompassing 208,042 bp) and 
206 mismatches were found when aligned to the human reference genome (Fig. 15). Genome 
position and sequencing coverage for each mismatch were detailed in Appendix 4. Out of 206, 
only 36 polymorphisms were novel (not in dbSNP129) and homozygous (highlighted in grey in 
Appendix 4). Finally, using SeqWare tools and the "knownGene" gene model from the UCSC 




Figure 15: Sequencing workflow and number of mismatches found following loci-capturing and re-
sequencing of the genomic candidate region 16q12.2-q21 
Detail of the 206 mismatches is provided in Appendix 4. 
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Out of 4 mismatches, two distinct base insertions, causing frameshifts (early-termination), were 
found at different positions in the KATNB1 gene which encodes the protein KATANIN p80.  
Gene_Abbreviation UCSC_Gene Mutation_Position Mutation Codon_Change AA_Change
KATNB1 uc002eml.1 chr16:56333218-56333219 INS:-->A  (230:23:10.0%[F:13:5.7%|R:10:4.3%]) NA->NA NA
KATNB1 uc002eml.1 chr16:56344571-56344572 INS:-->G  (208:28:13.5%[F:2:1.0%|R:26:12.5%]) NA->NA NA  
KATNB1 was excluded as a candidate gene because the reported mutations could not be 
confirmed by traditional sequencing in either family members. 
 
A non-synonymous mutation in the SLC12A3 gene coding for a sodium-chloride co-transporter 
was also uncovered.  
Gene_Abbreviation UCSC_Gene Mutation_Position Mutation Codon_Change AA_Change
SLC12A3 uc010ccm.1 chr16:55456728-55456729 C->G  (162:134:82.7%[F:109:67.3%|R:25:15.4%]) AGC->AGG S->R  
Mutations in the SLC12A3 gene cause Gitelman syndrome (MIM263800) which did not share 
overlapping clinical features with HMMS (Mastroianni et al., 1996). Moreover, although the 
mutation was found homozygous in all affected and heterozygous in unaffected individuals, the 
missense amino acid change took place in a residue that was not conserved through evolution. 
The SLC12A3 gene was therefore excluded. 
 
Finally, a one base pair variation c.498C>A, causing a non-synonymous mutation, was identified 
in exon 2 of IRX5 (NM_005853.5), a member of the Iroquois homeobox gene family (Gomez-
Skarmeta and Modolell, 2002; McNeill et al., 1997). This IRX5 variant led to the amino-acid 
change p.Asn166Lys or N166K (Fig. 16). 
Gene_Abbreviation UCSC_Gene Mutation_Position Mutation Codon_Change AA_Change









Figure 16: One base pair change is detected in IRX5 using capture array re-sequencing 
Homozygosity mapping delineated a single candidate locus encompassing 73 genes on chromosome 
16q12.2-q21. Massive parallel re-sequencing in patient 1 identified a single biallelic base pair change 
c.[498C>A];[498C>A] in the IRX5 gene resulting in a missense mutation p.[Asn166Lys];[Asn166Lys] in 





1.2.3. IRX5 is found to be independently mutated in both families 
By traditional Sanger sequencing, exon 2 of IRX5 was re-analysed using the PCR primers given 
in Appendix 1. 
The non-synonymous mutation c.498C>A in IRX5 gene was confirmed in the three affected 
Jordanian patients by Sanger sequencing (Fig. 17a). According to the autosomal recessive mode 
of inheritance of the causative allele, both parents and the unaffected sister were found to be 
heterozygous or non-carriers (Fig. 17a).  
In the Turkish family, a distinct mutation c.448G>C segregating with the disease was also 
identified in the IRX5 gene. Both parents were heterozygous whereas the unaffected sibling was 
found to be non-carrier for this private mutation (Fig. 17b). This IRX5 variant led to the amino-













Figure 17: Two novel independent homozygous mutations in IRX5 gene are verified by traditional 
sequencing in both families. 
(a) Sequence chromatograms of the Jordanian parents (carriers), the un-affected sibling (carrier), and the 
three affected cases (mutants) showing c.498C>A missense mutation in heterozygous and homozygous 
state, respectively. The red arrow represents the position of the mutation (heterozygous state). (b) Sequence 
chromatograms of Turkish parents (carriers), the un-affected sibling (wild type), and the affected case 
(mutant) showing c.448G>C missense mutation in heterozygous and homozygous state, respectively. The 






Iroquois (Iro/Irx) genes were initially discovered during mutagenesis experiments in Drosophila 
(Dambly-Chaudiere and Leyns, 1992; Gomez-Skarmeta et al., 1996; Gomez-Skarmeta and 
Modolell, 1996). Mutations in Iroquois locus induced loss of sensory bristles, leaving only two 
stripes on each side of the notum, which evoked the hair style of the native American Indian tribe 
the Iroquois. 
Iroquois genes are found from nematodes to humans. Whereas in Caenorhabditis elegans there is 
only one Iroquois gene irx-1, in Drosophila there are three (Ara, Caup and Mirr) (Gomez-
Skarmeta et al., 1996; Kehl et al., 1998). Most vertebrates contain six Irx genes, except in 
zebrafish genome where eleven Irx genes were identified (Dildrop and Ruther, 2004; Feijoo et al., 
2004).  
The six genes are grouped in 2 paralog clusters of three genes each. The IrxA cluster contains 
Irx1, Irx2 and Irx4 (Chr. 13 in mouse; Chr. 15 in human) while the IrxB cluster contains Irx3, 
Irx5 and Irx6 (Chr. 8 in mouse; Chr. 16 in human). These two clusters are the result of a 
segmental or chromosomal duplication of a single ancestral cluster, as the IRX1, IRX2, and IRX4 
proteins are clear paralogs of IRX3, IRX5, and IRX6, respectively (Peters et al., 2000).  
By amino-acid alignment of IRX5 proteins found in annelids, insects, amphibians, fishes and 
mammals, I found that each mutated residue resides in the highly conserved homeodomain (HD) 
region of the protein IRX5 whose sequence was invariable (Fig. 18a). The HD was also highly 
conserved in proteins encoded by the duplicated genes of IRX5 namely IRX1, IRX2, IRX3, IRX4 
and IRX6 (Fig. 18b), suggesting that alteration of any of these two amino-acids may have a strong 








Figure 18: Both mutated amino-acids reside in the highly conserved IRX5 homeodomain 
(a) Human IRX5 bears two conserved regions, a TALE super class homeodomain (HD) and an Irobox 
(Ibo). The three dimensional structure of the HD shows helix turn helix motif. The p.Ala150Pro and 
p.Asn166Lys missense mutants map to the IRX5 HD helix 2 and helix 3 respectively. These two residues 
are invariant in all vertebrate and invertebrate IRX5 homologs. (b) Amino-acid alignment of the 
homeodomain of all human IRX paralogs shows total conservation for both residues mutated (p.Ala150Pro 
and p.Asn166Lys). The amino-acid sequences were retrieved from http://www.ncbi.nlm.nih.gov/protein/ 





Using homozygosity mapping and capture array re-sequencing, two independent mutations were 
found in the highly conserved homeodomain (HD) of the IRX5 transcription factor that cause a 
rare congenital disorder affecting the ontogeny of multiple organs during embryogenesis and 
postnatal homeostasis. 
IRX5 plays multiple roles during pattern formation of invertebrate and vertebrate embryos 
(Cavodeassi et al., 2001). Therefore, the next step was to understand how alteration of amino-
acids that are invariant in all IRX homologs may affect IRX5 expression, stability and function. 
Biochemical experiments and disease modeling in animals such as mouse and Xenopus were 
undertaken to investigate the role of IRX5 during embryogenesis, and to understand how the 
mutations found in its HD can account for the pathogenesis of the disease observed at birth and 
during childhood in humans. 
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2. Irx5 expression during embryogenesis and effects of mutation on IRX5 function 
After isolating the causative gene for HMMS syndrome, the next step was to analyze the 
spatiotemporal expression pattern of Irx5 in developing embryos in order to understand when and 
where this gene may play role during embryogenesis. In vivo and in vitro experiments also helped 
document its function during blood, heart and craniofacial morphogenesis. 
2.1. Developmental expression pattern of Irx5 in mouse embryos 
In mouse, Irx5 expression was first documented by Bosse and Houweling (Bosse et al., 2000; 
Houweling et al., 2001). By whole embryo in situ hybridization, Irx5 expression was confirmed at 
different stages of mouse development. While Irx1-3-4 genes started to be expressed from E6.5, 
Irx5 was first detected at E8.0 in the neural epithelium of the head-fold and in the lateral plate 
mesoderm lining the coelomic cavity (Fig. 19a). From E9 onwards, Irx5 was expressed during the 
nervous system development, especially in the dorso-lateral region of the mesencephalon 
(midbrain) and ventro-lateral region of the metencephalon (anterior part of hindbrain) and along 
the entire spinal cord excluding the floor and roof plates of the neural tube (Fig. 19b,c,e). At 
E13.5, Irx5 was expressed within the thalamus region, in the motor neurons and notochord 
(Houweling et al., 2001). Irx5 expression was found in the medial region of the otic vesicle and in 
discrete area of the neural retina where all the other Irx genes were also expressed (Bosse et al., 
2000). Irx5 transcripts were also found at the tip of developing external ears (Fig. 19f). 
Expression of Irx5 was detected as well in the developing teeth, in the nasal cap cartilage and 
weakly in the epidermis, dermis and epidermis derived vibrissae (Houweling et al., 2001) (Fig. 
19f). Discrete regions in ectoderm of the first brachial arch and frontonasal prominence strongly 
expressed Irx5 especially at E10.5 of development (Fig. 19c). Irx5 was also confirmed at E10.5 in 
the mesenchyme of the anterior proximal region of the limb bud (Fig. 19c,d) followed by 
interdigital mesenchyme expression from E13.5 onwards (Houweling et al., 2001; McDonald et 
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al., 2010). Irx5 was shown to be highly expressed in skull bone compare to limb bone (Rawlinson 
et al., 2009).  
At E11.5 and E13.5, Irx5 expression was restricted to the endoderm of the groove, foregut, the 
outer curvature of the stomach and the epithelial layer of the lung buds and bronchia. Excluding 
Irx3 that was strongly expressed in the gonads, only Irx5 was weakly detected. Irx5 was also 
expressed in mammary gland primordia (Houweling et al., 2001).  
Primary detection of Irx5 transcripts in the heart field could be detected at E12 (Fig. 19d). After 
14 days of development Irx5 was predominantly distributed throughout the interventricular 
septum and the endocardial layer that lines the atrial and ventricular chambers (Christoffels et al., 
2000; Mummenhoff et al., 2001). An expression gradient of Irx5 was shown to control the cardiac 
repolarization gradient (Costantini et al., 2005).  
To conclude it is important to note that Irx3, which is part of the IrxB cluster, was co-expressed 
with Irx5 in most of the tissues of mouse embryos. The other Irx genes were also co-expressed 
with Irx5 but to a much lesser extent (Houweling et al., 2001). In other organisms analyzed, the 
Irx3/Irx5 and Irx1/Irx2 pairs also shared similar expression patterns, while Irx4 and Irx6 were 
more divergent (Alarcon et al., 2008; Wang et al., 2001). On the other hand, in some tissues, all 
the genes of one or both clusters were identically expressed. Divergent or overlapping Irx 
expression patterns among embryonic tissues were explained by the presence of large intergenic 
regions containing cis-regulatory elements (or enhancers) between each Irx gene, acting on the 
entire set of Irx genes in a cluster or on all the Irx genes present in both clusters (Tena et al., 
2011). These regulatory elements were conserved throughout evolution since homologous Irx 
genes shared expression pattern among different vertebrate species (de la Calle-Mustienes et al., 




Figure 19: Irx5 gene expression pattern during mouse development analyzed by WISH 
(a) At E8, Irx5 transcripts are detected in the neural epithelium and in the lateral plate mesoderm lining the 
coelomic cavity. (b) At E9, Irx5 is expressed in the midbrain, hindbrain, along the spinal cord, in the first 
branchial arch and foregut. (c)  Expression of Irx5 is seen in discrete regions of the first branchial arches, 
frontonasal processes and dorsal part of the optic cups at E10.5. Irx5 is also expressed in brain, spinal cord 
and proximal region of the limb buds. (d) At E12, Irx5 transcripts are seen in frontonasal prominences, 
around otic vesicles, proximal part of limb buds and heart field. (e) Section of embryo head at E14.5 
allowed us to observe Irx5 expression in the ventral part of the neural tube (red arrowhead) but not in the 
floor plate. (f) Irx5 is also expressed at the tip of developing ears and epidermis derived vibrissae (red 
arrowheads) at E14.5. 
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2.2. Irx5 expression pattern during embryogenesis in Xenopus 
Irx5 expression was described in developing eyes, brain and spinal cord in Xenopus (Garriock et 
al., 2001). Frog being the main animal model used in our lab, expression pattern of Irx5 was 
examined at different stages of development. At closure of the neural tube, Irx5 was firstly 
expressed in the midbrain and hindbrain (Fig. 20a). Its expression in the neuroepithelium was 
expanded to the spinal cord and eye vesicles from stage 24, followed by expression in retinas and 
otic vesicles at stage 28 (Fig. 20b-d). From stage 32 onwards, Irx5 expression was also found in 
pharyngeal pouches and otic vesicles (Fig. 20e-g). Although Irx5 should be expressed in the heart 
field, transcripts were not detected until late stage of Xenopus development, suggesting that Irx5 
was maybe too weakly or too discretely expressed to be visible by the whole embryo in situ 
hybridization technique. Hybridization on section of embryos or immunostaining may be more 
adequate methods to detect its expression. 
To conclude, most of the embryonic tissues that displayed abnormal development in patients with 
HMMS expressed Irx5 in mouse and Xenopus embryos. Observing similar expression patterns in 
these two animal models indicated high evolutionary pressure to maintain precise spatiotemporal 
role of IRX5 during vertebrate development. Therefore, we can speculate that IRX5 is also 
expressed during central nervous system, face, brain, eye, ear, heart and limb development in 
humans. Therefore, to gain further insights into the role of IRX5 on the ontogeny of these organs, 









Figure 20: Irx5 gene expression pattern during Xenopus development analyzed by WISH 
(a-c) From stage 20 to stage 24, Irx5 transcripts are mainly detected in the midbrain, hindbrain and anterior 
part of the spinal cord. At stage 24, Irx5 starts to be detected in the eye vesicles. (d) Irx5 is highly 
expressed in the eye vesicles, midbrain, hindbrain and along the spinal cord at stage 26. (e-g) Besides the 
nervous system and eyes, Irx5 expression is seen in pharyngeal pouches and otic vesicles from stage 32 up 
to stage 37. Xenopus embryo is cleared in benzyl alcohol/benzyl benzoate in panel d. 
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2.3. Irx5 knock-down (KD) in Xenopus partially phenocopies human disease 
For over 10 years, the role played by Irx5 has been mainly addressed in mice. First discovered in 
2000 (Bosse et al., 2000), its role was examined during heart patterning (Christoffels et al., 2000) 
and neurogenesis (Cohen et al., 2000). Irx5 was required for retinal cone bipolar cell development 
(Cheng et al., 2005) and established the cardiac ventricular repolarization gradient in mice 
(Costantini et al., 2005; He et al., 2009). The mild phenotypic defects in eyes and heart reported 
in Irx5 knock-out (KO) mice were believed to be due to compensatory up-regulation of other Irx 
genes (Bruneau et al., 2001; Cheng et al., 2005; Lebel et al., 2003). More severe development 
defects in brain patterning, head morphogenesis and heart formation were observed when the 
IrxB cluster was deleted, such as in the mutant mouse Fused-toes (Anselme et al., 2007; Gotz et 
al., 2005; Peters et al., 2002). In Xenopus embryos, Irx5 KD by morpholino injection was 
performed by the group of Gomez-Skarmeta. Irx5 was found to be needed for neural patterning, 
especially for formation of posterior forebrain, midbrain, hindbrain and spinal cord tissues 
(Cavodeassi et al., 2001; Rodriguez-Seguel et al., 2009). Here, we extended this analysis and 
reported that Irx5 was also involved during blood, heart and craniofacial development. Other Irx 
gene KD experiments showed that Irx1 and Irx3 were required for kidney development (Alarcon 
et al., 2008) and Xiro1 (also known as Irx1) was involved in the specification of the cranial 










2.3.1. Hematopoiesis is markedly impaired in Irx5-depleted Xenopus embryos 
Since all the Jordanian patients displayed microcytic hypochromic iron deficiency anemia with 
dysmorphic red blood cells (Hamamy et al., 2007b), a total cell count and biochemistry analysis 
of blood sample drawn from the Turkish patient were requested. Blood test results were 
summarized in Table 2. As expected, the number of red blood cells (RBC) was normal, but values 
concerning HGB (Hemoglobin), HCT (Hematocrit), MCV (Mean Cell Volume) and MCH (Mean 
Cell Hemoglobin) were much lower than that of standard values (Table 2). 
Blood tests also revealed low levels of iron, suggesting that this anemia was most probably 
caused by an iron deficiency. Each iron atom, loaded in the heme of each alpha and beta globins, 
binds one oxygen molecule that causes the entire hemoglobin molecule to turn a bit redder. 
Consequently, less iron induces pallid RBC.  
It was unlikely that iron deficiency diagnosed in all HMMS patients was due to poor diet. It was 
also improbable that anemia was caused by a globin defect as the percentage of hemoglobin 
HbA2 (2.3%) was normal, excluding beta thalassemia (Table 2). However, iron deficiency 
anemia in IRX5 patients may be caused by either defects in heme synthesis, iron availability or 
iron acquisition by the erythroid precursors (Iolascon et al., 2009). Impaired intestinal absorption 
could also be the consequence of low circulating iron. Dosing the levels of Ferritin, a protein that 
stores iron in cells and releases it in a controlled manner, could be tested, as it is a good marker of 
iron homeostasis. Transferin may also be a valid marker to examine, as this protein transports 
iron in the blood and is recognized by RBC receptors for iron transfer inside the cells. High 
vitamin B12 level could also cause anemia. Very high alkaline phosphatase in blood of HMMS 






Patient Unit Lower limit Upper limit Comments
Hormons:
Vitamin B12 938.7 pg/ml 191 663 HIGH
Folat 6.41 ng/ml 3.1 17.5
Count cells:
WBC (White Blood Cell) 10.4 103/ul 4.5 13.5
RBC (red Blood Cell) 4.96 10^6/ul 4 5.1
HGB (Hemoglobin) 9.7 g/dL 11.8 15 LOW
HCT (Hematocrit) 30.2 % 35 45 LOW
MCV (Mean Cell Volume) 61 fL 76 90 LOW
MCH (Mean Cell Hemoglobin) 19.5 pg 23 31 LOW
MCHC (Mean Corpuscular Hemoglobin Conc.) 32 g/dL 33 36
PLT (Platelet) 461 103/ul 170 380 HIGH
RDW-CV (Red Cell Distribution Width) 24.2 % 11 15 HIGH
PDW fL 9 17
MPV 9.2 fL 7.2 10
PCT 0.425 %
NEUtrophil # 7.38 103/ul 2 7.1 upper limit
LYMPHocyte # 2.12 103/ul 1.5 6.5
MONOcyte # 0.72 103/ul 0 0.8
EOsinophil # 0.09 103/ul 0.05 0.7
BASOphil # 0.09 103/ul 0 0.2
RETiculocyte # (immature RBC) 0.032 10^6/ul
NEUtrophil % 70.9 % of WBC
LYMPHocyte % 20.4 % of WBC
MONOcyte % 6.9 % of WBC
EOsinophil % 0.9 % of WBC
BASOphil % 0.9 % of WBC 0 1
RETiculocyte % 0.6 % of RBC 0.7 2.2 lower limit
Biochemistry:
Calcium 10 mg/dL 8.5 10.5
Phosphore 5.1 mg/dL 2.7 4.5 HIGH
Alkaline Phosphatase 596 U/L 90 260 HIGH
Iron 15 ug/dL 50 175 LOW
Total iron-binding capacity (TIBC) 459 ug/dL 250 410 upper limit
Diagnostic:
high Vit. B12 can be linked to blood or liver disorder
hypochromic microcytic anemia
anisocytosis (RBC with unequal size - ref. MCV)
few acanthocytes (RBC with spikes)
few eliptocytes (RBC shape variation from elongated to oval)
few target cells (shape as a bullseye)
no normoblasts
Hb A2 = 2.3% - normal, not a beta thalassemia carrier
 
Table 2: Blood cell analysis of the Turkish patient shows microcytic hypochromic anemia 
The blood test was performed by Merkez Biokimya Rutin laboratory in Istanbul (2009). 
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To further document the microcytic hypochromic anemia, blood samples of the Turkish patient 
and his mother were collected, and by Ficoll density gradient centrifugation (2000 rpm at 18°C 
for 20 minutes with no break) two red blood cell populations were isolated (Fig. 22a’). A blood 
smear of the same individuals stained with H&E revealed that a fraction of the patient 
erythrocytes were smaller in size, with abnormal shapes and had low level of hemoglobin 
compared to non-anemic RBC (Fig. 22a,a’). 
During Xenopus embryogenesis, hematopoiesis starts at stage 13 and occurs in two successive 
waves and tissues (Turpen et al., 1997). Blood cells are first derived from ventral mesoderm early 
in embryonic development. Primitive hematopoiesis takes place in the nascent ventral blood 
island (VBI, equivalent to the extra-embryonic yolk sac of mammals) and gives rise 
predominantly to erythrocytes that are distinct from definitive red blood cells as they are 
nucleated and express embryonic globin chains. At later stage, definitive hematopoiesis occurs in 
the dorsal lateral plate (DLP, equivalent to the intra-embryonic aorta-gonad-meso-nephros region 
of mammals) which leads to the production of all the blood lineages and especially definitive 
RBC which are enucleated (only for high vertebrates) and which express adult globin chains. 
Primitive and definitive blood cell formation was therefore examined using a set of marker genes 
expressed in blood progenitor cells present in VBI and DLP. 
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To gain further insights into the precise role of IRX5 during blood formation, loss-of-function 
experiments in Xenopus embryos were carried out by morpholino (MO) knock-down.  
4 nl of pure Irx5 MO (123 ng), whose specificity was previously validated (Rodriguez-Seguel et 
al., 2009), was microinjected into each blastomere of 4-cell stage Xenopus embryos (Fig. 21). 
 
 
Figure 21: Irx5 morpholino (MO) oligo sequence and schematic representation of MO injection in 4-
cell stage Xenopus embryo 
 
Expression of Scl (Stem cell leukemia) gene and Hba3 (Hemoglobin alpha 3 subunit) was 
considerably reduced in VBI of Irx5-depleted embryos compared to controls (Fig. 22b-c’). 
Transcription levels of Lmo2 and Gata1, 2 and 3, factors which play synergistic role during 
Xenopus erythropoiesis (Mead et al., 2001), were also dramatically reduced or at times absent in 
DLP of Irx5 morphant embryos (Fig. 22d-e’). Since growth delay was observed in Irx5-depleted 
embryos, the same blood markers were examined at later stages of development. A net reduction 
of their expression was confirmed in DLP of morphant embryos compared to controls. Further 
evidence of lower hemoglobin level in RBC was documented when Irx5-depleted tadpoles were 
stained with o-dianisidine (Sigma, cat# D9143) (Fig. 22f,f’), a marker for mature RBC (Huber et 
al., 1998). Taken together, these results showed that IRX5 controlled hematopoiesis especially 
formation of RBC by controlling genes such as Scl, Lmo-2 and Gatas. Targeted disruption of 
each of these genes in mice also resulted in failure of hematopoiesis and anemia (Shivdasani et 




Figure 22: Irx5 KD in Xenopus embryos partially phenocopies blood disorders in HMMS 
(a,a’) Blood density gradient centrifugation and blood smear of mother of patient 5 (a) and patient 5 (a’) 
reveal microcytic hypochromic anemia. Scale bar, 10 µm. (b-c’) Marked down-regulation of Hba3 and Scl 
expression in primitive red blood cells of ventral blood islands is seen in Irx5 morphant embryos relative to 
controls at stage 32 (n = 7/8). Lateral view, anterior is left. Ventral view of embryos on the right side of 
each panel. (d-e’) At stage 26, Irx5 MO-injected embryos show absence of Lmo2 (XL023e21) expression 
in their dorsal lateral plate (DLP) (black arrowhead). Likewise, decreasing Gata3 expression is observed in 
DLP of Irx5 morphant embryos compared to controls (n = 6/9). (f,f’) O-Dianisidine staining, which marks 
red blood cells, is markedly reduced when IRX5 is depleted. 
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2.3.2. Heart development is compromised in Irx5 KD Xenopus embryos 
Murine Irx genes are part of a complex transcription factor network which regulates heart 
formation at late stage of development and during postnatal physiology (Christoffels et al., 2000; 
Mummenhoff et al., 2001). Individual deletion of Irx gene in mice did not lead to main defects in 
heart morphogenesis. However, single KO experiments revealed that Irx4 protected from 
cardiomyopathy (Bruneau et al., 2001), Irx5 controlled the cardiac ventricular repolarization 
gradient (Costantini et al., 2005) and Irx3-deletion induced slower ventricular conduction (Zhang 
et al., 2011). Moreover, mice lacking miR-1, a microRNA that binds to 3’UTR of Irx5 and 
represses IRX5 protein production, displayed cardiac conduction abnormalities (Zhao et al., 
2007). Interestingly, while single gene deletion did not lead to major heart morphogenesis 
defects, complete removal of 3 Irx genes, i.e. Irx3-5-6 in the Fused-toes mutant mouse, induced 
major embryonic cardiac anomalies in utero (Peters et al., 2002). 
Since only structural heart defects (ranging from mild mitral regurgitation to total AV canal) were 
described in IRX5 patients (Table 1) (Hamamy et al., 2007b), electrocardiogram tests were 
requested to measure their heart electrical activity. As a result, all patients were diagnosed with 
intraventricular conduction delay (Fig. 23a). The role of IRX5 during heart development was 
therefore further investigated using Irx5 KD Xenopus embryos. 
Although Irx5 could not be detected by whole embryo in situ hybridization until tadpole stage, 
major defects were observed in the expression pattern of heart markers such as Nkx2.5, Gata5, 
Bmp2 and Tbx5, from stage 26 to stage 32 when the heart tube was formed (Gessert and Kuhl, 
2009; Warkman and Krieg, 2007) (Fig. 23b-f’). The first heart field, which gives rise to the linear 
heart tube, seemed to be the most affected by depletion of Irx5. Moreover, Irx5 morphant 
tadpoles displayed underdeveloped heart, with a lower beating pace relative to controls (Fig. 
23g). The heart beat rate of Irx5-depleted embryos was 30% lower than controls until heart 




Figure 23: Irx5 KD in Xenopus embryos partially phenocopies heart disorders in HMMS 
(a) Electrocardiogram (ECG) of patients 1-3 revealing left intraventricular (V1) conduction delay (QRS 
complex >100 ms). The ECG was performed by the Department of Pediatrics at Jordan University Hospital 
(2010). (b-c’) At stage 26 and 32, impaired heart development in Irx5 morphant embryos is shown by 
altered Nkx2.5 expression in the first heart field (n = 10/14). (d-e’) Decreased expression of the first heart 
field markers Gata5  and Bmp2 is observed in stage 26-28 Irx5 morphant embryos relative to control 
embryos (n = 4/5). (f,f’) Increase of Tbx5 expression in heart fields is seen in Irx5-depleted embryos 
relative to controls at stage 30 (n = 9/10). Anterior ventral view of embryos. Black line marks cement 
gland. Black dashed line marks the first heart field while red dashed line marks the second heart field. (g) 
The heart beat of Irx5-depleted embryos (red line) is reduced by 30% in comparison to that of control 
embryos (blue line). Data are presented as mean ± S.D. (error bars represented on chart lines). 
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2.3.3. Irx5 depletion induces aberrant NCC migration in Xenopus embryos 
Besides blood and heart defects, Irx5-depleted Xenopus embryos also displayed craniofacial 
deformities. At tadpole stage, smaller heads with rudimentary eyes were observed in Irx5 
morphants compared to control embryos (Fig. 24a-a’). Alcian blue and alizarin red staining (data 
not shown), followed by hematoxylin and eosin (H&E) staining of tadpole head sections revealed 
disorganized head skeletal structures. Cartilage and bone hypoplasia, muscle agenesis, neural tube 
defects (Fig. 24b,b’) suggested possible alteration in either the induction or proliferation or 
migration of the cranial neural crest cells (NCCs). Therefore, to investigate if IRX5 plays a role 
during migration of this transient cell population from the midbrain/hindbrain into the branchial 
arches, NCC expressing marker Twist was examined (Linker et al., 2000).  
Whole embryo in situ hybridization showed for 62% of the embryos injected with MO (119/190) 
a defective migration of NCC into the first branchial arch (BA) (Fig. 24c-g’) compared to 
controls. Delay of NCC population was also noticed in the 2nd, 3rd and 4th BAs of Irx5 morphant 
embryos as well as ectopic migration over the eye vesicles in a posterior to anterior direction 
(Fig. 24d’,g’). A series of other markers were used to confirm NCC migration defects. For 
instance, Neuropilin 2 (Nrp2) and iXL069c09 also marked defective migration of the cranial 
NCCs in the first branchial arch and on the eye vesicle of Irx5 morphant embryos (Fig. 24f-g’) 
compared to controls. NCC-expressing Neuropilin receptors are usually repelled by Semaphorin 
ligands (Koestner et al., 2008), suggesting that the NCC migration defect observed in branchial 





Figure 24: Dysmophic head and eyes observed in Irx5 morpholino injected Xenopus embryos are 
caused by cranial neural crest cell (NCC) migration defects 
(a,a’) Irx5 morphant (a’) displays dysmorphic head with hypoplastic eyes and bent tail compared to control 
embryo (a) at stage 40. (b,b’) Head sagittal sections of 6-day old Xenopus control embryo (b) and Irx5 
MO-injected embryo (b’). Irx5 morphants display a disorganized neurocranium with neural tube (nt) and 
cartilage (ca) dysplasia, muscle (mu) dysgenesis, neural retina (nr) and retinal pigment epithelium (rpe) 
expansion as well as mislocalized lens (le). Sections and H&E staining were performed by the 
Histopathology facility at the Institute of Molecular and Cell Biology, Singapore. (c-e’) Twist marker 
demonstrates defective migration of the cranial neural crest cells (NCC) in branchial arches (BA) at 
different stages of development (St. 20, 24 and 26). Dorsal view, anterior is up (c,c’). Lateral view, anterior 
is left (d-e’). Dashed red line outlines the eye vesicle and dashed black line the first BA. Red arrowhead 
indicates ectopic NCC migration over the eye vesicle. (f-g’) Nrp2 and iXL069c09 also mark NCC 
migration defects in the first BA of Irx5 morphant embryos compared to controls (n = 10/16 and 13/20 
respectively). Front view (f,f’). 
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2.4. IRX5N166K missense mutant behaves as hypomorph in vivo 
To verify the specificity of the Irx5 morpholino (MO) and to examine the allelic strength of the 
IRX5 HD mutations in vivo, the capacity of IRX5A150P and IRX5N166K proteins to rescue Irx5 
morphant embryos was compared to that of wild type IRX5. It is known that missense mutations 
can have different consequences on a gene function, ranging from complete loss-of-function to 
constitutively activated forms (Muller, 1946). Classification of mutations was therefore proposed 
and categorized as being amorph, hypomorph, hypermorph, antimorph and neomorph, depending 
on their behavior in various genetic situations (Wilkie, 1994).  
To investigate how Irx5 mutants behaved, a series of Irx5 MO + mIrx5 DNA co-injection were 
performed in Xenopus embryos. In order to mimic human variations found in the HD, point 
mutations were created in the wild type (wt) mouse Irx5 ORF using site-directed mutagenesis kit 
(Stratagene, cat# 200522) and a pair of complementary primers that contained the exact human 
polymorphisms (Appendix 1). Before injection, a HA-Tag was added in frame after the start 
codon of wild type Irx5, mutants Irx5A150P and Irx5N166K to render these constructs immune to MO 
inhibition (Fig. 25).  
Rescue experiments are usually done either by mRNA or pCS2+-DNA construct injections 
(Cleaver and Krieg, 1999). The DNA method was chosen because transcription from DNA 
template starts only after the mid-blastula stage, avoiding potential non specific effects of gene 
overexpression at early stage of development. Endogenous Irx5 being expressed from stage 20 











Figure 25: Irx5 morpholino (MO) oligo cannot anneal to mIrx5-HA-Tag constructs, allowing HA-




In 75% of co-injected embryos, wt mIrx5 rescued the NCC migration in the first BA, confirming 
the specificity of the MO (Fig. 26a-c). The unstable form IRX5A150P could not rescue the 
phenotype in about 60% of the co-injected embryos (Fig. 26a,d), suggesting a total loss-of-
function of this mutein. However, injection of IRX5N166K together with Irx5 MO allowed partial 
re-population of NCCs to the first BA (Fig. 26a,e), indicating a partial loss-of-function of this 
missense mutant.  
To verify the level of IRX5 protein produced in the co-injected embryos, whole embryos were 
lysed and proteins were detected by western blotting using a mouse monoclonal anti-IRX5 
(Sigma, cat# WH0010265M1). The IRX5A150P mutein was found to be unstable in embryos 
relative to wt IRX5 and IRX5N166K proteins (Fig. 26f) even though the same amount of DNA was 
injected in each embryo. Q-PCR confirmed that all mIrx5-HA-Tagged constructs were equally 
transcribed (Fig. 26f).  
Taken together, these data argued that the p.Ala150Pro variant behaved as protein-null allele 








Figure 26: IRX5 orchestrates migration of cranial neural crest cells (NCCs)  
(a-e) Irx5 is required for proper NCC migration in Xenopus embryos. Lateral view of head region of stage 
26 embryos, anterior to the left. (a) Expression of Twist demarcates NCCs in the 4 branchial arches (1-4) (n 
= 36/36). Dashed red line outlines the eye vesicle and dashed white line the first branchial arch (BA). Scale 
bar, 0.25 mm. (b) Irx5 morpholino (MO) injected-embryos specifically lack NCCs in the first BA (n = 
23/38). Red arrowhead indicates ectopic NCC migration over the eye vesicles. (c) Injection of wt mIrx5 
DNA in Irx5 morphant embryos rescues NCC migration to the first BA (n = 30/40). (d) Injection of A150P 
mIrx5 DNA in Irx5 morphant embryos fails to rescue NCC migration to the first BA (n = 27/48). (e) In 
contrast, injection of N166K mIrx5 DNA partially rescues NCC migration in Irx5 morphant embryos 
suggesting that this Irx5 missense mutant may behave as a hypomorph (n = 23/48). (f) IRX5A150P protein is 
rapidly degraded in embryos relative to wt IRX5. α-ACTIN serves as a loading control. qRT-PCR results 





2.5.  HD mutations cause protein instability and abrogate IRX5 transcriptional output 
To examine the allelic strength of the missense IRX5 mutants, in vitro luciferase reporter gene 
assays were also carried out using mouse Irx5 expression constructs (pCS2+ plasmid) and the 
IRX5 target gene Kcnd2 whose promoter was conjugated to luciferase (Costantini et al., 2005). 
Kcnd2 encodes a voltage-gated potassium channel subunit (also called Kv4.2), which coordinates 
the cardiac repolarization current. While Irx5 levels were inversely correlated to that of Kv4.2 
transcripts in heart tissues, it was shown that IRX5 directly trans-activated Kcnd2 transcription in 
C3H10T1/2 cells (Costantini et al., 2005). This murine embryonic mesenchymal cell line served a 
useful tool for all our subsequent cell culture experiments. 
By transient co-transfections in 10T1/2 cells of Irx5 expression constructs together with the 
Kcnd2 luciferase reporter, the consequence of each IRX5 missense mutation was monitored in 
their ability to trans-activate this reporter. Behaving like an Irx5 construct lacking its homeobox 
(Irx5∆HD) (Costantini et al., 2005), neither of the two Irx5 missense mutants (Irx5A150P and 
Irx5N166K) were able to trans-activate Kcnd2 compared to wt Irx5 (Fig. 27a). Change of amino-
acids outside the HD (Irx5S36D/S63D) however did not affect Kcnd2 trans-activation, confirming 
that IRX5 transcriptional regulation was driven by conserved amino-acids present in its HD. The 
luciferase activity of both mutants was equivalent to background activity of the luciferase reporter 
alone (Control), suggesting that these missense mutations behave as total IRX5 loss-of-function 
rather than hypomorph as was observed in vivo for IRX5N166K during Xenopus rescue 
experiments. Abrogation of trans-activation can be caused by disruption of the DNA binding of 
IRX5 on its target gene but also to inherent instability of the protein synthesized as was observed 





While wt IRX5 and IRX5N166K proteins were stable (Fig. 27b lanes 1,5), the IRX5A150P was found 
to be rapidly degraded (Fig. 27b lane 3). This finding was replicated when using the two distinct 
monoclonal anti-IRX5 antibodies as well as an anti-HA antibody (which was specific to the HA-
Tag added after the start codon of mIrx5). It was worth noting that the rapid degradation of 
IRX5A150P compared to wt IRX5 and IRX5N166K proteins was in agreement with results obtained 
in Xenopus embryos overexpressing these proteins (Fig. 26f). 
The rapid IRX5A150P protein degradation was secondary to ubiquitin-mediated proteolysis since 
addition of 10 µM of MG-132 (Calbiochem, cat# 1474790) (Bonuccelli et al., 2003) overnight 
(Fig. 27b lanes 2,4,6) was able to increase IRX5A150P protein half life to visible levels. Similar 
results were also obtained when another inhibitor of proteolysis Lactacystin (Sigma, cat# L6785) 
was added in the culture medium (Fenteany et al., 1995) (Fig. 27b). Mono-ubiquitinated form of 
β-catenin was detected assuring that proper proteolysis inhibition had been achieved. 
The stability of the IRX5N166K protein being higher than that of the IRX5A150P, we can hypothesize 
that the abrogation of trans-activation in this mutant was caused by disruption of DNA binding 
affinity rather than protein instability. This was in line with previous reports describing mutations 
in the same homeodomain hotspot residues of helices 2 (A>P) and 3 (N>K) which affected 









Figure 27: Abrogation of trans-activation observed in IRX5 mutants is due to protein instability 
(a) Transient co-transfections in 10T1/2 cells of mouse Irx5A150P, Irx5N166K and Irx5∆HD with an IRX5 
reporter construct (rat Kcnd2 promoter luciferase) show total abrogation of transcriptional activity relative 
to wild type (wt) Irx5 or Irx5S36D/S63D constructs. Data are presented as mean ± S.D. (error bars represented 
on top of charts). Statistical significance was determined by one-tailed Student's t test (** p value < 0.005). 
(b) In agreement with results obtained in Xenopus embryos, the IRX5A150P protein is rapidly degraded in 
10T1/2 cells (lane 3) compared to wt IRX5 (lane 1). Addition of MG132 or Lactacystin, to prevent 
ubiquitin-conjugated protein degradation, partially restores IRX5A150P protein stability (lane 4). The 
IRX5N166K protein stability is not overtly affected by ubiquitination (lanes 5,6). β-CATENIN serves as an 



















2.6.  IRX5N166K missense mutant may also display neomorphic activities in vitro 
Previous experiments showed that change of one amino-acid in the helix 3 of the IRX5 
homeodomain (IRX5N166K) induced either a total or a partial loss-of-function depending on the 
experimental context. Since binding of the transcription factor GATA3 to IRX5 was shown to 
change IRX5 transcriptional activity (refer to paragraphs 5.4 and 5.5), we reversely tested 
whether IRX5 could modulate a GATA3-regulated GCMB (Glial Cells Missing homolog 2) 
reporter (Grigorieva et al., 2010). It was first found that, as GATA3, wt IRX5 alone trans-
activated GCMB promoter while mutant IRX5N166K did not (Fig. 28, bars 1, 2 and 3). Decrease of 
GCMB trans-activation by GATA3 was also observed in presence of wt IRX5, and this 
transcriptional repression was stronger when IRX5N166K was used (Fig. 28, bars 4 and 5).  
This result drew our attention to the possible neomorphic activities for the IRX5N166K missense 
mutant vis-à-vis its protein partners. Depending on cell environment and signals,  IRX5N166K may 








Figure 28: The IRX5N166K may also have neomorphic activities 
Transient co-transfections in 10T1/2 cells of a human GCMB promoter luciferase reporter together with 
either wt Irx5 or Irx5N166K or/and Gata3 expression constructs. Wt IRX5 represses trans-activation of the 
GCMB reporter by GATA3. Surprisingly, this inhibition is stronger when mutant Irx5N166K is co-expressed 
with Gata3, highlighting the possible neomorphic properties of this IRX5 missense mutant vis-à-vis its 
protein partners. Under the bar chart, schematic representation of the activation or repression of the GCMB 
reporter by IRX5,  IRX5N166K and GATA3. Data are presented as mean ± S.D. (error bars represented on 





Analysis of Irx5 expression in embryonic tissues together with Irx5 KD experiments in Xenopus 
embryos provided tangible evidence that the Irx5 gene played an essential role during red blood 
cell formation, heart morphogenesis and craniofacial development. The compensatory effect 
believed to be exerted by other Irx genes in the Irx5 KO mouse may not be at play in Xenopus, 
since depletion of Irx5 had stronger phenotypic impact during frog development. This may be 
explained by the presence of cross-regulatory sequences found in mouse but not in Xenopus (de la 
Calle-Mustienes et al., 2005). For instance it has been noted that Irx5 was the only gene 
expressed in the developing eyes in Xenopus whereas in mouse neural retina all the Irx genes 
were expressed (Bosse et al., 2000). IRX5 patients displayed more severe defects than Irx5 KO 
mice. It is possible that abnormalities were not detected in KO mouse due to constraints in the 
examination procedures. Moreover, rescue mechanisms by other Irx genes may be more active in 
KO mice than in HMMS patients since IRX5 mutations found in humans did not always induce a 
total loss of function as in rodents. In fact, we demonstrated that, depending on the experimental 
environment in which Irx5 was expressed, the mutein IRX5N166K may act either as hypomorph, 
neomorph or as a complete loss of function allele. 
As a strong conservation exists among vertebrates, it is expected that the IRX5 gene plays a 
similar role during human embryogenesis as it does in other vertebrates. Further investigations 
described on the following paragraph have attempted to uncover the exact molecular mechanism 




3. IRX5 orchestrates NCC and germ cell migration by repressing SDF1 
As described in the previous paragraph 2.3.3, depletion of IRX5 during Xenopus embryo 
development induced major cranial NCC migration defects into the pharyngeal arches. In 
particular, the NCCs did not populate the first branchial arch and ectopic migration was observed 
on the optic vesicles of Irx5 morphant embryos.  
The cranial NCCs delaminate from the dorsal midbrain/hindrain in a rostro-caudal manner and 
migrate dorso-laterally following defined and precise pathways in the head and branchial arches. 
During their travel, NCCs interact with diverse cells and tissues and receive signals from 
mesenchyme, ectoderm and extracellular matrix (ECM). At the end of their route, these 
multipotent cells differentiate into diverse cell types such as cartilage, bone, facial nerves, 
neurons and glia of cranial ganglia, connective tissues, middle ear ossicles and teeth. Any 
alteration during induction, proliferation, migration and differentiation of the NCCs can lead to 
significant structural and functional diversity seen in vertebrates but also to congenital diseases 
with craniofacial dysmorphisms in humans.  
To gain mechanistic insight into the etiology of NCC migration defects seen in Irx5 morphants, 
an exploratory microarray comparing gene expression profiles of Irx5 MO-injected and control 
embryos was conducted at neurulation (stage 20). We anticipated that finding target genes which 
were up or down regulated by the depletion of IRX5 should help clarify the mechanisms or 
signaling pathways that were controlled by this transcription factor during craniofacial 
morphogenesis.  
3.1. Xenopus gene expression microarrays identify potential IRX5 target genes 
The Xenopus laevis gene expression microarray contained about 44000 probes (Agilent, cat# 
G2519F-023448 v2.1). To make the analysis of 44000 probes more straightforward, a series of 
96 
 
filters were applied to reduce the complexity of the data and minimize the number of genes to 
analyze. Therefore, all bad spots were excluded; intensities were normalized; all probes with 
extremely low (< 20) or high (>4000) raw intensities or with a fold ratio (or fold change) inferior 
or equal to 2.5 were removed; probes without Gene ID or GenBank Accession numbers were put 
aside; average fold ratios and p-values were calculated per gene. To rule out false positives, any 
probe with a high fold change found in other sets of experiments (different MO-injected 
embryos/control embryos) was rejected as well. As a result, 94 genes (111 probes) were kept for 
further analysis (Table 3).  
As a first screen, 4 known genes with the highest fold change were chosen. Sdf1 and Tspan33 
were found to be significantly up-regulated in Irx5-depleted embryos whereas C22orf39 and 
Cd82 were down-regulated. Mark2 (also known as Par-1) was kept aside as the intensity level of 
the 3 represented probes were too low to be detected by in situ hybridization or Q-RT-PCR as 
described below (Appendix 1). 
Cd82 (also known as Kai1) and Tspan33 (also known as Penumbra) encode membrane 
glycoproteins of the tetraspanin superfamily. Cd82 was described as a metastasis suppressor via 
multiple mechanisms (Tsai and Weissman, 2011) including inhibition of cell motility and 
invasion (Ono et al., 1999; Takaoka et al., 1998), promotion of cell polarity as well as induction 
of senescence and apoptosis in response to extracellular stimuli (Bandyopadhyay et al., 2006; 
Schoenfeld et al., 2004). Expression of this gene was shown to be down-regulated during tumor 
progression of human cancers (Tsai and Weissman, 2011) and overexpression demonstrated 
decrease of cell motility (Yang et al., 2001). The main function of CD82 is to promote cell–cell 
adhesion, mainly by stabilizing E-cadherin/β-catenin complex formation, that is important in 
metastasis (Abe et al., 2008) and epithelial-mesenchymal-transition (EMT), suggesting that it 





(MO/Ctl) Average Ctl Raw MO Raw Gene Symbol Description
Genbank 
Accession
A_10_P051726 4.84 3.93 149.117 28.142 mark2 Xenopus laevis MAP/microtubule affinity-regulating kinase 2 (mark2), mRNA [NM_001086956] NM_001086956
A_10_P048035 4.07 95.334 21.422 mark2 Xenopus laevis MAP/microtubule affinity-regulating kinase 2 (mark2), mRNA [NM_001086956] NM_001086956
A_10_P259197 2.90 81.242 25.615 mark2 Xenopus laevis MAP/microtubule affinity-regulating kinase 2 (mark2), mRNA [NM_001086956] NM_001086956
A_10_P039746 2.96 2.88 1319.171 406.497 MGC154481 Xenopus laevis protein arginine N-methyltransferase 3 (MGC154481), mRNA [NM_001096891] NM_001096891
A_10_P273752 2.86 1186.761 379.018 MGC154481 Xenopus laevis protein arginine N-methyltransferase 3 (MGC154481), mRNA [NM_001096891] NM_001096891
A_10_P156178 2.81 235.439 76.426 MGC154481 Xenopus laevis protein arginine N-methyltransferase 3 (MGC154481), mRNA [NM_001096891] NM_001096891
A_10_P152768 6.11 5.74 681.324 101.953 c22orf39 Xenopus laevis UPF0545 protein C22orf39 homolog (LOC100037072), mRNA [NM_001097796] NM_001097796
A_10_P044196 5.37 928.498 158.063 c22orf39 Xenopus laevis UPF0545 protein C22orf39 homolog (LOC100037072), mRNA [NM_001097796] NM_001097796
A_10_P163563 4.98 4.23 158.571 29.062 LOC398450 Xenopus laevis similar to tissue specific transplantation antigen P35B, mRNA (cDNA clone IMAGE:5514    BC073614
A_10_P066509 3.47 1476.183 388.946 LOC398450 Xenopus laevis similar to tissue specific transplantation antigen P35B, mRNA (cDNA clone IMAGE:5514    BC073614
A_10_P139968 3.56 3.50 1529.975 392.177 MGC81803 Xenopus laevis MGC81803 protein (MGC81803), mRNA [NM_001092575] NM_001092575
A_10_P005917 3.44 1476.756 392.273 MGC81803 Xenopus laevis MGC81803 protein (MGC81803), mRNA [NM_001092575] NM_001092575
A_10_P141393 3.46 3.43 937.252 247.288 LOC100037193 Xenopus laevis hypothetical protein LOC100037193 (LOC100037193), mRNA [NM_001097884] NM_001097884
A_10_P042631 3.39 885.346 238.585 LOC100037193 Xenopus laevis hypothetical protein LOC100037193 (LOC100037193), mRNA [NM_001097884] NM_001097884
A_10_P005605 4.24 3.40 2041.974 440.184 cd82 Xenopus laevis MGC80828 protein (MGC80828), mRNA [NM_001092348] NM_001092348
A_10_P190370 2.56 403.490 143.927 cd82 Xenopus laevis MGC80828 protein (MGC80828), mRNA [NM_001092348] NM_001092348
A_10_P140953 3.22 3.20 423.066 119.860 LOC496208 Xenopus laevis hypothetical LOC496208 (LOC496208), mRNA [NM_001095396] NM_001095396
A_10_P009253 3.17 1467.727 423.064 LOC496208 Xenopus laevis hypothetical LOC496208 (LOC496208), mRNA [NM_001095396] NM_001095396
A_10_P000351 3.37 3.02 256.699 69.566 cml-A Xenopus laevis N-acetyltransferase Camello-like (cml-A), mRNA [NM_001085621] NM_001085621
A_10_P048621 2.66 280.225 96.276 cml-A Xenopus laevis N-acetyltransferase Camello-like (cml-A), mRNA [NM_001085621] NM_001085621
A_10_P142218 3.02 3.01 965.612 292.534 pgk1 Xenopus laevis phosphoglycerate kinase 1 (pgk1), mRNA [NM_001086901] NM_001086901
A_10_P002471 3.01 981.742 298.013 pgk1 Xenopus laevis phosphoglycerate kinase 1 (pgk1), mRNA [NM_001086901] NM_001086901
A_10_P140133 3.08 2.94 1244.698 369.505 MGC52864 Xenopus laevis similar to RNA binding motif protein 14 (MGC52864), mRNA [NM_001086145] NM_001086145
A_10_P002922 2.81 3032.921 987.418 MGC52864 Xenopus laevis similar to RNA binding motif protein 14 (MGC52864), mRNA [NM_001086145] NM_001086145
A_10_P129707 3.09 2.84 578.733 170.871 MGC83258 Xenopus laevis hypothetical protein MGC83258 (MGC83258), mRNA [NM_001091062] NM_001091062
A_10_P181413 2.58 1539.199 545.850 MGC83258 Xenopus laevis hypothetical protein MGC83258 (MGC83258), mRNA [NM_001091062] NM_001091062
A_10_P008659 2.79 2.74 330.478 108.114 spns1 Xenopus laevis hypothetical LOC495202 (spns1), mRNA [NM_001094889] NM_001094889
A_10_P230488 2.70 361.856 122.568 spns1 Xenopus laevis hypothetical LOC495202 (spns1), mRNA [NM_001094889] NM_001094889
A_10_P006886 5.13 5.13 1352.827 240.813 sh3glb2 Xenopus laevis SH3-domain GRB2-like endophilin B2 (sh3glb2), mRNA [NM_001093410] NM_001093410
A_10_P006737 4.89 4.89 377.011 70.495 gstcd Xenopus laevis MGC82215 protein (MGC82215), mRNA [NM_001093309] NM_001093309
A_10_P042981 4.79 4.79 148.594 28.346 spop-b Xenopus laevis hypothetical protein MGC154338 (MGC154338), mRNA [NM_001097009] NM_001097009
A_10_P049859 4.78 4.78 609.465 116.547 LOC733412 Xenopus laevis cDNA clone IMAGE:8532588, partial cds [BC128904] BC128904
A_10_P148078 4.37 4.37 2647.071 553.759 MGC80673 Xenopus laevis MGC80673 protein (MGC80673), mRNA [NM_001092283] NM_001092283
A_10_P008841 4.18 4.18 578.979 126.641 rad9 Xenopus laevis PCNA-like DNA checkpoint protein Rad9 (rad9), mRNA [NM_001089131] NM_001089131
A_10_P004322 4.02 4.02 2045.661 465.290 LOC398157 Xenopus laevis peroxisomal membrane protein PMP34 (LOC398157), mRNA [NM_001088515] NM_001088515
A_10_P006347 4.00 4.00 312.504 71.324 bcap31 Xenopus laevis B-cell receptor-associated protein 31 (bcap31), mRNA [NM_001093027] NM_001093027
A_10_P039821 3.96 3.96 745.873 172.224 MGC69051 Xenopus laevis twisted gastrulation (MGC69051), mRNA [NM_001086401] NM_001086401
A_10_P053234 3.86 3.86 630.732 149.296 LOC100158266 Xenopus laevis hypothetical protein LOC100158266, mRNA (cDNA clone IMAGE:8821228), partial cds [ BC159342
A_10_P006657 3.83 3.83 292.286 69.800 acyp1 Xenopus laevis acylphosphatase 1, erythrocyte (common) type (acyp1), mRNA [NM_001093244] NM_001093244
A_10_P009590 3.76 3.76 601.163 146.061 MGC85036 Xenopus laevis hypothetical protein MGC85036 (MGC85036), mRNA [NM_001095847] NM_001095847
A_10_P047561 3.71 3.71 1275.563 313.998 MGC131026 Xenopus laevis hypothetical protein MGC131026 (MGC131026), mRNA [NM_001096391] NM_001096391
A_10_P002612 3.70 3.70 1350.405 333.277 MGC54016 Xenopus laevis similar to macrophage stimulating 1 (hepatocyte growth factor-like) (MGC54016), mRN  NM_001086058
A_10_P002464 3.67 3.67 347.395 86.397 mdm4 Xenopus laevis Mdm4 protein (mdm4), mRNA [NM_001088965] NM_001088965
A_10_P002448 3.51 3.51 865.237 225.429 facl2 Xenopus laevis fatty acid Coenzyme A ligase (facl2), mRNA [NM_001086974] NM_001086974
A_10_P008677 3.44 3.44 394.043 104.536 LOC495213 Xenopus laevis UPF0547 protein (LOC495213), mRNA [NM_001094897] NM_001094897
A_10_P202843 3.36 3.36 433.215 117.916 pcbp2b Xenopus laevis poly(rC) binding protein 2 b (pcbp2b), mRNA [NM_001086654] NM_001086654
A_10_P001939 3.35 3.35 291.916 79.504 LOC398611 Xenopus laevis PP2A B'' subunit PR74 (LOC398611), mRNA [NM_001089158] NM_001089158
A_10_P004074 3.33 3.33 362.706 99.561 MGC81046 Xenopus laevis hypothetical protein MGC81046 (MGC81046), mRNA [NM_001091235] NM_001091235
A_10_P057622 3.22 3.22 1676.394 476.065 MGC69168 Xenopus laevis hypothetical protein MGC69168, mRNA (cDNA clone IMAGE:4724964), partial cds [BC04 BC041739
A_10_P035661 3.21 3.21 144.151 41.031 MGC154753 Xenopus laevis hypothetical protein MGC154753 (MGC154753), mRNA [NM_001096924] NM_001096924
A_10_P043637 3.21 3.21 1212.919 345.537 LOC398501 Xenopus laevis similar to stromal cell derived factor receptor 1 (LOC398501), mRNA [NM_001089013] NM_001089013
A_10_P002328 3.17 3.17 1003.143 288.743 gldc Xenopus laevis glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage syste      NM_001086672
A_10_P002582 3.16 3.16 2267.578 654.864 MGC53995 Xenopus laevis hypothetical protein MGC53995 (MGC53995), mRNA [NM_001086043] NM_001086043
A_10_P009163 3.09 3.09 527.928 155.865 LOC496029 Xenopus laevis hypothetical LOC496029 (LOC496029), mRNA [NM_001095296] NM_001095296
A_10_P009010 3.07 3.07 151.698 45.129 glt25d1a Xenopus laevis glycosyltransferase 25 domain containing 1 a (glt25d1a), mRNA [NM_001095154] NM_001095154
A_10_P007475 3.07 3.07 347.487 103.505 MGC86401 Xenopus laevis MGC86401 protein (MGC86401), mRNA [NM_001093980] NM_001093980
A_10_P030186 3.06 3.06 475.276 141.704 MGC83836 Xenopus laevis hypothetical protein MGC83836 (MGC83836), mRNA [NM_001091428] NM_001091428
A_10_P026984 3.02 3.02 895.732 271.220 LOC397772 Xenopus laevis heterogeneous nuclear ribonucleoprotein A3 homolog 1 (LOC397772), mRNA [NM_001 NM_001087849
A_10_P043461 2.98 2.98 850.106 260.482 MGC154930 Xenopus laevis hypothetical protein MGC154930 (MGC154930), mRNA [NM_001096974] NM_001096974
A_10_P004298 2.97 2.97 233.454 71.794 MGC83195 Xenopus laevis hypothetical protein MGC83195 (MGC83195), mRNA [NM_001091166] NM_001091166
A_10_P007868 2.92 2.92 2130.253 665.567 MGC84356 Xenopus laevis MGC84356 protein (MGC84356), mRNA [NM_001094289] NM_001094289
A_10_P027108 2.86 2.86 662.514 211.632 b4 Xenopus laevis histone H1-like maternal protein (b4), mRNA [NM_001088066] NM_001088066
A_10_P002744 2.83 2.83 104.018 33.629 MGC80993 Xenopus laevis MGC80993 protein (MGC80993), mRNA [NM_001092418] NM_001092418
A_10_P026569 2.82 2.82 492.920 159.924 MGC130933 Xenopus laevis hypothetical protein MGC130933 (MGC130933), mRNA [NM_001096235] NM_001096235
A_10_P086900 2.80 2.80 542.839 176.882 LOC779055 Xenopus laevis poly(A) polymerase type 1 mRNA, partial cds [U19973] U19973
A_10_P044741 2.77 2.77 544.866 179.869 bing4-b Xenopus laevis BING4 protein (bing4-b), mRNA [NM_001122879] NM_001122879
A_10_P006664 2.76 2.76 150.281 49.826 MGC81149 Xenopus laevis MGC81149 protein (MGC81149), mRNA [NM_001093250] NM_001093250
A_10_P067267 2.75 2.75 429.316 142.741 LOC446929 Xenopus laevis hypothetical protein LOC446929, mRNA (cDNA clone IMAGE:7010050), partial cds [BC0 BC081063
A_10_P004840 2.75 2.75 1107.074 368.326 MGC78973 Xenopus laevis hypothetical protein MGC78973 (MGC78973), mRNA [NM_001091755] NM_001091755
A_10_P003228 2.73 2.73 408.786 136.775 MGC53924 Xenopus laevis similar to catecholamine-O-methyltransferase (MGC53924), mRNA [NM_001086246] NM_001086246
A_10_P160388 2.70 2.70 90.829 30.701 LOC100174797 Xenopus laevis hypothetical protein LOC100174797 (LOC100174797), mRNA [NM_001130942] NM_001130942
A_10_P044516 2.70 2.70 827.949 280.496 LOC100127340 Xenopus laevis hypothetical protein LOC100127340 (LOC100127340), mRNA [NM_001112893] NM_001112893
A_10_P009026 2.69 2.69 300.972 102.343 LOC495686 Xenopus laevis hypothetical LOC495686 (LOC495686), mRNA [NM_001095165] NM_001095165
A_10_P145463 2.67 2.67 665.723 227.519 MGC68574 Xenopus laevis hypothetical protein MGC68574 (MGC68574), mRNA [NM_001089709] NM_001089709
A_10_P007144 2.65 2.65 351.923 121.135 MGC81027 Xenopus laevis MGC81027 protein (MGC81027), mRNA [NM_001093597] NM_001093597
A_10_P034501 2.64 2.64 1468.794 507.935 LOC100190770 Xenopus laevis hypothetical protein LOC100190770 (LOC100190770), mRNA [NM_001135224] NM_001135224
A_10_P009130 2.63 2.63 577.376 200.333 LOC495989 Xenopus laevis hypothetical LOC495989 (LOC495989), mRNA [NM_001095256] NM_001095256
A_10_P142883 2.63 2.63 68.067 23.655 zdhhc2 Xenopus laevis zinc finger, DHHC domain containing 2 (zdhhc2), mRNA [NM_001094458] NM_001094458
A_10_P074580 2.61 2.61 148.204 51.848 LOC733330 Xenopus laevis cDNA clone IMAGE:5515566, partial cds [BC073639] BC073639
A_10_P075608 2.59 2.59 388.704 137.306 LOC446973 Xenopus laevis hypothetical protein LOC446973, mRNA (cDNA clone IMAGE:6953903), partial cds [BC0 BC082482
A_10_P042821 2.58 2.58 286.737 101.447 MGC131060 Xenopus laevis hypothetical protein MGC131060 (MGC131060), mRNA [NM_001096401] NM_001096401
A_10_P079070 2.58 2.58 746.984 264.673 LOC733425 Xenopus laevis hypothetical protein LOC733425, mRNA (cDNA clone IMAGE:5155787), partial cds [BC1 BC108883
A_10_P009285 2.58 2.58 241.270 85.528 bnip3l Xenopus laevis BCL2/adenovirus E1B 19kD-interacting protein 3-like (bnip3l), mRNA [NM_001096800] NM_001096800
A_10_P172988 2.56 2.56 60.569 21.574 LOC397895 Xenopus laevis gelsolin (LOC397895), mRNA [NM_001088058] NM_001088058
A_10_P067462 2.56 2.56 574.887 205.142 LOC398577 Xenopus laevis similar to testis specific, 10, mRNA (cDNA clone IMAGE:4884572), partial cds [BC04802 BC048022
A_10_P042896 2.56 2.56 1183.502 422.533 Apr-03 Xenopus laevis apoptosis related protein APR-3 (apr3), mRNA [NM_001095923] NM_001095923
A_10_P007066 2.54 2.54 375.891 135.123 MGC80694 Xenopus laevis MGC80694 protein (MGC80694), mRNA [NM_001093542] NM_001093542
A_10_P002037 2.52 2.52 279.013 101.069 LOC432341 Xenopus laevis cyclase associated protein 2 (LOC432341), mRNA [NM_001091774] NM_001091774
A_10_P006905 2.51 2.51 905.127 328.794 rnft1 Xenopus laevis RING finger and transmembrane domain-containing protein 1, mRNA (cDNA clone MGC     BC077617
A_10_P072345 3.44 3.36 1152.737 3625.898 gs17 Xenopus laevis GS17 protein (gs17), mRNA [NM_001088064] NM_001088064
A_10_P044686 3.28 1279.299 3836.238 gs17 Xenopus laevis GS17 protein (gs17), mRNA [NM_001088064] NM_001088064
A_10_P154898 2.70 2.62 150.731 371.390 LOC100158339 Xenopus laevis hypothetical protein LOC100158339 (LOC100158339), mRNA [NM_001127785] NM_001127785
A_10_P035811 2.55 112.907 262.524 LOC100158339 Xenopus laevis hypothetical protein LOC100158339 (LOC100158339), mRNA [NM_001127785] NM_001127785
A_10_P004009 21.51 21.51 56.508 1110.282 sdf-1 Xenopus laevis stromal-derived factor 1 (sdf-1), mRNA [NM_001090163] NM_001090163
A_10_P005145 5.36 5.36 56.054 274.448 tspan33 Xenopus laevis MGC80105 protein (MGC80105), mRNA [NM_001091985] NM_001091985
A_10_P002380 4.25 4.25 57.548 223.649 cmah Xenopus laevis cytidine monophospho-N-acetylneuraminic acid hydroxylase (cmah), mRNA [NM_0010 NM_001086828
A_10_P002725 4.02 4.02 342.077 1254.806 MGC154837 Xenopus laevis, Similar to hypothetical protein LOC93380, clone IMAGE:5543271, mRNA [BC044280] BC044280
A_10_P090060 3.83 3.83 114.366 400.549 LOC733409 Xenopus laevis hypothetical protein LOC733409, mRNA (cDNA clone IMAGE:7210402), partial cds [BC1 BC108614
A_10_P084230 3.81 3.81 77.004 267.864 LOC734188 Xenopus laevis ecto-nucleotidase triphosphate diphosphohydrolase 8 mRNA, partial cds [DQ117606] DQ117606
A_10_P009168 3.37 3.37 114.344 351.770 LOC496037 Xenopus laevis hypothetical LOC496037 (LOC496037), mRNA [NM_001095304] NM_001095304
A_10_P017381 3.31 3.31 68.032 205.515 MGC114842 Xenopus laevis UPF0561 protein (MGC114842), mRNA [NM_001096563] NM_001096563
A_10_P006071 3.24 3.24 49.624 146.664 MGC84137 Xenopus laevis MGC84137 protein (MGC84137), mRNA [NM_001092728] NM_001092728
A_10_P260602 3.06 3.06 28.381 79.342 MGC83352 Xenopus laevis MGC83352 protein (MGC83352), mRNA [NM_001094229] NM_001094229
A_10_P003824 2.93 2.93 49.772 133.072 MGC68790 Xenopus laevis hypothetical protein MGC68790 (MGC68790), mRNA [NM_001089679] NM_001089679
A_10_P004377 2.72 2.72 272.733 676.941 mizip Xenopus laevis melanin-concentrating hormone receptor 1 interacting zinc-finger protein, mRNA (cDN       BC070586
A_10_P045866 2.71 2.71 144.449 357.358 MGC69140 Xenopus laevis hypothetical protein MGC69140 (MGC69140), mRNA [NM_001086425] NM_001086425
A_10_P090560 2.69 2.69 125.411 308.239 LOC100101311 Xenopus laevis hypothetical protein LOC100101311, mRNA (cDNA clone IMAGE:8072918), partial cds [ BC142584
A_10_P041791 2.62 2.62 95.907 229.879 lyrm1 Xenopus laevis LYR motif-containing protein 1 (lyrm1), mRNA [NM_001114832] NM_001114832
A_10_P046891 2.62 2.62 531.947 1271.807 rxrb Xenopus laevis retinoid X receptor, beta (rxrb), mRNA [NM_001088361] NM_001088361
A_10_P031526 2.59 2.59 418.875 993.036 LOC733180 Xenopus laevis hypothetical protein LOC733180 (LOC733180), mRNA [NM_001095606] NM_001095606
A_10_P120331 2.54 2.54 532.104 1236.119 rpl17 Xenopus laevis ribosomal protein L17 b (rpl17), mRNA [NM_001166299] NM_001166299  
Table 3: List of 94 genes down or up-regulated in Xenopus embryos (St. 20) upon Irx5 depletion 
Fold change = intensity Irx5 Morpholino (MO Raw) / intensity control (Ctl Raw). The 4 genes selected for 




Tspan33 was also an interesting candidate as it was highly expressed in erythroid progenitors and 
promotes effective erythropoiesis. Penumbra KO mice developed basophilic macrocytic red 
blood cells and anemia as they aged (Heikens et al., 2007), which was reminiscent of the red 
blood cells abnormalities and anemia seen in IRX5 human patients. EST profiles in mouse 
showed Tspan33 expression in eye, brain and first branchial arch in E8.5 mouse embryo (Tamplin 
et al., 2008), and in bone, bone marrow, brain, eye, inner ear, intestine, mammary gland, kidney, 
lung, liver, pancreas, salivary gland, spleen of adult mice. Penumbra also exhibited growth-
suppressive activity (Chen et al., 2005). 
Even if little is known about C22orf39, I selected this gene because it was the second most down-
regulated (fold change 5.7).  EST in mouse showed C22orf39 expression in brain, bone marrow, 
blood, eye, heart, kidney, lung and mammary glands, which were organs that either expressed 
Irx5 or had defective function in IRX5 patients. 
Finally, Sdf1 for Stromal cell-derived factor 1 (also known as Cxcl12) was the most attractive 
candidate. First because this gene had the highest fold ratio showing 20-fold up-regulation in 
Irx5-depleted embryos relative to control embryos, but most importantly because Sdf1 encodes a 
chemokine essential for cranial NCC migration into pharyngeal arches. Sdf1 plays also a role in 
the subsequent patterning and morphogenesis of the neural crest derived tissues during 
craniofacial development (Theveneau and Mayor, 2011). Depletion or overexpression of Sdf1b 
and its receptor Cxcr4a in zebrafish embryos caused abnormal cranial NCC migration and 
resulted in ectopic craniofacial cartilages (Olesnicky Killian et al., 2009). Sdf1 and its receptors 
were also reported to regulate hematopoiesis (Horuk, 1998; Zou et al., 1998) and to promote 
migration and formation of germ cells (Molyneaux et al., 2003; Staton et al., 2011; Takeuchi et 
al., 2010).  
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3.2. Validation of putative IRX5 downstream genes by WISH 
To verify the accuracy of the microarray results and validate the changes in expression level of 
the 4 candidate genes following Irx5 depletion, in situ hybridization with antisense RNA probes 
were performed in whole Irx5 morphants and control embryos. Full length cDNA cloned into 
plasmids were ordered from Openbiosystems (https://www.openbiosystems.com/Query/), and 
probes were prepared accordingly. 
Of the two down-regulated genes, Cd82 gave the most striking results (Fig. 29a,a’), as its 
expression pattern resembled that of Irx5, especially in the head region of embryos at stage 28 
(Fig. 29a). Like Irx5, Cd82 was highly expressed in the optic vesicles, midbrain, hindbrain and 
slightly in the branchial arches. Cd82 was not expressed in the midbrain/hindbrain boundary as 
for Irx5. The expression of Cd82 in the pronephric territory overlapped with expression of other 
Iroquois genes, Irx1, 2 and 3 (Alarcon et al., 2008; Rodriguez-Seguel et al., 2009). Upon 
depletion of Irx5 by morpholino injection, Cd82 transcript levels were dramatically reduced in the 
whole embryo (Fig. 29a’), suggesting that IRX5 may act upstream, directly or indirectly, to trans-
activate Cd82 expression, especially in eye and brain regions where both genes were highly 
detected. The down regulation of Cd82 in regions where Irx5 was not expressed, such as 
pronephros, lateral mesoderm and tail bud, may be caused by a cascade of downstream events 
caused by Irx5 depletion.  
The decrease of C22orf39 expression in Irx5 morphants compared to control embryos (Fig. 
29b,b’) was confirmed by in situ hybridization, validating the microarray results. C22orf39 
transcripts were highly detected in the head region, especially in eye vesicles, four branchial 
arches, otic vesicles and somites of control embryos. This pattern of expression became weaker in 
Irx5-depleted embryos, suggesting that C22orf39 may be another potential downstream target 
gene whose expression partly requires IRX5.  
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The up-regulation of Tspan33 and Sdf1 transcription was also confirmed by in situ hybridization 
(Fig. 29c-d’). Tspan33 transcripts were seen in the dorsal ectoderm surrounding the neural fold 
and tissues near the cement gland of neurula embryos, but also in the posterior dorsal part of stage 
25 embryos. Even though Tspan33 overexpression was verified when Irx5 was depleted, the 
transcriptional regulation of this Tetraspanin by IRX5 remained unclear since their pattern of 
expression did not overlap (Fig. 29c,c’). 
Finally, the ectopic expression of Sdf1 in developing Irx5 morphant embryos was confirmed by in 
situ hybridization at three different stages (Fig. 29d-e’). As observed for Cd82, the pattern of Sdf1 
expression was correlated with that of Irx5, especially in the pharyngeal arches and other discrete 
regions of the developing head at stage 32.  
To further validate the up-regulation of Sdf1 in Irx5 morphants, Q-RT-PCR experiments were 
performed on RNA extracted from Irx5 morphants and control embryos collected at stage 20. 
Likewise, a 6-fold increase of Sdf1 expression was observed in Irx5-depleted embryos (data not 
shown). Taken together, these results suggested that the IRX5 transcription factor may inhibit 





Figure 29: WISH in Xenopus embryos confirms activation or repression of IRX5 target genes 
(a-b’) At different stages of development, Cd82 and C22orf39 gene expression is down regulated when 
Irx5 is depleted (a’,b’) compared to control embryos (a,b). (c-d’) On the contrary, up regulation of Tspan33 
and Sdf1 expression is seen in Irx5 morphants (c’,d’) compared to un-injected embryos (c,d). (e,f’) From 
stage 22 up to stage 32, Sdf1 is markedly overexpressed in the head region of Irx5 morphants relative to 





3.3. SDF1 expression is repressed by IRX5 
To further investigate Sdf1 transcription repression by IRX5 in vivo, a human SDF1 promoter 
luciferase reporter (Garcia-Moruja et al., 2005) was co-injected with Irx5 morpholino in each 
blastomere of 4-cell stage Xenopus embryos. Decreasing endogenous IRX5 levels by MO 
injections resulted in a significant increase of luciferase activity, suggesting that Sdf1 was 
repressed by IRX5 (Fig. 30a). Irx5 repressor activity was also verified on SDF1 transcription in 
vitro, by co-transfecting Irx5 expression construct together with the SDF1 luciferase reporter in 
various cell lines. Overexpression of wild type mIrx5 DNA in 10T1/2 and 293T cultured cells 
was sufficient to mediate significant SDF1 promoter trans-repression (Fig. 30b). However, since 
basal level of SDF1 expression was relatively low in these two cell lines, we sought to find cell 
lines where endogenous SDF1 activity was higher. LC5 (human lung fibroblast), MS5 (stromal 
cells) or U373 (astrocytoma) were previously shown to trans-activate SDF1 reporter in specific 
culture conditions (Garcia-Moruja et al., 2005). Since MS5 cells were readily available in our 
Institute, tests were first performed in this cell line (Fig.30b). Basic levels of Sdf1 transcription 
was low (even lower than previous tested cell lines), therefore co-transfections were concurrently 
repeated on “non-activated” and “gamma-irradiated” MS5 cells. Irradiation consisted on a sub-
lethal dose of 3Gy (30 minutes at 86 rad/min) from a cobalt source (300000 V, 10 mA) (Garcia-
Moruja et al., 2005). Unfortunately, gamma irradiation did not significantly improve the basal 
level of SDF1 expression (Fig. 30c), indicating that a longer exposure to irradiation may have 
been necessary (up to 2 hours) to detect significant SDF1 activation. Regardless, repression by 
IRX5 was observed in both experimental set ups. 
To conclude, we confirmed by luciferase reporter assays that SDF1transcription was repressed by 










Figure 30: In vivo and in vitro experiments show repression of SDF1 by IRX5 
(a) Injection of a human SDF1 promoter reporter in Xenopus embryos reveals increased basal luciferase 
activity in Irx5 depleted embryos. (b-c) Overexpression of mIrx5 in three different cell lines (10T1/2, 293T 
and MS5) is sufficient to repress trans-activation of the SDF1 reporter. Contrary to previous report (Garcia-
Moruja et al., 2005), basal SDF1 activity is not increased after gamma irradiation (γ irrad.). Data are 
presented as mean ± S.D. (error bars represented on top of charts). Statistical significance was determined 
by one-tailed Student's t test (* p value < 0.05; ** p value < 0.005). 
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3.4. NCC migration is rescued when endogenous SDF1 levels are lowered 
Based on our previous results, we showed that IRX5 was needed to down-regulate Sdf1 
expression. Modulation in SDF1 secretion in the head region of Xenopus laevis embryos may 
participate in the control of migratory movements of NCCs. To test if ectopic Sdf1 expression in 
Irx5 morphant embryos was in part responsible for the defective NCC migration, endogenous 
Sdf1 levels were reduced by co-injection of a Sdf1 morpholino (MO) (Theveneau et al., 2010). As 
previously described, Irx5 was depleted by injecting a total of 123 ng of MO in 4-cell stage 
embryos. To avoid causing major craniofacial anomalies upon Sdf1 depletion, the quantity of 
Sdf1 MO was progressively reduced down to 20 ng. Even though injection of low dose of Sdf1 
MO did not overtly affect NCC migration, proper streaming of NCCs into the first BA was 
recovered in 70% of embryos co-injected with both Irx5 and Sdf1 MOs (Fig. 31a-d). This 
suggested that IRX5 controlled NCC migration by repressing or adjusting the levels of SDF1. 
Since this secreted chemokine was also shown to control other migratory cell population such as 
primordial germ cells (PGCs) (Staton et al., 2011; Takeuchi et al., 2010), the dorso-lateral 
trajectory of PGCs was examined during Xenopus development using the PGC-specific marker 
Xpat (Hudson and Woodland, 1998). In Xenopus, the PGCs migrate from the center of the 
endodermal cell mass at stage 23, to the uppermost dorsal part of the endoderm at stage 40 until 
they reach the genital ridges at stage 46, where they proliferate and differentiate into mature 
PGCs (Nishiumi et al., 2005). We found that germ cells were mis-localized, spread out in the 
endodermal mass and reduced in numbers within Irx5 morphants relative to control embryos (Fig. 
31e,f). However, the rescue of germ cell migration by Irx5/sdf1 double KD was not as significant 
as for the neural crest cell population. This may be due to the difficulty of detecting germ cells 
that were located deep inside mesodermal tissues of Xenopus.  
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This observed germ cell migration defect prompted us to re-examine index cases for gonadal 
activity. Scintillography tests were performed on all male IRX5 patients and revealed minimal 
testis activity (Fig. 31g,h) consistent with the observed hydrocele and cryptorchidism.  
Finally, reduction of endogeneous level of SDF1 by MO injection should also be considered to 
investigate whether hematopoietic defects seen in Irx5-depleted embryos was also due to ectopic 





Figure 31: IRX5 controls migration of cranial NCCs and primordial germ cells (PGCs) by repressing 
Sdf1 expression  
 (a) Twist expression demarcates NCCs in the 4 branchial arches (1-4) (n = 70/70). Dashed red line outlines 
the eye vesicle. Scale bar, 0.25 mm. (b) Irx5 MO-injected embryos lack NCCs in the first BA (n = 37/58). 
Dashed black line outlines absence of the first BA. (c) Sdf1 MO-injected embryos do not display overt 
NCC migration defects (n = 46/46). (d) Reduction of Sdf1 by injection of Sdf1 MO rescues NCC migration 
to the first BA of Irx5 morphants (n = 42/58). (e,f) Defective migration of PGCs marked by Xpat is seen in 
Irx5 morphant embryos (n = 33/40). Scale bar, 0.5 mm. Embryos in panels e,f were cleared in BA/BB. 
(g,h) Total body scan of technetium pertechnetate in patient 2 shows minimal uptake in both gonads (red 
arrowhead) compared to control male (same age). DSG was performed at the Jordan University Hospital 





The comparison of gene expression profiles in Irx5 MO-injected and control embryos proved to 
be a valid approach to uncover new target genes regulated by IRX5 but most importantly to gain 
further mechanistic insights on how this transcription factor orchestrated cell migration during 
embryo morphogenesis. 
Cd82 and Sdf1 were two appealing candidates since both of them were previously described as 
playing a role in migration of different cell types during metastasis cancers and embryonic 
development respectively. I chose to investigate first Sdf1 rather than Cd82 since previous studies 
described this chemokine as a key regulator of NCC migration during craniofacial 
morphogenesis. However, the expression overlap of Cd82 with Irx5 in developing Xenopus 
embryos together with the drastic reduction of Cd82 transcript level at depletion of IRX5, suggest 
that Cd82 would be an interesting IRX5 target gene to study.  
Our in situ hybridization and luciferase assays showed that, by controlling Sdf1 expression in the 
ectoderm of pharyngeal arches, IRX5 orchestrated chemo-attraction of the NCCs expressing 
CXCR4 to migrate into the mesodermal tissues. Depletion of IRX5 causing ectopic Sdf1 
expression in the BA mesenchyme, we could speculate that an overload of this chemokine on 
migrating NCCs expressing CXCR4 receptors may cause aberrant migration patterns. Works 
done by the group of Marsh showed that SDF1 induced CXCR4 internalization via endocytosis in 
cultures cells (Signoret et al., 1997). It would be worthwhile testing whether this is also true in 
vivo. It is expected that surface CXCR4 receptors on migratory NCCs of Irx5-deficient embryos 




Alteration of NCC migration due to overload of SDF1 ligands observed in Irx5-depleted embryos 
suggest that craniofacial dysmorphisms observed in human IRX5 patients may in part stem from 
a partial SDF1 gain-of-function during development. 
Besides pharyngeal arches, IRX5 transcripts were also highly detected in the neural tube and eye 
vesicles in Xenopus embryos (Fig. 20). Because the eyes, independent of its role in vision, were 
shown as a key organizer of facial development, we further investigated putative targets that 
could be controlled by IRX5. We focused our attention on other target genes, mainly Bmp4 since 
it was highly expressed in developing eyes, otic vesicles and neural tube and most importantly 
because this morphogen is known to be essential for face and eye patterning (Kobayashi et al., 
2010; Nie et al., 2006). 
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4. IRX5 controls eye patterning and midface expansion via BMP4 and SHH 
Proximo-distal and dorso-ventral patterning of the eyes depend on intrinsic signals such as 
transcription factors, cell-cell contact and extracellular signaling molecules that promote optic 
vesicle interaction with the extra ocular mesoderm, the neural crest cells and the surface ectoderm  
(Fuhrmann, 2010). From early stage of development, the two antagonist morphogens SHH and 
BMP4 regulate asymmetric expression of a complex network of transcription factors that 
progressively specify dorso-ventral polarity of the eye vesicles (Lupo et al., 2005; Ohkubo et al., 
2002). 
A few studies have shed light that the Iroquois (Irx) genes also play a role during eye 
development in metazoans. Although the eyes of Drosophila have anatomical and physiological 
differences with vertebrates, gene network and regulatory pathways seem to be conserved. In 
fruitfly eye, Iroquois genes (Iro-C) organized the dorso-ventral patterning of the eye imaginal 
discs (Dominguez and de Celis, 1998; McNeill et al., 1997). All the murine Irx genes were 
expressed in developing retina while Irx5 was specifically required for the development of retinal 
ganglion cells and cone bipolar neurons (Cheng et al., 2005). Irx5 KO mouse also displayed 
smaller eye opening compared to wild type siblings (Fig. 32). Irx genes were also expressed in 
eyes of zebrafish embryos, and Irx1a/Irx2a regulated Hedgehog waves during retinogenesis 
(Cheng et al., 2006; Choy et al., 2010). Contrary to mouse and fish, only Irx5 was transcribed in 
Xenopus retina (Garriock et al., 2001) and studies on frog Irx genes mainly focused on their role 
for neural patterning (Rodriguez-Seguel et al., 2009). Finally, the role of IRX genes during eye 







Figure 32: Small eye opening observed in Irx5 KO mouse (right) compared to control (left) 
High panel, lateral view. Low panel, front view. Pictures were provided by Dr. Nathalie Gaborit (2011), 
Gladstone Institutes, UCSF. 
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Since IRX5 patients displayed severe telecanthus, myopia, hypoplasia of the lacrimal punctuae 
and sensorineural hearing impairment, we hypothesized that IRX5 may also play an important 
role during eye and ear formation in humans. In view of the robustness of HMMS modeling in 
Xenopus embryos, it was worthwhile to extend our analysis using Irx5 morphant embryos and 
examine the function of this gene during eye development. Irx factors being linked to signaling 
pathways such as BMP (Gomez-Skarmeta et al., 2001; Kudoh and Dawid, 2001) and SHH 
(Wilson and Maden, 2005) in different animal models and organs, we also investigated the role of 
Irx5 in controlling these two morphogens during dorso-ventral eye patterning. 
4.1. IRX5 patients display hypertelorism and severe eye abnormalities 
Since the first report by Prof. Hamamy in 2007 describing eye phenotype (Hamamy et al., 
2007b), further tests have been conducted by Dr. Osama Ababneh, an ophthalmologist in Jordan, 
to ascertain and document eye defects associated to HMMS. Fundus examination was undertaken 
for the three Jordanian patients and full field (Ganzfeld) ISCEV standard electroretinography 
(ERG) (Marmor et al., 2009) was performed in the eldest patient. Eye abnormalities were also 
documented in the Turkish patient by Prof. Kayserili. 
All HMMS patients displayed similar eye defects consisting on telecanthus (tele = far; canthus = 
palpebral commissures), progressive axial severe myopia and epiphora (tear overflow onto the 
face) caused by lacrimal punctuae agenesis (Fig. 33a,b). Dacryoscintigraphy showed signs of 
systemic dye absorption which suggested a higher rate of ocular absorption compared to control 
(data not shown). To investigate the etiology of the severe myopia diagnosed in HMMS patients, 
ophthalmic examination was requested. The three Jordanian propositi revealed a larger cup to 
disc ratio which may be due to enlargement of the optic nerve or loss of ganglion cells entering 
the optic disc (Fig. 33c). Rod and cone responses detected by ERG showed moderate to 
subnormal changes of b-wave amplitude compared to normative data in both photopic and 
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scotopic conditions (Marmor et al., 2009) (Fig. 33d). Defective response of these two retina 
photoreceptors was more prominent in the left eye and was accompanied by oscillatory response 
changes (Fig. 33d). These results suggested a possible myopic retinal degeneration and were 
reminiscent of the defective signal transmission (from photoreceptors to ganglion cells) observed 
in Irx5 null mice caused by improper development of cone bipolar cells (Cheng et al., 2005). 
Patients with BMP4 mutations also showed moderate to severe amplitude reduction and peak 
time delay consistent with generalized retinal dysfunction affecting rods and cones (Bakrania et 
al., 2008; Hayashi et al., 2008; Reis et al., 2011). Besides eye abnormalities, sensorineural 
hearing loss was also diagnosed for all IRX5 patients. Syndromes caused by SHH mutations were 
also reported with eye abnormalities that partially overlap with those of HMMS (Bakrania et al., 
2010; Schimmenti et al., 2003). Figure 33 summarizes all the naso-ocular anomalies observed in 






Figure 33: Naso-ocular symptoms in patients with HMMS 
(a) Face picture of a HMMS proband with craniofacial dysmorphisms including epiphora (red arrowhead). 
(b) Eye picture of a HMMS patient illustrating agenesis of lacrimal punctuae (red arrowhead). (c) Eye 
fundus picture of a HMMS patient reveals a large cup to disc ratio (>0.5). Dashed back line outlines the 
disc; dashed red line outlines the cup. (d) A full field (Ganzfeld) standard electroretinography (ERG) of a 
HMMS proband showed subnormal b-wave (blue arrow) in amplitude (Rod response and bright light 
stimulation) and slight change in oscillatory responses (green stars) in the left eye in scotopic conditions. 
Red arrows show a-waves. Fundus examination and ERG were performed by Dr. Osama Ababneh, Jordan 
University Hospital (2011) (e) Detailed description of ocular and ear manifestations in HMMS patients and 
overlapping phenotypes with related syndromes (BMP4; MIM112262 and SHH; MIM600725). +, 




4.2. Changes in Irx5 levels in Xenopus embryos cause eye patterning defects 
In Xenopus embryos, Irx5 was expressed in the midbrain, hindbrain, neural tube, otic vesicles and 
branchial arches at different stages of development (Fig. 34a-e). It was also expressed in the optic 
vesicles at stage 21 and throughout the developing retina up to the tadpole stage (Garriock et al., 
2001). To investigate the role of IRX5 during eye development, Irx5 was knocked-down by 
morpholino (Irx5 MO) injections (Rodriguez-Seguel et al., 2009). Its depletion in frog proved to 
be insightful since Irx5 morphant embryos exhibited smaller eyes with evident structural defects 
(Fig. 34f). At tadpole stage, the organized layers of the retina such as the outer nuclear layer 
(onl), the inner nuclear layer (inl) and the ganglion cell layer (gcl) in control embryos were 
overtaken by an expanded and disorganized neural retina (nr) in Irx5-depleted embryos (Fig. 
34g). Mis-localized or missing lens (le) was also observed. These eye defects indicated that optic 
vesicle invagination may have failed. Ectopic growth of retinal pigment epithelium (RPE) 
observed in the optic stalk (Fig. 34g) of Irx5 morphant embryos and loss of ventral sector of the 
optic cup (Fig 34h,i) also implied a possible ventralization during eye dorso-ventral patterning.  
Overexpression of Irx5 in Xenopus embryos, by injection of 80 pg of pCS2+-mIrx5 in 4-cell 
stage embryos, did not remarkably affect the eye structure but rather the distance between the eye 
cups resembling cyclopia phenotype (Fig. 34f). The absence or reduction of brain or neural tube 
(nt) together with expansion of cartilage (ca) and muscle (mu) tissues observed in the head region 
of Irx5 overexpressing embryos (Fig. 34f) was evocative of holoprosencephalic phenotypes, a 
classical craniofacial abnormality associated with disruptions of SHH or increased BMP4 










Figure 34: IRX5 is required for eye patterning during Xenopus development 
(a-e) In situ hybridization shows that Irx5 expression in the eye vesicles starts from stage 24 (red 
arrowhead). Irx5 transcript level is increasing over time in optic vesicles, midbrain, hindbrain, pharyngeal 
pouches and otic vesicles (red arrowhead) at stage 35. Embryo in panel e was cleared in BA/BB. (f,g) Irx5-
depleted embryos display dysmorphic head with loss of the ventral sector of the optic cup. (h,i) Cross 
section of an eye of a 5-day old Xenopus control (h) and Irx5 morphant embryo (i). Irx5 morphant retina 
displays disorganized layers with neural retina (nr) hyper-proliferation, ectopic formation of retinal pigment 
epithelium (rpe) and external lens (le). nt, neural tube; onl, outer nuclear layer; inl, inner nuclear layer; gcl, 









4.3. IRX5 is required for eye development via Shh 
SHH controls progenitor proliferation, patterning and cell fate during central nervous system 
development (Fuccillo et al., 2006). Depending on the neural tube region, SHH is secreted in the 
ventral midline of the telencephalon (Kiecker and Lumsden, 2004), in the zona limitans 
intrathalamica (Zli) (Zeltser, 2005), in the floor plate of the diencephalon and spinal cord, but also 
in non-neural tissues such as the underlying notochord and the prechordal plate (two mesodermal 
derivatives) (Ericson et al., 1997; Gunhaga et al., 2000; Ingham and McMahon, 2001). SHH 
expression at the anterior embryonic midline patterns midface expansion (Belloni et al., 1996) 
and any disruption of this signaling pathway can result in severe ocular anomalies (Bakrania et 
al., 2010; Schimmenti et al., 2003) and/or holoprosencephaly (Traiffort et al., 2004). More 
precisely, together with retinoic acid (RA) and FGF (Lupo et al., 2005), SHH controls 
specification of the ventral retina and expansion the optic stalk, and indirectly antagonizes BMP4 
which is strictly expressed in the dorsal retina (Zhao et al., 2010). Shh expressed in retinal 
ganglion cells (RGC) modulates development of the optic disc and stalk and controls axon 
guidance (Charron and Tessier-Lavigne, 2005; Dakubo et al., 2003).  
The striking retina defects in Irx5-depleted embryos, as well the cyclopia phenotype in Irx5 
overexpressing tadpoles, together with the established roles of Shh during eye and brain 
development, prompted us to precisely examine Shh transcriptional activity in the midline and 
brain tissues of Xenopus when IRX5 was up or down regulated.  
By whole embryo in situ hybridization using antisense RNA probe, Shh transcripts were detected 
in Xenopus embryos cleared in benzyl alcohol/benzyl benzoate (BA/BB). Ectopic Shh 
transcription was distinctively detected in the forebrain vesicle, the prechordal plate and 
frontonasal process of Irx5 MO-injected embryos at stage 26 (Fig. 35a). Up-regulation of the 
direct SHH target genes, Pax2 and Vax2, seen in the ventral optic vesicles of Irx5 morphant 
embryos confirmed an increase of Hedgehog activity relative to control embryos (Fig. 35b-d). 
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Therefore, by direct or indirect inhibition of Shh expression, IRX5 controlled proper growth of 
the multi-layered retina and lens of the eyes. This result was in line with previous reports showing 
that expansion of Shh expression in the anterior midline of blind cavefish promoted lens 
degeneration and arrest of eye development (Yamamoto et al., 2004). Microphthalmia, loss of 
lens and expansion of the optic stalk were also observed in Xenopus embryos that overexpressed 
Shh due to depletion of the Shh-antagonist Xhip (Cornesse et al., 2005). Finally, decrease in the 
number of retinal ganglion cells in chick retina by ectopic administration of Shh (Spence et al., 
2004) was evocative of retinal degeneration and ganglion cell loss observed in IRX5 human 
patients. 
To examine the effect of IRX5 overexpression on Shh transcription, increasing quantity of 
pCS2+-mIrx5 expression construct was injected into 4-cell stage Xenopus embryos. mIrx5 DNA 
induced cyclopia phenotype and dose-dependently repressed Shh expression until it was entirely 
abrogated in midline tissues of Xenopus embryos injected with 80 pg of mIrx5 (Fig. 35e). Note 
that Shh expression was not affected in branchial arches of embryos overexpressing IRX5, 
suggesting that Irx5-mediated inhibition of Shh was tissue specific and time dependent (Fig. 35e). 
Taken together, these results showed that IRX5 was sufficient and required to repress Shh 
expression in the midline tissues to drive eye morphogenesis and eyefield separation. Severe 
telecanthus, degeneration of the retina and enlargement of the optic nerve observed in human 







Figure 35: IRX5 is required and sufficient for Shh repression in midline tissues  
(a) In Irx5-depleted embryos, Shh expression is increased in the prechordal plate and forebrain vesicle. (b) 
Pax2, normally confined to the ventral retina, extends to the dorsal region of the eye in Irx5 morphants 
relative to control embryos. Note an enhanced expression of Pax2 at the midbrain-hindbrain boundary and 
the otic vesicles of Irx5 morphants. (c,d) Vax2, an immediate Shh target, is expanded dorsally in the optic 
cup of Irx5 morphants. Note increased Vax2 expression in the ventral region of the forebrain vesicle as 
well. Side view (c) and frontal view (d) of Xenopus embryos. (e) At stage 28, Shh transcription is dose-
dependently repressed by Irx5 overexpression in midline tissues but not in the branchial arches. (f,f’) 
Sagittal section of 5-day old Irx5 over-expressing Xenopus embryo (f) shows near cyclopia, with cartilage 
and muscle hyperplasia compared to control (f’). nr, neural retina; le, lens; mu, muscle; ca, cartilage. 
Embryos in panels a and e were cleared in BA/BB. 
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4.4. IRX5 activates Bmp4 for dorsal eye patterning  
While Irx5-mediated repression of SHH signaling pathway was critical for the growth and ventral 
patterning of the eye, we were also interested in the regulation of the opposite dorsal morphogen 
BMP4 by IRX5. Numerous studies showed that SHH antagonized BMP4 which was strictly 
expressed in the dorsal retina (Zhao et al., 2010), whereas other reports showed that BMP 
signaling was inhibited by antagonists such as Ventroptin (Chordin-like 1) expressed in the 
ventral part of the eyes (Sakuta et al., 2001). Midline expansion which was shown to be regulated 
by SHH, may also be related to disruption in BMP signaling pathway as was demonstrated in 
mice by Fernandez and Lana-Elola (Fernandes et al., 2007; Lana-Elola et al., 2011). 
At stage 26 of Xenopus development, Bmp4 expression overlapped with Irx5 in the dorsal retinas 
and in the otic vesicles suggesting possible interaction of these two genes. Whole embryo in situ 
hybridization showed that depletion of IRX5 in Xenopus embryos induced loss of Bmp4 
expression in the dorsal eyes, otic vesicles and a decrease of Bmp4 transcripts in the dorsal neural 
tube (Fig. 36a), suggesting that IRX5 may activate Bmp4 transcription during morphogenesis of 
different sense organs. Moreover, the direct BMP4 target genes, such as Vent2 and ET, were 
affected by the depletion of Bmp4 in Irx5 MO embryos, confirming a possible IRX5 dependant 
regulation of Bmp4 (Fig. 36b,c). Expression of Bambi, an inhibitor of BMP4 signaling pathway 
was unchanged (Fig 36d). We also observed that Bmp4 expression in the heart field was not 
changed in Irx5 MO embryos compared to controls (Fig. 36a), confirming that regulation of 
Bmp4 by IRX5 was tissue specific. 
Staining for nuclei revealed that optic placodes did not invaginate properly in Irx5 morphant 
embryos compared to controls at stage 26 of Xenopus development. Disruption or delay in 
invagination process may lead to formation of a disorganized neural retina with dislocated lens 
observed in Irx5-depleted embryos (Fig. 36e).  
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Finally, to verify whether IRX5 controls Bmp4 transcription, in vitro luciferase assays were 
carried out using mouse Irx5 expression constructs and a 2-kb human BMP4 promoter reporter 
(Puskaric et al., 2010). As with the Kcnd2 promoter assays (Costantini et al., 2005), BMP4 was 
10-fold more up-regulated when Irx5 wild type was added compared to the baseline activity of 
this promoter (Fig. 36f). Abrogation of trans-activation using Irx5 missense mutants was in line 
with our previous results and confirmed that IRX5 was sufficient to activate expression of BMP4. 
Mutated forms of IRX5 may therefore induce lower BMP4 activity during eye morphogenesis in 





Figure 36: IRX5 controls eye patterning via trans-activation of Bmp4 
(a) In Irx5-depleted embryos, Bmp4 expression is entirely abrogated in the dorsal eyes and otic vesicles. 
Note unchanged Bmp4 expression in the heart field of both control and Irx5 morphant embryos. (b,c) Vent2 
and ET, immediate Bmp4 targets, are also not expressed in the optic vesicles at depletion of IRX5. (d) 
Expression of Bambi, an upstream inhibitor of BMP4 signaling pathway, is however unaffected in Irx5 
morphant embryos. (e) Dysplasia or invagination defect in optic vesicles of Irx5 MO-injected embryos is 
revealed by nuclei staining. (f) Transient co-transfections in 10T1/2 cells of wild type mouse Irx5 with a 
hBMP4 reporter construct show 8-fold increase of transcriptional activity relative to control. Conversely, 




4.5. IRX5 also activates Bmp4 for ear morphogenesis 
Besides craniofacial dysmorphisms and eye patterning defects observed in Irx5-depleted Xenopus 
embryos, ear placode malformations were also noticed following in situ hybridization. Expression 
of genes such as Gata3, Pax2 and Fgf10 were markedly altered in the otic vesicles of Irx5 
morphant embryos (Fig. 37a-c) and nuclei staining confirmed hypoplasia/dysplasia of ear anlagen 
(Fig. 37d). 
Beside structural anomalies, depletion of IRX5 in Xenopus embryos also induced a loss of Bmp4 
expression in the otic vesicles (Fig. 36a) at stage 26 of development. Expression overlap of Irx5 
and Bmp4 suggested that IRX5 may also activate Bmp4 transcription during ear morphogenesis as 
it did during eye patterning. Phenotypic resemblance between HMMS and BMP4 associated 
disorders was also noticed such as protruding and malformed ears accompanied with 
sensorineural hearing impairment (Bakrania et al., 2008; Hamamy et al., 2007b), sustaining that 
these two genes may interact at limited points in time and in discrete embryological tissues during 
embryogenesis, especially during morphogenesis of sensory organs such as eyes, external and 
internal ears. Finally, since previous reports showed that Hedgehog signalling was required for 
correct patterning of the otic vesicles in zebrafish (Hammond et al., 2010), we speculated that 
dysplasia of the otic structures observed in Irx5 morphant Xenopus embryos may also be caused 
by ectopic Shh secretion in the head region. 
Finally, other studies demonstrated that BMP and SHH signaling pathways play a role during 
invagination of nasal pits (Vicki Metzis’s poster; Hedgehog 2012 conference) or lingual epithelial 
invagination during teeth formation (Dassule et al., 2000). Therefore, it is probable that IRX5, by 
regulating Bmp4 expression, controls formation of the optic and otic cups, but may also 








Figure 37: Xenopus embryos display defective otic invagination in the absence of IRX5 
(a-c) Altered or diminished expression of Gata3 (a, inset), Pax2 and Fgf10 (c, red arrowhead) in the otic 
vesicles of Irx5 morphants suggests improper ear development compared to control embryos at Stage 26. 




4.6. Bmp4 transcription is directly regulated by IRX5 in vivo 
To explore whether the Bmp4 activation by IRX5 occurred through direct binding, chromatin 
immunoprecipitation (ChIP) was performed in vivo using whole Xenopus embryos at stage 26. 
Even though ChIP method was previously used to investigate transcription factor-DNA 
interactions in Xenopus laevis embryos (Blythe et al., 2009; Buchholz et al., 2005), some 
optimizations were still necessary to get the best enrichment. I chose to test whether IRX5 protein 
could be found on the Bmp4 promoter at stage 26 of Xenopus development, when these two genes 
were co-expressed. 
4.6.1. ChIP cross-linking and sonication optimization 
First, fixation and sonication were optimized in order to yield the best cross-linked and sheared 
chromatin and generate ideal fragments of less than 1000 bp in size. Fixation time course (20, 30 
and 45 min) was performed on embryos collected at 4 different stages (10, 19, 24 and 29) (Fig. 
38). While genomic DNA (gDNA) from embryos fixed 20 minutes showed no resistance to 
shearing, gDNA from embryos fixed 30 minutes and above presented evidence of cross-linking 
and sonication-resistance (Fig. 38a-d). Instead of 1 hour of formaldehyde treatment usually 
performed to gastrulas (Blythe et al., 2009), an optimal time of 25 minutes was finally used for 
stage 26 embryos (Fig. 38e). This timing was still much higher than in other systems such as 
yeast and cultured cells for which the fixation was performed for 10 to 15 minutes (Luo et al., 
1998). It was also noticed that for the same time of cross-linking (30 or 40 minutes), older 
embryos (stage 29) were more resistant to shearing than gastrula embryos, suggesting that time of 
formaldehyde fixation needed to be adjusted (Fig. 38c-d). These results indicated that the binding 
kinetic of chromatin proteins to DNA varied and depended on the quantity of non-chromatin 
proteins which increased over time of embryo development. Somatic levels becoming higher in 
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late stage embryos (or quantity of non-chromatin proteins increasing) compared to gastrula 
embryos may explain the necessity of reducing the formaldehyde fixation time from 1 hour to 25 
minutes in Xenopus embryos, down to 10 minutes in somatic cultured cells. Finally, increasing 
the number of sonication rounds up to 15 improved the quantity of cross-linked chromatin 
fragments which sized between 300 to 1000 bp. However, rising sonication cycles in over cross-
linked samples did not help to get rid of the fragments above 1 kb, which confirmed that fixation 
time and sonication optimizations were essential to get optimal yield (90%) with maximal 






Figure 38: Crosslinking and sonication optimization on Xenopus embryos 
(a-d) Embryos were collected at different stages of development (St.19, St. 24, St.29 and St. 10). For each 
batch of embryos, 3 different crosslinking times were tested (20, 30 and 45 min). After 0, 5, 10 and 15 
cycles of sonication, fragmented gDNAs were detected by 1.2% agarose gel electrophoresis. (e) For 
embryos at stage 26, 25 minutes of 1% formaldehyde crosslinking, followed by 15 cycles of sonication 
(16% amplitude) in 2 ml eppendorf tube were the best conditions to obtain DNA fragments sized between 
200 to 600 bp.  
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4.6.2. Validation of a custom antibody specific to Xenopus laevis IRX5 
A custom polyclonal antibody raised against Xenopus laevis IRX5 (anti-X-IRX5) was generated. 
The antigen was chosen on the basis that it needed to be specific to IRX5 and not to any other 
IRX protein, and that it could be easily accessible to the antibody while IRX5 was bound to 
DNA. The last 26 carboxy amino acid residues of IRX5 protein of Xenopus laevis (X-IRX5) 
proved to be a good antigen for ChIP purposes (Fig. 39a). The antigen peptide was synthesized, 
purified and injected in rabbits by the company GL Biochem (Shanghai).  
Before using an antibody for ChIP experiments, it is recommended to test its quality, specificity, 
affinity for the target protein. To assess X-IRX5 antibody specificity, protein extracts from 
control and Irx5-depleted embryos were compared by western-blotting. Whole cell protein 
extraction was performed on five Xenopus embryos at stage 25 homogenized in 100 µl of RIPA 
buffer. Using our classical western blot conditions (Chapter 2 Materials and methods), no 
differences could be seen between control and Irx5 morphant embryos. Therefore, different 
experimental conditions were evaluated for each step of the western blot process. First, since 
IRX5 is a transcription factor, nuclear protein extraction was performed instead of a whole cell 
extract. Before loading into the gel, samples were usually prepared in denaturing condition (by 
addition of SDS and DTT) to enable access of the antibody to the epitope which may reside 
inside the folded protein. However, in case our anti-X-IRX5 antibody recognizes the epitope only 
if it exists in the folded three-dimensional structure of the protein, samples under non-denaturing 
condition were also prepared. Moreover, besides semi-dry protein transfer from the gel onto 
PVDF membrane, a wet transfer onto nitrocellulose membrane was also undertaken. Finally, two 
different blocking solutions were used, 5% non-fat milk and Bovine Serum Albumin (BSA). 
Unfortunately, none of these conditions above allowed us to detect specifically IRX5 protein with 
this custom antibody anti X-IRX5. 
127 
 
Performing a ChIP assay requires that the antibody recognizes a chromatin complex composed of 
fixed proteins bound to gDNA. Therefore, nuclear extracts from crosslinked and sonicated 
embryos were used. After a series of high speed centrifugations to get rid of the embryo yolk, X-
IRX5 was detected at the expected size of 50 KDa of control embryos but not Irx5-MO injected 
embryos (Fig. 39b). Other bands were detected due to unspecific binding of the anti-X-IRX5 
polyclonal antibody, especially on contaminating proteins from yolk (>75 KDa). Besides 
validating the specificity of this antibody, the Irx5 MO efficiency to block IRX5 protein 




Figure 39: Production of a custom polyclonal antibody which is specific to Xenopus laevis IRX5 
(a) After amino-acid alignment of vertebrate IRX5 homologs and all Xenopus laevis IRX paralogs, a C-
terminal 26 amino-acid antigen (red square) was selected for antibody production. (b) The specificity of 
this custom antibody to Xenopus laevis IRX5 protein was verified by western blot on proteins extracted 
from whole Xenopus embryos. This antibody anti-X-IRX5 recognized specifically crosslinked endogenous 
Xenopus IRX5, which is absent in Irx5 morphant (MO) embryos (red arrowhead). 
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4.6.3. Quantitative PCR (Q-PCR) analysis of ChIP 
After DNA purification from the ChIP complexes, quantitative PCR was used to detect small 
quantities of immunoprecipitated DNA. Even if Xenopus laevis genome has not been sequenced 
yet, the Bmp4 promoter has been identified (Metz et al., 1998). To predict occupancy of the 
transcription factor IRX5 on the Bmp4 promoter region that contains a putative consensus IRX5 
binding site ACAnnTGT (Bilioni et al., 2005), a set of 6 PCR primer pairs (XBmp4-1 to XBmp4-
6) were designed on a region located 2 kb upstream of the start codon ATG (Fig. 40) (Appendix 
1). Two pairs of PCR primers were also designed inside the Bmp4 Opening Reading Frame 
(ORF) (XBmp4-7 and XBmp4-8) and one pair on the Xbra promoter region that was not predicted 




Figure 40: Schematic representation of the Xenopus Bmp4 genomic locus  
IRX5 is predicted to bind on Bmp4 promoter region which contains a putative consensus Irx binding site 
(ACAagTGT) (Bilioni et al., 2005). PCR primer pairs (1 to 8) were designed in non-coding and coding 




Two methods are usually used to analyze ChIP Q-PCR data: the “percent input” method and the 
“fold enrichment” method. “Immunoprecipitation efficiency” for a given genomic region is 
defined as the amount of PCR product in the immunoprecipitated sample divided by the amount 
of PCR product in the input sample, also called “percent input”. “Percent input” method was 
preferred because calculation includes normalization for both the background level and the input 
chromatin going into the ChIP in contrast to the “fold enrichment” method that takes into account 
only the background signal. The starting input fraction was 10% and the input sample was diluted 
1 in 50 before Q-PCR, therefore a dilution factor of 500 or 8.965 cycles (i.e., log2 of 500) was 
subtracted from the Ct value of the input sample which was called “adjusted input Ct”. The 
“percent input” was calculated as follows: 100 x 2 ^ (adjusted input Ct – average ChIP Ct). 
The first set of experiments demonstrated the specificity of the anti-X-IRX5 when IRX5 could 
only be pulled down by this custom antibody and not by IgG. Four out of six PCR primer pairs 
showed that the Bmp4 promoter region was enriched (Fig. 41). Primer set XBmp4-3 formed 
dimers during PCR reaction, and primer set XBmp4-6 resulted in low PCR efficiency especially 
in control embryos. In order to increase the chance of IRX5 immunoprecipitation and improve 
ChIP efficiency, XIrx5 was overexpressed in Xenopus embryos by injecting a XIrx5-pCS2+ 
expression construct at 4-cell stage of development. Enrichments obtained in Irx5-overexpressed 
embryos were lower than the one from control embryos, maybe due to improper embryo 
development when Irx5 was increased. However, the ratio of “anti-X-IRX5 percent input” to 
“IgG percent input” was much higher in embryos overexpressing IRX5, proving that our custom 





Figure 41: IRX5 activates Bmp4 expression via direct binding to its promoter region 
Only the custom antibody anti-Xenopus IRX5 (anti-X-IRX5) specifically pulls down endogenous or 



























Input 24.7 25.2 24.9 25.1 24.8
Adjusted input * 15.7 16.2  15.9 16.2  15.8  
α-X-IRX5 R2 28.5 0.0146 0.0047 30.2 0.0062 0.0020 28.5 0.0175 0.0089 30.4 0.0066 0.0049 32.2 0.0016 0.0011
α-IgG R 33.1 0.0009 0.0010 34.9 0.0002 0.0000 33.7 0.0005 0.0003 32.5 0.0012 0.0001 30.3 0.0075 0.0085
ratio X-IRX5 / IgG 16.0 26.0 35.3 5.4 0.2
Input 25.1 25.6 25.1 25.5 25.3
Adjusted input 16.1 16.7  16.0  16.5  16.0  
α-X-IRX5 R2 29.3 0.0107 0.0023 32.7 0.0016 0.0004 28.9 0.0144 0.0074 28.5 0.0252 0.0078 28.1 0.0237 0.0020
α-IgG R 36.9 0.0001 0.0000 35.1 0.0003 0.0002 37.0 0.0000 0.0000 - 0.0000 0.0000 34.6 0.0003 0.0002







Table 4: ChIP Q-PCR data analysis (1st experiment) 
Avrg. = Average; α-X-IRX5 R2 = sample immunoprecipitated with antibody anti Xenopus laevis IRX5 
(Rabbit 2); α-IgG R = sample immunoprecipitated with IgG anti Rabbit; * Adjusted Input = the starting 
input fraction was 10%, and the input sample was diluted 1/50 before Q-PCR, therefore a dilution factor 
(DF) of 500 or 8.965 cycles (i.e., log2 of 500) is subtracted from the Ct value of input; ** % input = 




These experiments were replicated with different set of embryos, reagents and beads, and all of 
them gave similar results as described above. More experimental controls validated our ChIP 
protocol. For instance, the fact that no enrichment was observed on the Bmp4 ORF (X-Bmp4-8) 
or on another unrelated gene such as Xbra, confirmed the specificity of IRX5 binding (Fig. 42). 
Taken together these data argued that IRX5 could directly bind to the Bmp4 promoter in vivo and 
regulated its expression.  
Direct interaction of IRX5 on the Shh promoter was not investigated since its promoter sequence 
in Xenopus laevis is unknown. Attempts were made to design a series of  PCR primer pairs based 































Input 24.7 24.6 26.5 24.2 24.6
Adjusted input 15.7 15.6 17.5 15.2 15.6
α-X-IRX5 R2 24.9 0.1859 0.0839 25.8 0.0889 0.0357 27.9 0.0743 0.0117 32.8 0.0004 0.0002 34.6 0.0002 0.0000
α-IgG R 34.1 0.0003 0.0002 34.5 0.0003 0.0003 36.6 0.0002 0.0001 35.1 0.0001 0.0001 36.7 0.0000 -
ratio X-IRX5 / IgG 572.7 318.9 388.3 3.2 4.2
α-X-IRX5 R2 29.4 0.0079 0.0033 27.7 0.0236 0.0063 30.4 0.0141 0.0056 31.2 0.0018 0.0010 30.9 0.0027 0.0010
α-IgG R 32.5 0.0014 0.0016 31.1 0.0022 0.0011 32.0 0.0044 0.0008 30.9 0.0019 0.0003 35.3 0.0001 0.0001
Control 
Dynabeads





Figure 42: Direct activation of Bmp4 by IRX5 expression is confirmed 
Only the promoter region of Bmp4 (amplicons 1, 4 and 5) is enriched compared to Bmp4 ORF (amplicon 8) 
or to XBra promoter. After Q-PCR amplification of ChIPed samples, products were run on 1% agarose gel. 




We showed that IRX5 controlled dorso-ventral eye patterning, ear morphogenesis and midface 
expansion by regulating two antagonistic morphogens namely Shh and Bmp4. By direct binding, 
IRX5 activated Bmp4 transcription which may in turn antagonize SHH signaling in the ventral 
midline of the embryos. The absence of co-expression of Shh and Irx5 in developing optic 
vesicles of Xenopus embryos supports the indirect repression of Shh by IRX5 via the BMP4 
gradient. Negative regulation of Shh transcription by BMP activity was previously described 
during patterning of different tissues and organs, as for instance during limb development in 
chick and mouse (Bastida et al., 2009). 
The down-regulation of Bmp4 expression in the dorsal retina of Irx5-depleted embryos may 
therefore lead to an overexpression of Shh in the ventral part of the developing eye cup in a non 
cell-autonomous manner. This may explain the retina degeneration and the enlargement of the 
optic stalk observed in human IRX5 patients. BMP4 unbalance causing partial gain of function of 
SHH in the neural tube and prechordal plate may also lead to telecanthus observed in HMMS, a 
phenotype that was opposite to cyclopia/holoprosencephaly when SHH signaling was lost. These 
speculations are in line with previous work done in zebrafish showing that Iroquois genes play 
conserved functions in the control of Shh expression during retinogenesis in a cell-autonomous or 
non-cell autonomous way (Cheng et al., 2006). Finally, the over-secretion of the chemokine 
SDF1 causing cell migration defects and ectopic NCCs over the eye vesicles of Irx5-depleted 




5. IRX5 interacts with transcription factors to regulate craniofacial morphogenesis 
As shown in previous paragraphs, IRX5 can act as a transcriptional repressor or activator 
depending on its cellular and developmental context. For instance, IRX5 was shown to negatively 
regulate the potassium channel gene Kcnd2 (also known as Kv4.2) in the heart whereas it 
activated Kcnd2 transcription in non-cardiac cells such as 10T1/2 (Costantini et al., 2005). This 
change of activity can be driven by protein partners that bind to IRX5 and modulate its 
transcriptional output. For instance, by recruiting the cardiac transcriptional repressor mBOP 
expressed in cardiac cells, IRX5 inhibited Kcnd2. However, the absence of mBOP expression in 
10T1/2 resulted in transcriptional activation of the same gene by IRX5. This was further 
demonstrated when co-expression of mBop and Irx5 in 10T1/2 cells resulted in a marked 
abrogation of the Irx5-dependent activation of Kcnd2-luciferase reporter (Costantini et al., 2005). 
Another example of a protein partner that inhibited the Irx5-induced activation of the Kv4.2 
promoter in fibroblastic cells was IRX4 (He et al., 2009).  
To gain further insights into the transcriptional output exerted by IRX5, we searched for protein 
partners which would modulate its activity using two different methods. First we looked for genes 
that were highly correlated with IRX5 expression by a meta-analysis of human Affymetrix 
microarrays using a web-based tool developed at UCLA (Day et al., 2007). Concurrently, we also 
looked for putative protein partners of mouse IRX5 using a yeast two-hybrid system. Potential 






5.1. IRX3, GATA3 and TRPS1 define a syn-expression group with IRX5 
The gene-gene correlation tool (http://genome.ucla.edu/~jdong/GeneCorr.html) developed by 
UCLA allowed us to retrieve genes that were highly correlated in expression with IRX5 in 
humans (using HG-U133_Plus platform). The first four genes highly correlated with IRX5 were 
IRX3, GATA3, TRPS1 and SCL39A6 with an average correlation score of 0.59, 0.57, 0.55 and 
0.54 respectively (Table 5).  
Finding IRX3 as the first gene whose expression was linked to that of IRX5 was an excellent 
validation of the pertinence of this in silico approach, demonstrating the accuracy and power of 
this tool. Irx3 and Irx5 were shown to be highly co-expressed in different tissues and organs 
during mouse development (Houweling et al., 2001) and immunoprecipitation experiments 
already demonstrated that IRX3 bound to IRX5 although it did not alter the IRX5 induced 
regulation outcome (He et al., 2009). Therefore, since IRX3 has been validated as a partner of 
IRX5, our analysis was focused on the two GATA zinc-finger transcription factors TRPS1 and 
GATA3 which were next in the IRX5 syn-expression list (Table 5).  
Chromosome Position Gene Symbol Probe.Set.ID Correlation Average
chr16:53523484-53525482 IRX5 210239_at 1
chr16:52874718-52877268 IRX3 229638_at 0.59
chr10:8136778-8156493 GATA3 209604_s_at 0.62
chr10:8136675-8157219 GATA3 209602_s_at 0.57
chr10:8136675-8157219 GATA3 209603_at 0.53
chr8:116489899-116750429 TRPS1 222651_s_at 0.58
chr8:116489899-116750429 TRPS1 218502_s_at 0.57
chr8:116493965-116750103 TRPS1 224218_s_at 0.54
chr8:116495305-116685863 TRPS1 234351_x_at 0.52
chr18:31943196-31963203 SLC39A6 202089_s_at 0.56
chr18:31942458-31963203 SLC39A6 202088_at 0.55





Table 5: Computed IRX5 transcript correlation with genes encoding for IRX3, GATA3, 
TRPS1 and Zinc transporter ZIP6 (SLC39A6) according to UCLA Gene Expression Tool  
1: correlated, indicative of co-expression; 0: not correlated. 
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5.2.  WISH in Xenopus and mouse confirm co-expression of Irx5, Gata3 and Trps1 
To confirm co-expression of Gata3 and Trps1 with Irx5, in situ hybridization in Xenopus 
embryos were performed at different stages of development. Since Trps1 has not been previously 
studied in Xenopus, 2 kb of its cDNA (reverse transcribed from RNA extracted from stage 28 
embryos) was amplified (Appendix 1) and cloned into pSC-B-amp/kan. The full length cDNA of 
Gata3 was also amplified in the same way as Trps1 (Appendix 1) and cloned into pCS2+ 
plasmid. Subsequently, these constructs were linearized and RNA antisense probes were 
synthesized for in situ hybridization.  
Focusing our analysis on IRX5 transcriptional activity during craniofacial morphogenesis, 
expression patterns of Trps1, Gata3 and Irx5 were specifically examined in developing head. 
WISH showed that these three genes shared craniofacial domains of expression in Xenopus 
embryos at stage 33 (Fig. 43a-c,g). Irx5 was co-expressed with Trps1 in discrete embryonic 
tissues in the three branchial arches (BA) (Fig. 43g). Irx5 and Gata3 were co-expressed only in 
developing lens whereas Irx5, Trps1 and Gata3 transcripts were co-localized to the ventral region 
of the four BA, otic vesicles and frontonasal process (Fig. 43g).  
Expression overlapping of these 3 transcription factors during craniofacial development was 
further confirmed by in situ hybridization in mouse embryos at E10.5 (Fig. 43d-f,h). mTrps1 
RNA antisense probe was synthesized using a construct provided by Dr. Malik (Malik et al., 
2001). mGata3 was amplified from mouse cDNA (reverse transcribed from RNA extracted from 
stage E9.5 embryos) (Appendix 1) and cloned into pCS2+ plasmid. As observed in Xenopus, Irx5 
was co-expressed with Trps1 in discrete ectodermal tissues of the maxillary and mandibular 
processes of the first branchial arch (Fig. 43h). Irx5 and Gata3 were co-expressed only in the 
dorsal part of the eyes whereas Irx5, Trps1 and Gata3 transcripts were co-localized in the 





Figure 43: Irx5, Trps1 and Gata3 are co-expressed in nested regions of the developing Xenopus and 
mouse head 
(a-c,g) In Xenopus embryos at stage 33, Irx5, Trps1 and Gata3 transcripts (pink) are co-localized to the 
ventral region of the four branchial arches (BA) (1-4), otic vesicle (ov) and frontonasal process (fp). Irx5 
and Trps1 (yellow) are co-expressed in three branchial arches (1-3). Irx5 and Gata3 mRNA (green) are 
seen in developing lens (le). (d-f,h) In mouse embryos at E10.5, Irx5, Trps1 and Gata3 transcripts (black 
dots) are co-localized to the most anterior region of the maxillary process of the first pharyngeal arch. Irx5 
and Trps1 (black strips) are co-expressed in discrete regions of the maxillary and mandibular processes of 




This syn-expression group suggested that GATA3 and TRPS1 transcription factors could interact 
with IRX5 at limited points in time and in discrete embryological tissues of the growing branchial 
arches, frontonasal process, eyes and ears. These protein interactions may modulate IRX5 
transcriptional output, which could then act as a repressor or activator depending on the type of 
complex formed. Interaction of these two zinc-finger transcription factors with IRX5 was 
clinically relevant given that mutations found in TRPS1 and GATA3 caused congenital disorders 
that shared discrete clinical features with HMMS syndrome.  
 
5.3. IRX5, GATA3 and TRPS1 patients share congenital craniofacial anomalies 
Mutations found in TRPS1 and GATA3 genes are responsible for Trichorhinophalangeal Type 1 
Syndrome (Momeni et al., 2000) (TRPS1; MIM190350) and Hypoparathyroidism Sensorineural 
Deafness and Renal Disease (Van Esch et al., 2000) (HDR; MIM131320) respectively. As shown 
in Table 1 and in Figure 44a-d, TRPS1 patients shared discrete clinical features with HMMS 
including sparse bilateral eyebrows, flat philtrum, high arched palate, thin upper lip, mild 
micrognathia, teeth anomalies and hip dysplasia (Ludecke et al., 2001). A few TRPS1 patients 
also displayed mental retardation (Gonzalez-Huerta et al., 2007; Hamers et al., 1990) and, as 
recently reported, osteopenia (Shao et al., 2011). Abnormalities shared with HDR were less 
pronounced than those shared with TRPS1, despite the sensorineural hearing impairment and 
hypoparathyroidism were significant features present in both HDR and HMMS. 
These phenotypic resemblances in eyebrow patterning, mouth shape and deafness may be the 
result of spatiotemporal interactions between these transcription factors during craniofacial 
morphogenesis. For instance, we can speculate that IRX5 and TRPS1 are expressed at the same 
time and in the same tissues, and therefore physically bind when the maxillary prominences fuse 
with the medial nasal process to form the philtrum and the upper lip. Any imperfection on one of 
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these two genes may give rise to the same phenotypic anomalies such as a flat philtrum and thin 
upper vermillion border present in both syndromes. And because we believe that TRPS1 and 
GATA3 serve as transient partners but certainly not as obligate chaperones of IRX5, there cannot 
be a complete clinical overlap but instead discrete phenotypic resemblance as previously 




Figure 44: HMMS and TRPS1 syndromes share craniofacial abnormalities. 
 (a-b) IRX5 patients 1 and 5 display sparse bilateral eyebrows (black square), flat philtrum (red arrowhead) 
and thin upper lip (black arrow). (c-d) Sparse eyebrows, smooth philtrum and thin upper vermillion are 
discrete abnormalities also present in two independent TRPS1 patients. The pictures of TRPS1 patients 




5.4. IRX5 interacts with GATA3 and TRPS1 by co-IP 
To test if IRX5 bound to GATA3 and/or TRPS1, co-immunoprecipitation (co-IP) were carried 
out using anti-Protein C (PC) affinity matrix (Roche, cat# 11815024001).  
The full length mTrps1 and mGata3 cDNAs were cloned in the expression construct pCS2+ with 
a 5’ PC tag, in order to produce N-terminally PC-tagged proteins in cell cultures.  
Firstly, PC-tagged proteins (PC-mTRPS1 and PC-mGATA3) were individually 
immunoprecipitated with anti-PC matrix (also called PC beads), followed by co-incubation 
overnight with the protein of interest (in our case mIRX5). Western blotting demonstrated co-
immunoprecipitation of IRX5 by TRPS1 or by GATA3, warranting possible protein-protein 
interactions (Fig. 45a,b lanes 1-2). IRX5N166K, which was previously shown to be more resistant 
to ubiquitin-mediated proteolysis and therefore to be more stable than IRX5A150P (Paragraph 2.5), 
showed a weaker interaction with both protein partners (Fig. 45a,b lane 3). We also noted that 
wild type IRX5 co-immunoprecipitated to a lesser extent with TRPS1C318X variant (Malik et al., 
2001) (Fig. 45a lane 4), validating the specificity of our co-IP experiments and reliability of 
previous findings. Assuming that these three transcription factors might form a heterotrimeric 
complex, GATA3 was first showed to bind TRPS1 alone (Fig. 45c lanes 1-2). It was also 
observed that GATA3 could better co-immunoprecipitate IRX5 in the presence of increasing 
amount of TRPS1 (Fig. 45d). 
To conclude, our in situ hybridization in frogs and mice and co-IP results together with the 
nosological analysis of craniofacial manifestations in human syndromes demonstrated that 
TRPS1 and GATA3 transcription factors interacted individually or together with IRX5 during 
head morphogenesis. Further analysis such as simultaneous detection of transcripts by double or 






Figure 45: IRX5 interacts with the zinc-finger transcription factors GATA3 and TRPS1 in a tri-
molecular complex 
(a) IRX5 is co-immunoprecipitated by wt TRPS1 (lane 2), and to a lesser extent by TRPS1C318X mutant 
(lane 4) (Malik et al., 2001). Mutated IRX5N166K protein can still be pulled down by wt TRPS1 (lane 3). (b) 
GATA3 co-immunoprecipitates wt IRX5 (lane 2), and to a lesser extent mutant IRX5N166K (lane 3). (c) 
GATA3 is co-immunoprecipitated by TRPS1 in the absence of IRX5 (lane 1). (d) Increasing amounts of 




5.5. IRX5 transcriptional output is modulated by its interaction with GATA3 and 
TRPS1 
Previous reports showed that transcriptional activity of IRX5 could be modulated in presence of 
protein partners such as mBOP or other IRX (Costantini et al., 2005; He et al., 2009). To analyze 
if TRPS1 and GATA3 alter IRX5 transcriptional activity, reporter luciferase assays described in 
previous paragraphs were repeated in presence of these two new protein partners.  
By transient co-transfections in 10T1/2 cells of mIrx5 together with mGata3 or mTrps1, the 
trans-activation of both rKcnd2 and hBMP4 promoter reporters was examined. Luciferase assays 
revealed that Trps1 dose-dependently potentiated Irx5 trans-activation (Fig. 46a,d), while Gata3 
significantly decreased Irx5-mediated trans-activation of both reporters (Fig. 46b,d). In the 
scenario of a tri-molecular complex, a stronger transcriptional repression of rKcnd2 and hBMP4 
was observed when IRX5 was co-expressed with GATA3 and TRPS1 (Fig. 46d). Similar results 
were observed with the hSDF1 promoter reporter. Co-transfections of MS5 cells with mIrx5 
showed an enhanced inhibition of SDF1 expression when GATA3 was overexpressed (Fig. 46e). 
This repression was stronger when both GATA3 and TRPS1 were co-expressed with IRX5 in 
MS5, lending further support to the possible interactions of these transcription factors during 
embryogenesis. 
To validate the repression exerted by the complex IRX5-GATA3, the activity of a GATA3-
regulated hGCMB reporter was examined upon addition of increasing amount of IRX5. Trans-
activation of the hGCMB promoter was documented when either GATA3 or IRX5 were 
transfected individually (Fig. 28). Surprisingly, its trans-activation was inhibited when both 
factors were co-expressed, suggesting that activity of two “activator” proteins could be reversed 







Figure 46: Regulation of key signaling molecules essential for craniofacial morphogenesis is 
modulated by interaction of IRX5 with the zinc-finger transcription factors GATA3 and TRPS1 
(a) Trps1 promotes Irx5-dependent trans-activation of the Kcnd2 promoter luciferase construct in 10T1/2 
cells. (b) Conversely, Gata3 inhibits Irx5-dependent trans-activation of the Kcnd2 reporter. (c) Increasing 
amounts of Trps1 potentiates the inhibitory role of Gata3 on the Irx5-mediated trans-activation of the 
Kcnd2 reporter. (d) Activation of hBMP4 promoter by IRX5 is also repressed upon increasing amount of 
Gata3 while improved with Trps1 in 10T1/2 cells. (e) Trps1 also potentiates the inhibitory role of Gata3 on 
the Irx5-mediated repression of the SDF1 promoter reporter in MS5 cells. Data are presented as mean ± 
S.D. (error bars represented on top of charts). Statistical significance was determined by one-tailed 




The aforementioned experiments indicated that the stoichiometry of the GATA3, TRPS1 and 
presumably IRX3 bound individually or in a molecular complex to IRX5, can modulate its 
transcriptional activity creating a large spectrum of craniofacial features. Haploinsufficiency seen 
in HDR and TRPS1 syndromes supports a gene dosage effect for these transcriptional regulators 
(Momeni et al., 2000; Van Esch et al., 2000). Likewise, monosomy of IRX3, IRX5 and IRX6, 
causing a disorder (Chang et al., 2010) similar to that of biallelic IRX5 mutants, argues that IRX3 
and IRX6 are needed to circumvent IRX5 haploidy. A picture emerges whereby the IRX proteins 
and their co-modulators regulate the expression of key signaling molecules such as BMP4, SDF1 
and KCND2 during organogenesis and in the pathogenesis of Hamamy syndrome. 
Finally, it was brought to our attention that children exposed to folate antagonists can share 
similar facial features with IRX5 patients (Bawle et al., 1998). This observation recalled us that 
strong correlative expression existed between IRX5 and SLC39A6 (Table 5), a transporter 
associated with the uptake of the folate inhibitor methotrexate (French et al., 2009). Similarly, the 
ear, dental and lacrimal anomalies witnessed in IRX5 probands were reminiscent of the 
Lacrimoauriculodentodigital (MIM149730) syndrome caused by mutations in the FGF10 
pathway (Rohmann et al., 2006), raising the possibility that the SLC39A6 and FGF10 genes may 




5.6. New IRX5 interacting proteins are uncovered by yeast two-hybrid screening 
As previously shown, IRX5-mediated trans-activation or trans-repression was regulated by other 
transcription factors that interacted with IRX5 in the cell nucleus. However, IRX5 activity may 
also be modulated by its post-translational modifications which can happen in the cell cytoplasm. 
Before its translocation in the nucleus, IRX5 may transiently interact with kinases, phosphatases, 
transferases, proteases for its modifications and other kind of proteins for its intra-cellular 
transport. Immunostaining of 10T1/2 cells transfected with wild type mIrx5 using monoclonal 
mouse IRX5 antibody (Sigma, cat# WH0010265M1) showed that IRX5 was indeed localized in the 
nucleus but also found in cytoplasmic vesicles (Fig. 47). Interestingly, cells transfected with 
mIrx5 lacking its homeobox displayed staining only in cytoplasmic vesicles (Fig. 47), suggesting 
that without homeodomain IRX5 could not be translocated into the nucleus. This observation, 
also reported by Costantini in 2005, may indicate that mutations in the IRX5 homeodomain could 
block its nuclear shuttling (Costantini et al., 2005).  
Therefore, in order to uncover such protein partners of IRX5 in the course of embryonic 
development, the CytoTrap two-hybrid system (Agilent) was used to study interaction of the 
transcription factor mIRX5 (bait) with proteins (targets) expressed in E9.5 mouse embryo 
(Agilent, cat# 975316). This system uses the yeast S. cerevisiae mutant strain cdc25H which is 
temperature-sensitive; the cells can grow at 25°C, but not at 37°C unless rescued with a protein-
protein interaction. Further details in the principle and its methods were described in Chapter 2 








Figure 47: Besides nucleus localization, IRX5 is also present in cytoplasmic vesicles suggesting its 
possible interaction with proteins present in cell cytoplasm. 
mIRX5 (in green) was detected by immnunofluorescence using a monoclonal anti-IRX5 antibody (Sigma, 
cat# WH0010265M1). Wild type (wt) IRX5 was localized in nucleus (DNA visualized with Dapi in blue) 
and in cytoplasmic vesicles whereas IRX5 lacking its homeodomain (∆HD) was localized only in 




5.6.1. cDNA library screening of E9.5 mouse embryos 
After cloning the full length mIrx5 into pSos plasmid, yeast cdc25H were co-transformed with 
the pMyr library (containing 3.95x106 primary clones of E9.5 mouse embryos) and pSos-mIrx5. 
More than 300 yeast colonies grew under non-selective conditions on glucose plates after 4-5 
days of incubation at 24°C. These clones were replicated on galactose plates and incubated at 
37°C for 4-5 days until growing colonies were visible.  
240 clones were picked up and pMyr plasmids were extracted for each of these clones. In order to 
identify each cDNA cloned into pMyr, plasmids were amplified using bacteria transformation and 
selection with chloramphenicol.  
Out of the 240 clones, 235 could be amplified (98%), extracted and sequenced, demonstrating the 
robustness of our protocol. Out of 235 sequenced cDNAs, 177 genes were represented (Table 6). 
80 cDNAs sequenced were found more than one time, suggesting that the probability that these 
genes were real candidates was higher than a gene found only once. However, out of the 80 
repeated cDNAs, Rras2 was found in 16 clones, Hras1 in 15 clones, and many other cDNAs 
(16%) were related to the Ras signaling pathway. As reported previously, the mammalian Ras 
cDNAs seemed to be the most abundant false positives in SOS recruitment system library 
screening (Huang et al., 2001), which was confirmed in our study.  A way to reduce the isolation 
of Ras false positives and enhance the efficiency of this system was to introduce mammalian 
GTPase activating protein (Aronheim, 1997). Besides the Ras genes, Pmpcb was found in 7 
clones and 19 other genes were found in 2 or 3 different clones (Table 7). 
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1 1110007L15Rik Get4 golgi to ER traffic protein 4 homolog (S. cerevisiae) 89 LOC100047713 Similar to Mipep protein 
2 2510003E04Rik RIKEN cDNA 2510003E04 gene 90 LOC546298 similar to ribosomal protein S2 
3 2700060E02Rik RIKEN cDNA 2700060E02 gene 91 Mapre1 microtubule-associated protein, RP/EB family, member 1 
4 2810433K01Rik Ska1 spindle and kinetochore associated complex subunit 1 92 Mat2a methionine adenosyltransferase II, alpha 
5 4930402E16Rik Pyruvate dehydrogenase phosphatase regulatory subunit 93 Mesdc2 mesoderm development candiate 2 
6 Aco2 aconitase 2, mitochondrial 94 Mettl3 methyltransferase-like 3 
7 Actc1 actin, alpha, cardiac 95 Mex3c mex3 homolog C (C elegans)
8 Actg1 actin, gamma, cytoplasmic 1 96 Mif macrophage migration inhibitory factor 
9 Actr1a ARP1 actin-related protein 1 homolog A  (yeast) 97 mito Cox2 cytochrome c oxidase subunit II
10 Afp alpha fetoprotein 98 mito Cox3 cytochrome c oxidase subunit III
11 Akap1 A kinase (PRKA) anchor protein 1 99 Mrps11 mitochondrial ribosomal protein S11 
12 Akr1b3 aldo-keto reductase family 1, member B3 (aldose reductase) 100 Mtmr4 myotubularin related protein 4 
13 Api5 apoptosis inhibitor 5 101 Myo9a myosin IXa, transcript variant 2 
14 Arl5a ADP-ribosylation factor-l ike 5A 102 Naca nascent polypeptide-associated complex alpha polypeptide 
15 Asb4 ankyrin repeat and SOCS box-containing protein 4 103 ND1 Mitochondrion, complete genome
16 Atad2 ATPase family, AAA domain containing 2 104 Ndnl2 necdin-like 2 
17 Atp5b ATP synthase, H+ transporting mitochondrial F1 complex, beta subunit, 105 Ndufv2 NADH dehydrogenase (ubiquinone) flavoprotein 2 
18 Atp5f1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit b, isoform 1 106 Npm1 nucleophosmin 1 
19 Atp5o ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit 107 Nras neuroblastoma ras oncogene 
20 ATP8-ATP6 mitochondrion, complete genome 108 Nup153 nucleoporin 153
21 Atxn10 ataxin 10 109 Otub1 OTU domain, ubiquitin aldehyde binding 1 
22 BC008155 cDNA sequence BC008155 110 Otud6b OTU domain containing 6B 
23 Bex2 brain expressed X-linked 2 111 P4hb prolyl 4-hydroxylase, beta polypeptide 
24 Calm1 calmodulin 1 112 Pdzd11 PDZ domain containing 11
25 Calr calreticulin 113 Peci peroxisomal delta3, delta2-enoyl-Coenzyme A isomerase 
26 Cap1 CAP, adenylate cyclase-associated protein 1  (yeast) 114 Pgam1 phosphoglycerate mutase 1 
27 Ccdc56 coiled-coil  domain containing 56 115 Pgrmc1 progesterone receptor membrane component 1 
28 Cct2 chaperonin subunit 2  (beta) 116 Phf10 PHD finger protein 10 
29 Cd164 CD164 antigen 117 Plaa phospholipase A2, activating protein 
30 Cdc42 Mus musculus cell  division cycle 42 homolog (S. cerevisiae) 118 Pmpcb peptidase (mitochondrial processing) beta 
31 Cdca2 cell  division cycle associated 2 119 Polr3k polymerase (RNA) III (DNA directed) polypeptide  K 
32 Cdk4 cyclin-dependent kinase 4 120 Pop4 processing of precursor 4, ribonuclease P/MRP family, (S. cerevisiae) 
33 Cdk5 cyclin-dependent kinase 5 121 Pop7 processing of precursor 7, ribonuclease P family, (S. cerevisiae) 
34 Chchd2 Coiled-coil-helix-coiled-coil-helix domain containing 2 122 Ppia peptidylprolyl isomerase A 
35 Chd4 chromodomain helicase DNA binding protein 4 123 Ppp3cb protein phosphatase 3, catalytic subunit, beta isoform 
36 Churc1 churchil l  domain containing 1 124 Ran RAN, member RAS oncogene family 
37 Clpp caseinolytic peptidase, ATP-dependent, proteolytic  subunit homolog (E. coli) 125 Ranbp1 RAN binding protein 1 
38 Cope coatomer protein complex, subunit epsilon 126 Rap2c RAP2C, member of RAS oncogene family 
39 Coro1c coronin, actin binding protein 1C 127 Rbm12 RNA binding motif protein 12
40 Cox1 mitochondrion, complete genome 128 Rbp4 retinol binding protein 4, plasma 
41 Cpt2 Carnitine palmitoyltransferase 2 129 Rcan1 regulator of calcineurin 1 , transcript variant 1
42 Crip2 cysteine rich protein 2 130 Rfwd2 ring finger and WD repeat domain 2 
43 Ddah2 dimethylarginine dimethylaminohydrolase 2 131 Rhbdd2 rhomboid domain containing 2 
44 Dis3l2 DIS3 mitotic control homolog (S. cerevisiae)-l ike 2 132 rig similar to insulinoma protein 
45 Eef1a1 eukaryotic translation elongation factor 1 alpha  1 133 Rit1 Ras-like without CAAX 1 
46 Eef1b2 eukaryotic translation elongation factor 1 beta 134 Rnf165 Ring finger protein 165 
47 Efha1 EF hand domain family A1 135 Rnf214 ring finger protein 214 
48 Eif4h eukaryotic translation initiation factor 4H 136 Rnr2 mitochondrion, complete genome
49 Elp2 elongation protein 2 homolog (S. cerevisiae) 137 Rpl10 ribosomal protein 10 
50 Emb embigin 138 Rpl12 Ribosomal protein L12 
51 Eno1 enolase 1, alpha non-neuron 139 Rpl13 ribosomal protein L13 
52 Farsb phenylalanyl-tRNA synthetase, beta subunit 140 Rpl5 ribosomal protein L5 
53 Fbxo21 F-box protein 21 141 Rpl7a ribosomal protein L7a 
54 Fbxo5 F-box protein 5 142 Rps23 ribosomal protein S23 
55 Fkbp1a FK506 binding protein 1a 143 Rps6 ribosomal protein S6
56 Foxj3 forkhead box J3 144 Rps7 ribosomal protein S7 
57 G430022H21Rik methyltransferase l ike 14 145 Rps8 ribosomal protein S8 
58 Gapdh glyceraldehyde-3-phosphate dehydrogenase 146 Rras2 related RAS (viral r-ras) oncogene homolog 2 
59 Glcci1 glucocorticoid induced transcript 1 147 Rtn4 reticulon 4 , transcript variant 2
60 Gna-rs1 guanine nucleotide binding protein, related sequence 1 148 Ruvbl1 RuvB-like protein 1 
61 Gnas GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus 149 Rwdd1 RWD domain containing 1 
62 Gnb2l1 guanine nucleotide binding protein (G protein), beta polypeptide 2 l ike 1 150 Scg5 secretogranin V 
63 Grp94 heat shock protein 90kDa beta 151 Sec22b SEC22 vesicle trafficking protein homolog B (S. cerevisiae) 
64 Hba-a1 hemoglobin alpha, adult chain 1 152 Senp3 SUMO/sentrin specific peptidase 3
65 Hba-x hemoglobin X, alpha-like embryonic chain in Hba complex 153 Serbp1 Serpine1 mRNA binding protein 1 
66 Hbb-y hemoglobin Y, beta-like embryonic chain 154 Slc4a8 solute carrier family 4 (anion exchanger), member 8 
67 Herc3 hect domain and RLD 3 155 Slc7a7 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 7 
68 Hmgb1 high mobility group box 1 156 Snrpe small nuclear ribonucleoprotein E 
69 Hmgn1 high mobility group nucleosomal binding domain 1 157 Srp72 signal recognition particle 72 
70 Hnrpa0 heterogeneous nuclear ribonucleoprotein A0, transcript variant 2 158 St13 suppression of tumorigenicity 13 
71 Hnrpa2b1 heterogeneous nuclear ribonucleoprotein A2/B1 159 Tbc1d19 TBC1 domain family, member 19 
72 Hnrpf heterogeneous nuclear ribonucleoprotein F 160 Tceal8 transcription elongation factor A (SII)-l ike 8 
73 Hras1 Harvey rat sarcoma virus oncogene 1 161 Thoc4 THO complex 4 
74 Hsbp1 heat shock factor binding protein 1 162 Thyn1 Thymocyte nuclear protein 1 
75 Hspa8 heat shock protein 8 163 Tigd5 tigger transposable element derived 5 
76 Huwe1 HECT, UBA and WWE domain containing 1 164 Tmed9 transmembrane emp24 protein transport domain containing 9 
77 Kras v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 165 Tmem14c transmembrane protein 14C
78 Lcmt1 leucine carboxyl methyltransferase 1 166 Tmem85 transmembrane protein 85 
79 Lman2 lectin, mannose-binding 2 167 Tomm70a translocase of outer mitochondrial membrane 70 homolog A  (yeast)
80 LOC100039924 similar to ribosomal protein S13 168 Tuba1b tubulin, alpha 1B
81 LOC100041163 similar to ribosomal protein L23a 169 Tubb5 tubulin, beta 5 
82 LOC100042049 similar to ribosomal protein L22 l ike 1 170 Ubc Ubc ubiquitin C
83 LOC100043346 similar to QM protein 171 Ube2v2 ubiquitin-conjugating enzyme E2 variant 2 
84 LOC100044124 similar to Nedd4 binding protein 2 172 Utp14a UTP14, U3 small nucleolar ribonucleoprotein, homolog A (yeast)
85 LOC100044342 hypothetical protein LOC100044342 , misc RNA 173 Vcan versican 
86 LOC100044916 similar to ribosomal protein L13 174 Wdr77 WD repeat domain 77 
87 LOC100046648 similar to ribosomal protein L10a 175 Ywhae tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein
88 LOC100047250 similar to ribosomal protein 176 Zfp143 zinc finger protein 143 
177 Zfp160 zinc finger protein 160  
Table 6: E9.5 mouse embryo library screening allowed the selection of 177 pMyr-target genes 



















135 Rras2 related RAS (viral r-ras) oncogene homolog 2 16 yes no Member of the R-Ras subfamily of Ras-l ike small GTPases
233 Hras1 Harvey rat sarcoma virus oncogene 1 15 yes no Member of Ras oncogene family (also include KRas and Nras)
4 Kras v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 2 yes / ? no Known to be false positif in SOS recruitment system library screening
284 Nras neuroblastoma ras oncogene 2 yes / ? no Known to be false positif in SOS recruitment system library screening
197 Hba-a1 hemoglobin alpha, adult chain 1 3 no no
110 Hba-x hemoglobin X, alpha-like embryonic chain in Hba complex 2 no no
279 Hbb-y hemoglobin Y, beta-like embryonic chain 2 yes / no no
43 mito Cox3 cytochrome c oxidase subunit III 3 no no
52 mito Cox2 cytochrome c oxidase subunit II 2 no no
124 Rnr2 mitochondrion, complete genome 2 ? no
171 Aco2 aconitase 2, mitochondrial 2 yes / ? no Role in iron homeostasis
280 ATP8-ATP6 mitochondrion, complete genome 2 no
202 Pmpcb peptidase (mitochondrial processing) beta 7 yes yes Zinc-binding motif protein located in the mito. matrix.  Catalyze the cleavage of 
the leader peptides of precursor proteins
131 Rhbdd2 rhomboid domain containing 2 3 not in 
coding reg
yes Novel cancer-related gene over-expressed in breast cancer (2009)
165 St13 suppression of tumorigenicity 13 3 yes yes
Encode for adaptor protein that mediates the association of the heat shock 
proteins HSP70 and HSP90. Involved in the assembly process of glucocorticoid 
receptor with molecular chaperones. Candidate tumor suppressor gene
268 4930402E16Rik
Pdpr
Pyruvate dehydrogenase phosphatase regulatory subunit 2 yes yes Function not known
303 Eef1a1 eukaryotic translation elongation factor 1 alpha  1 2 yes / no no Regulator of cell  growth and the cytoskeletal network. Expression is elevated in 
melanomas and tumors of the pancreas, breast, lung, prostate and colon
54 Gna-rs1 guanine nucleotide binding protein, related sequence 1 2 yes / not in 
coding reg
no Identified in the human major histocompatibil ity complex class I region
206 Hmgb1 high mobility group box 1 2 yes / no no
Chromatin protein, with 2 roles: extracellular function: trigger of inflammation 
and a stimulus for tissue reconstruction + intranuclear function: facil itate the 
assembly of DNA binding proteins (Transcription factors Hox, Pou...)
95 Gapdh glyceraldehyde-3-phosphate dehydrogenase 2 bad seq.
189 Mapre1 microtubule-associated protein, RP/EB family, member 1 2 bad seq. yes / no Also found by Dr. Ting Gang
181 Ranbp1 RAN binding protein 1 2 yes / no no
Member of Ras superfamily of GTPases. Velocardiofacial/DiGeorge syndrome 
candidate (congenital heart disease, defects in the palate, learning disabil ities, 
mild differences in facial features...). Expressed in frontonasal processes, 
branchial arches, aortic arches, l imb buds  
 
Table 7: List of 22 pMyr-target genes of the E9.5 mouse embryo library that were identified in more 





To verify the specificity of the interaction between the bait mIRX5 and the 22 selected target 
proteins, the yeast cdc25H cells were co-transformed with each individual candidate pMyr-cDNA 
together with either the original bait (pSos-mIrx5) or an irrelevant bait (such as pSos-empty), and 
then assayed for their ability to grow at 37°C on galactose plates. Surprisingly, out of 22 genes 
tested, only 4 could be confirmed (Fig. 48a-d), including Pmpcb (clone #202), St13 (clone #165), 
Mapre1 (clone #189) and 4930402E16Rik (clone #268). Mapre1 was excluded since the growth 
of co-transformed yeasts at 37°C on presence of galactose could not be confirmed on a second 
round of experiments (Fig. 48e). This gene may be a false positive as it was also found as a 
candidate target of the bait Spin1 during another library screening with CytoTrap (Dr. Ting Gang, 
IMB).  
We also checked whether the cDNA was cloned in frame in the pMyr plasmid, and surprisingly 6 
of them (Hba-a1, Hba-x, mito Cox3, mito Cox2, Rhbdd2, Gna-rs1) were found to be either 
mapped in non-translated regions or out of frame, indicating that rescue of the mutant strain 
cdc25H growth may not be related to the binding IRX5-myristylated target protein but rather be 







Figure 48: Interaction of IRX5 with either PMPCB or ST13 or PDPR (4930402E16Rik) rescue S. 
cerevisiae mutant strain cdc25H growth at 37°C in presence of galactose 
(a) Each yeast clone could grow at the non selective temperature of 24°C. (b) None of the clones could 
grow at 37°C when expression of Myr-target fusion proteins was not induced by the presence of galactose 
(c-d) Out of 22 genes tested, only 4 (red arrows, clones #202, 165, 189 and 268) could grow under the 
selective conditions (37°C, galactose) when interacting with IRX5 (+ pSos-mIrx5). Clones #135, 233, 284, 
4 and 131 are false positive since yeasts could grow in absence of IRX5 (pSos-empty) under selective 
conditions (37°C, galactose). (e) Mapre1 (clone#189) was excluded since co-transformed yeasts with IRX5 
could not grow at 37°C on presence of galactose. Gal.: Galactose; Glu.: Glucose. 
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To conclude, only 3 out of 177 initial target genes (representing 235 cDNAs) were further 
analyzed for interaction even though the link between the IRX5 transcription factor and these 
mitochondrial or cytoplasmic proteins was not obvious. Pmpcb encodes a peptidase located in the 
mitochondrial matrix that catalyzes the cleavage of the leader peptides of precursor proteins 
newly imported into the mitochondria. 4930402E16Rik also known as Pdpr (Pyruvate 
dehydrogenase phosphatase regulatory subunit) is also present in mitochondria (Diez-Roux et al., 
2011). Finally, St13 (suppression of tumorigenicity 13), also known as Hsp70 interacting protein 
(Hip), functions as a co-chaperone to other heat shock proteins such as HSP90 to mediate 
assembly of multi-protein complexes, protein folding, and transport of proteins within the cell 
(Shi et al., 2007). Interestingly, Hip was also shown to regulate the internalization of CXCR4, 
receptor of the chemokine SDF1 (Fan et al., 2002). This internalization may be regulated by 
direct binding of the C-terminal domain of HIP (residues 303-369) to G protein coupled receptor 
kinase (such as GRK5) (Fig. 49) (Barker and Benovic, 2011). The Hip ∆303-369 may therefore 




Figure 49: HIP phosphorylation regulates internalization of the chemokine receptor CXCR4.  
Adapted from Barker and Benovic (2011). 
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In the initial list of 177 genes, other potential candidates, for whom only one clone was collected, 
may be also interesting to study in future such as: 
- Cdc42 (Cell division cycle 42 homolog), a member of small Rho GTPases, is a main regulator of 
protrusion formation and stability of neural crest cells (Fuchs et al., 2009) but also play a role 
during nervous system regulation, blood formation, eye development and bone modelling 
regulation (Melendez et al., 2011). 
- Mif (Macrophage migration inhibitory factor 1)  which is highly expressed in developing eyes, 
tectum, branchial arches, pectoral fin buds, liver and gut of zebrafish. 
- Grp94 (a HSP90 family member) which may interact with IRX5 together with St13 
5.6.2. Co-IP confirms binding of IRX5 with the three potential candidate targets, 
PMPCB, PDPR and ST13 
To confirm whether IRX5 binds to PMPCB, PDPR and ST13, co-IP were carried out using anti-
PC affinity matrix. The cDNA full length of mPmpcb (1486 bp), mPdpr (2637 bp) and mSt13 
(1116 bp) were amplified from E9.5 mouse embryo cDNAs (Appendix 1).  Pmpcb and Pdpr were 
cloned in pCS2+ with a 3’ PC tag, in order to produce C-terminally PC-tagged PMPCB and 
PDPR proteins. St13 was cloned in pCS2+ with a 5’ PC tag, to generate a N-terminally PC-
tagged ST13 protein.  
After transient 293T cell transfections with each of these expression constructs, protein level was 
verified by western blot using antibody anti-PC (Roche, cat# 11814516001). For co-IP, PC-
tagged proteins (PC-PMPCB, PC-PDPR and PC-ST13) were individually immunoprecipitated on 
anti-PC matrix (Roche, cat# 11815024001), followed by co-incubation overnight with IRX5. 
Western blotting demonstrated co-immunoprecipitation of IRX5 by each of these new protein 
partners (Fig. 50, lanes 1-4), with a stronger interaction with PDPR. In view of these results, 
further experiments can be performed to verify whether weaker interaction is observed with the 
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mutant form of the bait such as IRX5N166K, or with a mutated target such as Hip ∆303-369 (Barker 
and Benovic, 2011). 
These results demonstrated that IRX5 can interact with mitochondrial enzymes and cytoplasmic 
proteins. Referring back to the 177 screened genes, some of them may be potential enzymatic 
candidates that interact only transiently with IRX5 for post-translational modifications, such as 
kinases (cyclin-dependent kinase), phosphatases and transferases (methyltransferase) (Table 6). It 
has been already shown that activity of an Iroquois gene Irx2 can be modulated by 
phosphorylation via mitogen-activated protein (MAP) kinase cascade (Matsumoto et al., 2004). 
Higher transcriptional activity of IRX5 was also observed when two Serine residues were 
changed into Aspartic acid (S46D and S63D) to mimic IRX5 phosphorylation (Fig. 51). 
Conversely, when the same Serine residues were changed into Alanine to mimic a 
dephosphorylated form of IRX5, the Kcnd2 trans-activation by IRX5 was repressed (Fig. 51). We 
assumed that IRX5 phosphorylation could also be mediated by a MAPK cascade, but this 
hypothesis has not been tested yet. Custom antibodies specific to the phosphorylated form of 
IRX5 (IRX5S46D/S63D) were generated to study the mechanisms mediating activation or inhibition 
of IRX5 by phosphorylation. 
To conclude, CytoTrap allowed us to find potential cytoplasmic candidates such as enzymes, co-
chaperones, cellular or nuclear receptors, which may transiently interact with IRX5 (Whiteside 
and Goodbourn, 1993). Although three proteins were validated by co-immunoprecipitation, 
further analysis need to be untaken to better understand the mechanisms behind these interactions 
and the effect on IRX5 which may act either as an activator or a repressor and most importantly 






Figure 50: IRX5 interacts with cytoplasmic and mitochondrial proteins such as ST13, PMPCB and 
PDPR during mouse development at E9.5 
IRX5 is co-immunoprecipitated by the PC-Tagged proteins ST13 (lane 2), PMPCB (lane 3) and to a 




Figure 51: IRX5 activity is modulated by phosphorylation  
IRX5 was mutated at putative phosphorylation sites Ser46 and Ser63. A double serine-to-alanine 
substitution (S46A/S63A), which mimics dephosphorylation, reduced Kcnd2 trans-activation by IRX5. 
Conversely a double serine-to-aspartic acid substitution (S46D/S63D), which mimics phosphorylation, 




Chapter 4 Conclusions and perspectives 
1. Aims, results and significance 
Mutations in IRX5 cause HMMS 
My research has allowed to partly uncover the genetic, embryological and biochemical etiology 
of Hamamy syndrome. Two distinct point mutations in the IRX5 gene were found in five affected 
children from two families. This Iroquois gene is part of a family of 6 IRX paralogs that encode 
transcription factors that control embryonic patterning in metazoans (Cavodeassi et al., 2001). 
This finding is of considerable importance since it is the first time that an IRX gene is linked to a 
genetic disorder in humans. 
The recessive missense mutations were found in two amino-acids located in the homeodomain of 
IRX5, residues which are invariant in both vertebrates and invertebrates. These biallelic single 
nucleotide polymorphisms were shown to have significant impact on the function of the encoded 
protein. Based on luciferase assays and western blotting, we confirmed that these mutations 
altered protein stability and most probably DNA binding activity. Depending on the cell type and 
embryological context, it was also found that these IRX5 muteins could display either 
hypomorphic or neomorphic activities, or behave as total loss-of-function alleles. 
The pathogenesis of HMMS is partly revealed by modeling in Xenopus embryos 
Detailed analysis of the clinical manifestations of HMMS provided insights into the role played 
by IRX5 during embryogenesis in humans, especially during craniofacial morphogenesis and for 
the ontogeny of major organs including heart, bone, blood and gonads. To characterize the 
function of the Irx5 gene in the context of normal embryonic development and disease state, in 
vivo modeling of this syndrome was developed by knocking down Irx5 in Xenopus laevis 
embryos. Irx5-morpholino-injected embryos exhibited to a certain extent comparable 
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physiological and anatomical defects as in HMMS patients. These anomalies mainly occurred as 
a result of impaired migration of neural crest cells (NCCs) that form different tissues in the face, 
heart, lacrimo-salivary glands and nervous system during embryogenesis. 
First, the anemia diagnosed in all IRX5 probands, could be partially phenocopied in Irx5-depleted 
embryos that displayed impaired expression of blood markers such as Scl, Lmo2, Gata3 and 
Hba3. This was the first time that an Iroquois gene was shown to play a noticeable role during 
hematopoiesis, a life-long process that takes place in bone marrow.  
Irx5 KD frog embryos also revealed cardiac structural anomalies and arrhythmia, two phenotypes 
that further lend support to the role played by IRX5 during heart morphogenesis and physiology. 
Genetic deletion of individual Irx gene in mouse resulted in significant defects in cardiac function 
but did not show main heart morphologic abnormalities as were observed in Xenopus. The lower 
heart beat rate in Irx5-depleted Xenopus embryos was reminiscent of repolarization defects 
reported in Irx5 KO mice (Costantini et al., 2005). However, the electrical conduction delay 
diagnosed in IRX5 patients was perhaps analogous to the post-natal conduction defects reported 
in Irx3 KO mice (Zhang et al., 2011). The protein homology of IRX3 and IRX5 and their 
overlapping patterns of expression in the mouse embryonic heart suggest possible functional 
redundancy that may mask their roles in cardiac development. HMMS patients displaying 
hypoplasia of NCC-derived valves and septum, we conjecture that besides regulating post-natal 
cardiac physiology, IRX5 may also controls septation and valve formation of the heart by driving 
cardiac NCCs. This remains to be tested. 
In addition to blood and heart anomalies, Irx5-depleted Xenopus embryos also displayed 
dysmorphic head structures with cartilage hypoplasia and muscle dysgenesis, which we found to 
be caused by defective migration of the cranial NCCs in branchial arches (BAs). 
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 IRX5 orchestrates cell migration by repressing SDF1   
To investigate the etiology of NCC migration defects, transcriptional profiling of Xenopus Irx5 
morphant embryos was undertaken using gene expression microarrays. This allowed us to 
characterize putative downstream genes that were either up or down regulated in absence of 
IRX5. 
We focused our attention on Sdf1 which was found to be the most over-expressed transcript in 
Irx5-depleted embryos (20-fold). WISH and luciferase assays confirmed that IRX5 strongly 
inhibited Sdf1 transcription, which codes for a secreted chemotactic agent that elicits cells 
migration (Olesnicky Killian et al., 2009). Aberrant migration of NCCs in the neurocranium of 
Irx5-depleted Xenopus embryos could be partially rescued by lowering endogenous levels of 
SDF1, suggesting that increased SDF1 signaling in Irx5 morphants could partly drive the 
pathogenesis of HMMS in humans. We proposed that IRX5 controls cell movements by 
modulating the amount of transcription of this secreted ligand in the mesenchyme of branchial 
arches. At the exception of irxl1, which was shown to be required for brain and pharyngeal arch 
morphogenesis in zebrafish (Chuang et al., 2010) and the Irx5 KO mice which displayed smaller 
eye openings (Cheng et al., 2005), no other studies have highlighted the role of a specific Irx gene 
during craniofacial morphogenesis. Deletion of the IrxB cluster in the mutant mouse Fused-toes 
however caused severe craniofacial defects indicative of the Irx gene roles during head 
morphogenesis (Anselme et al., 2007). Here we have provided evidence that IRX5 is indeed 
needed for head morphogenesis in humans and that its absence causes marked up-regulation of 
Sdf1 expression in developing frogs. It will be important to verify that our observations are also 
valid in Irx5 KO mice, where our work would predict that compound Sdf1/Irx5 KO mice might 
have a milder phenotype than null Irx5 mice. 
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In addition to defective migration of NCCs, it was also found that ectopic Sdf1 expression caused 
improper movement of the primordial germ cells in Irx5-depleted embryos, which was in 
agreement with previous reports in Xenopus (Takeuchi et al., 2010). Other studies demonstrated 
that targeted deletion of Sdf1 or its receptors Cxcr4 and Cxcr7 in the mouse led to ventricular 
septal defects, heart valve malformation and impaired migration of hematopoietic cells 
(Nagasawa et al., 1996; Sierro et al., 2007; Zou et al., 1998), suggesting that blood and cardiac 
defects observed in Xenopus Irx5 morphants may also be related to Sdf1 mis-regulation. Finally, 
co-expression of Irx5 and Sdf1 in osteoblasts during early bone development (Jung et al., 2006) 
may indicate a possible regulation of this chemokine by IRX5 for bone homeostasis. 
All together, these findings are noteworthy because we provide a new upstream “piece” of the 
complex machinery that controls cell migration. Craniofacial dysmorphisms, together with 
anemia, heart defects, sterility and bone fragility diagnosed in HMMS may in part stem from a 
gain-of-function of SDF1 during human development. Although I must caution myself from 
making simplistic predictions, I would anticipate that neutralizing antibodies for SDF1 or 
antagonists for the CXCR4/CXCR7 receptors could perhaps serve as therapeutic agents to 
alleviate bone fragility or anemia in HMMS patients. A few inhibitors against 
SDF1/CXCR4/CXCR7 complex have already shown promising results in the context of 
chemotherapies against cancers. For instance, the use of small interfering RNA specific to 
CXCR4 has delayed metastasis of breast and colorectal carcinoma (Lapteva et al., 2005). 
Moreover, the drug CTCE-9908, a CXCR4 antagonist, seems to decrease incidence of bone and 
lung metastasis (Richert et al., 2009). Finally, SDF1 expression being increased in patients with 
liver and lung fibrosis, therapeutic antibodies developed against CXCR7 give promising results to 
prevent organ fibrosis in several animal models (SIgN Immunology Seminar by Dr. Frederic 
Sierro, 9th Sept. 2011).  
160 
 
Besides Sdf1, microarray analysis and WISH in Xenopus embryos also revealed that IRX5 may 
act as a transcriptional activator of Cd82, especially in the eye and brain regions where both 
genes were highly co-expressed. Interestingly, SDF1 was shown to up-regulate Cd82 expression 
in decidual stromal cells (Li et al., 2011), which may indicate a possible link between the high 
fold change in expression of these two genes when IRX5 was depleted. Direct transcriptional 
regulation of Cd82 by IRX5 may be an appealing hypothesis to examine since this membrane 
glycoprotein was involved in different cell type migration, especially during metastatic cancers 
(Abe et al., 2008; Tsai and Weissman, 2011). 
IRX5 controls eye patterning and midface expansion via BMP4 and SHH  
Because Irx5 KD Xenopus embryos revealed eye abnormalities like in HMMS patients, the role 
of this transcription factor was further investigated during dorso-ventral eye patterning. Irx genes 
were shown to control eye development in various species (Cheng et al., 2005; McNeill et al., 
1997). At early stage of Drosophila development, Irx genes were required for the specification of 
dorsal region of the eyes (Cavodeassi et al., 1999), while in zebrafish, Irx1a and Irx2a were 
needed to retinal function and development respectively (Cheng et al., 2006; Choy et al., 2010). 
The role of Irx5 itself in the development of retinal cone bipolar cells was only described in mice 
(Cheng et al., 2005). BMP4 and SHH being the main patterning signals during eye development, 
WISH, luciferase assays and in vivo ChIP experiments were undertaken to examine how IRX5 
regulates these antagonistic morphogens in Xenopus. It was found that IRX5 was required and 
sufficient for Shh repression in midline tissues and that IRX5 directly activated Bmp4 
transcription in embryos. Bmp4 trans-activation by IRX5 may in turn serve to antagonize the Shh 
gradient produced in the midline tissues which drives eye morphogenesis and eye field 
separation. This part of my work is unpublished but will be the subject of a future manuscript 
which I intend to submit after my thesis defense. 
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To conclude, our research uncovered a new upstream regulator that is needed to modulate the 
concentration of the key morphogens SHH and BMP4 which mediate midface expansion and 
dorso-ventral eye patterning. Telecanthus, severe myopia, retinal degeneration and deafness 
diagnosed in HMMS may therefore originate from a partial gain-of-function in Shh and/or loss of 
BMP4 signaling during development. Since BMP signaling is also involved in morphogenesis of 
many other craniofacial structures such as skull, palate, tooth and skeletal muscle (Nie et al., 
2006), we can speculate that IRX5 protein expressed in the brain and branchial arch tissues may 
also control craniofacial morphogenesis by modulating BMP4 activity. We could extend this 
hypothesis to heart development as BMP4 signaling is known to mediate atrioventricular 
septation in the mouse heart as well (Jiao et al., 2003). It is noteworthy that mutations in BMP4 
and IRX5 genes giving rise to similar atrioventricular canal defects in human (Jiao et al., 2003), 
this further lends support for a possible interactions of these 2 genes during cardiac development. 
Finally, BMP4 which regulates bone homeostasis and blood formation via Scl and Gata2 
(Walmsley et al., 2002) may also be regulated upstream by the activity of IRX5 in this tissue. 
IRX5 transcriptional activity is modulated by GATA3 and TRPS1 
Finally our genetic and embryological studies were complemented by a biochemical approach to 
find possible protein partners of IRX5 that could change its transcriptional activity. Two GATA 
zinc-finger transcription factors, namely GATA3 and TRPS1, were shown to bind IRX5 and form 
a heterotrimeric complex. Comparison of clinical manifestations of HMMS with TRPS1 and 
HDR (caused by mutations in TRPS1 and GATA3 respectively) revealed discrete phenotypic 
overlaps suggesting possible spatiotemporal interactions of these three transcription factors 
during embryogenesis. The limited phenotypic resemblances suggested that their interactions may 
be transient and tissue specific rather than permanent and ubiquitous. We confirmed both in 
mouse and frog embryos that these three genes could be co-expressed during head 
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morphogenesis. In addition, it was also found that these protein partners modulated the 
transcriptional output of IRX5 on target genes such as Kv4.2, Sdf1 and Bmp4 (Fig. 52)  
 
Figure 52: IRX5, bound to GATA3 and TRPS1, regulates key signaling molecules during facial 
morphogenesis and dorso-ventral eye patterning 
 
Depending on the cell type and environmental context, IRX5 was found to act as an activator or 
repressor of target genes by recruiting different protein partners. The phosphorylation status of 
IRX5 may also change its activity as was demonstrated for the chick Irx2 (Matsumoto et al., 
2004). This could be further studied with antibodies that were raised against phosphorylated and 
non-phosphorylated forms of IRX5 (unpublished data). Potential interacting candidates found by 
yeast two-hybrid screening may also bring further insights into the “interactome” of IRX5. In 
particular, I found that ST13 (or HIP) which regulates the internalization of CXCR4 receptor (Fan 
et al., 2002) could bind IRX5. If this interaction was confirmed in vitro and in vivo, IRX5 would 
then serve to regulate SDF1/CXCR4 signaling both at the transcriptional levels as well as through 




2. Limitations and perspectives 
This study is the first to propose a mechanistic model implicating Iroquois proteins and co-
modulators, which all together regulate the expression of three potent morphogens i.e., SDF1, 
BMP4 and SHH during embryogenesis in particular during craniofacial morphogenesis.  
The role of IRX5 in bone homeostasis could not be addressed with animal models such as the 
Xenopus, as morphant embryos died within 2 weeks after fertilization before cartilage could 
differentiate into bone. The Irx5 KO mouse reports only described the role of Irx5 in cardiac 
physiology (Costantini et al., 2005) and in retina development (Cheng et al., 2005). Given that the 
Irx3 KO mouse did not present with overt developmental defects (Zhang et al., 2011), the study 
of double KO Irx3/Irx5 may be needed to evaluate the role of Iroquois genes during skeleton 
development.  
Although unpublished, I also obtained primary fibroblasts from skin biopsies of HMMS patients 
and their unaffected parents. The derivation of induced pluripotent stem cells (iPS) is being 
undertaken by collaborators in France and in the US. Following established differentiation 
protocols, these reprogrammed cells could be pushed towards different lineages and help examine 
the role played by muteins IRX5N166K and IRX5A150P in vitro (Park et al., 2008; Takahashi et al., 
2007). Comparison of maintenance and differentiation of these iPS cells into bone, cardiac or 
blood cell lineages may bring new insights on the role of IRX5 gene during bone homeostasis, 
heart formation and erythropoiesis in particular. Such a “disease in a dish” approach may prove to 
be a worthwhile endeavor given that several rare diseases have been successfully studied using 
patient specific iPS cells. Besides modeling the disease phenotypes and screening candidate 
drugs, the patient-specific iPS cells can also be corrected and then transplanted back into the 
patient for therapy purpose (Phillips, 2012; Zou et al., 2011). I only refer here to the anemia 
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present in HMMS patients which could be cured if hematopoietic precursors could be engrafted 
back using genetically-corrected patient specific donor cells. 
Even though the role of IRX5 during heart, blood and bone formation was not studied in depth 
during this thesis project, I am hopeful that this IRX5-driven pathology may trigger new interests 
into common ailments and possible therapeutic solutions to common diseases such as heart 
disease, anemia, osteoporosis and sterility which affect millions of people worldwide. I am very 
happy that my work has been instrumental in providing support to the two HMMS families. Not 
only have we been able to reach a clear genetic diagnosis for this syndrome but also I have had 
the opportunity to help the mothers with pre-natal diagnosis. 
3. Beyond development: evo-devo 
Another interesting aspect of the Iroquois genes is their conservation and variation throughout 
evolution. Comparable in several aspects to Hox genes (Santini et al., 2003), the genomic 
organization in clusters of the 6 Irx genes, their similar expression domains in several embryonic 
tissues and their equivalent patterns across different vertebrate species indicate a strong 
evolutionary conservation of their regulatory elements among the animal kingdom (de la Calle-
Mustienes et al., 2005). Genomic analysis of the two Iroquois clusters done by the Gomez-
Skarmeta group (Tena et al., 2011) shows that regulatory sequences that drive the activation of 
one or all Irx genes are evolutionarily conserved. The presence of shared Irx enhancers in mouse, 
Xenopus and zebrafish is probably the major evolutionary constraint that maintains the 
association of the Irx genes in clusters. The fact that these regulatory elements have been 
unchanged during evolution means that they must maintain precise spatiotemporal role of IRX 




Genetic variations in non-coding and coding regions of Irx clusters during evolution have altered 
the pattern of expression of Irx genes and the transcriptional activity of IRX proteins respectively. 
By regulating a series of key target genes, Irx genes appear to orchestrate development of the 
neural crest cells which is one of the great inventions of vertebrate species. From a phylogenetic 
perspective, changes in cranial NCC migration has allowed for a great diversity of head shape and 
function seen across vertebrate species such as fishes, amphibians, reptiles, birds and mammals 
(Fig. 53) (Gans and Northcutt, 1983; Le Douarin et al., 2007). Since we brought tangible 
evidence that IRX5 controls development of the frontonasal, nasal, mandibular and maxillary 
processes that form the midface, nose, philtrum and jaws of humans, it is tempting to speculate 
that it may also play similar role during craniofacial morphogenesis of other vertebrate species. 
For instance, the hyoid bone that primitively supports the jaw in fish that instead forms the stapes 
of the mammalian middle ear may be in part under the regulation of Irx genes. Furthermore, 
variation of the beak widths in Darwin's finches which were shown to be controlled by BMP4 







Figure 53: Is IRX5 playing a role in the huge diversity of head shape, color and function seen across 




To shed light on how Irx genes drive these remarkable changes in function and shape of cranial 
skeletal elements, analysis of the genomic loci containing Irx clusters should be undertaken 
across many phyla. Recent whole-genome comparisons have identified amino acid changes, 
divergent expressions, or variations in non-coding regulatory sequences that produce phenotypic 
effects while preserving viability (McLean et al., 2011). As craniofacial diversity is also seen 
among human ethnicities (Fig. 54), changes in regulatory elements or uncover SNPs may be 
found in coding or non-coding transcribed regions that are associated with specific phenotypes by 
comparing the sequences of the 1000 human genomes, in particular in the genomic regions within 
or near the IRX clusters (http://www.1000genomes.org/). IRX variants that segregate with certain 
human ethnicities may be found. It would be fascinating if using transgenic mouse models 
carrying these newly discovered rare IRX alleles, one could test whether these rare or common 
Iroquois genomic changes can drive specific traits of the human face and head. 
Although I realize that this may be very challenging to test, I wonder if this type of phylogenetic 
analysis could help us answering such questions as: Do IRX genes participate in silencing tooth 
formation in birds? Are IRX genes involved in development of the eagle’s sharp eyesight since 
HMMS patients suffer from congenital nearsightedness? Since IRX5 controls formation of the 
upper lip and philtrum in humans, does it also play a role in the growth of the elephant trunk?  








Figure 54: Could small variations in the regulation of IRX5 and other IRX genes account in part for 
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Appendix 1  
This table contains the list of primers and sequences used for different set of experiments. 
Species
Gene
Name Sequence 5'->3' Experiment
Human IRX5 CCGTAGGAAGCTGGAGTGC
Human IRX5 CTTCTGCTCAGCTCCTCCTG
Xenopus laevis Irx5 GCTGAAGTAGCAGGGACCAC
Xenopus laevis Irx5 AGGGTAAAAGGGGATGCTGT
Xenopus laevis Irx5 CACCACAGTAACCAGCCTCA
Xenopus laevis Irx5 TCTCTGCCAAGGACCAGAGT
Xenopus laevis Beta-actin GTGGATCAGCAAGCAGGAGT





Xenopus laevis Irx5 CAAGTAGCCCTGCGGATAGGACATG Morpholino for 
gene knock-down
Xenopus laevis Sdf1 AGAGCTAGAGTCCTTATGTCCATGT Morpholino for 
gene knock-down
Xenopus laevis Bmp4 AACTTCGAAGGCTGAGGTGA
Xenopus laevis Bmp4 AAACACCTGGCATGTTTCTG
Xenopus laevis Bmp4 CCACGTGATCCGCAAAAG
Xenopus laevis Bmp4 CCATGATTCTTGACAGCCAAT
Xenopus laevis Bmp4 GTAGCTGTCCCCCTGCATAG
Xenopus laevis Bmp4 GGCCAATGAATGCTGGTACT
Xenopus laevis Bmp4 ACACACGGCTCTGGCTACTT
Xenopus laevis Bmp4 ACGCTACACCCCCTAATTCC
Xenopus laevis Bmp4 GGCTGCAGTGGGACTGATA
Xenopus laevis Bmp4 TGGCAGCAGTCGCTATAGAA
Xenopus laevis Bmp4 ACAGGATGGCGGTGACTATC
Xenopus laevis Bmp4 GTCTCTGGAGGGTGCACAAC
Xenopus laevis Bmp4 CAGCCCAGTAAGGATGTGGT
Xenopus laevis Bmp4 TACTCACCCTCGTGATGGAAG
Xenopus laevis Bmp4 ACCCATAGCTGCAAATGGAC
Xenopus laevis Bmp4 TGAATGACCTCAATGGCAAG
Xenopus laevis XBra AGAGAGCTCTATGATAATCCTGGGA





Xenopus laevis Trps1 GGAATTCCCAGGCATGTGAGATCAAGCAGGA
Xenopus laevis Trps1 CCTTAAGAAGGCACCCCATATCTGCAC
Xenopus laevis Gata3 CGGAATTCATGGAAGATCAGGTAGATCCACGGTTAATCGATGGTAAGGAGGTCTCAGCCGAGCAGCC Cloning 
Xenopus laevis Gata3 GCTCTAGACTAACCCATTGCAGTGACCATAC with PC-Tag
Mouse Gata3 ATGGAGGTGACTGCGGAC
Mouse Gata3 CTAACCCATGGCGGTGAC
Mouse Gata3 CGGAATTCATGGAAGATCAGGTAGATCCACGGTTAATCGATGGTAAGGAGGTGACTGCGGACCAGCC Cloning 
Mouse Gata3 GCTCTAGACTAACCCATGGCGGTGACCATG with PC-Tag
Mouse Trps1 TGGATCCACCATGGAAGATCAGGTAGATCCACGGTTAATCGATGGTAAGGTCCGGAAAAAGCACCCCCCT Cloning 




Mouse Pmpcb CGGGATCCACTTTCTCCACCGCAGAGATG Cloning 
Mouse Pmpcb GCTCTAGATTACTTACCATCGATTAACCGTGGATCTACCTGATCTTCGTCACGAATCCAACGCATGTTA with PC-Tag
Mouse Pdpr CGGAATTCATGCTTTACCGGTTGCTCTCT Cloning 
Mouse Pdpr GCTCTAGATTACTTACCATCGATTAACCGTGGATCTACCTGATCTTCCTTCCCATGAAAGTCGCTCAG with PC-Tag
Mouse St13 CGGAATTCATGGAAGATCAGGTAGATCCACGGTTAATCGATGGTAAGGATCCCCGCAAAGTGAGCGA Cloning 



























List of the 157 genes in the 4 loci found by homozygosity mapping of the Jordanian family. 
# Gene Position Full name
1 WIPF3 7p15.1 WAS/WASL interacting protein family, member 3
2 SCRN1 7p14.3-p14.1 secernin 1
3 FKBP14 7p15.1 FK506 binding protein 14, 22 kDa
4 PLEKHA8 7p21-p11.2 pleckstrin homology domain containing, family A member 8
5 C7orf41 7p15.1 chromosome 7 open reading frame 41
6 ZNRF2 7p15.1 zinc and ring finger 2
7 DKFZp586I1420 7p15.1 hypothetical protein DKFZp586I1420
8 NOD1 7p15-p14 nucleotide-binding oligomerization domain containing 1
9 GGCT 7p15-p14 gamma-glutamyl cyclotransferase
10 GARS 7p15 glycyl-tRNA synthetase
11 CRHR2 7p15.1 corticotropin releasing hormone receptor 2
12 INMT 7p15.3-p15.2 indolethylamine N-methyltransferase
13 FLJ22374 7p15.1 hypothetical protein FLJ22374
14 AQP1 7p14 aquaporin 1 (Colton blood group)
15 GHRHR 7p14 growth hormone releasing hormone receptor
16 ADCYAP1R1 7p14 adenylate cyclase activating polypeptide 1 (pituitary) receptor type I
17 NEUROD6 7p15.1 neurogenic differentiation 6
18 CCDC129 7p15.1 coiled-coil domain containing 129
19 C7orf16 7p15 chromosome 7 open reading frame 16
20 PDE1C 7p15.1-p14.3 phosphodiesterase 1C, calmodulin-dependent 70kDa
21 LSM5 7p14.3 LSM5 homolog, U6 small nuclear RNA associated (S. cerevisiae)
22 AVL9 7p14.3 AVL9 homolog (S. cerevisiase)
23 LOC441208 7p14.3 hypothetical gene supported by AK094370
24 KBTBD2 7p14.3 kelch repeat and BTB (POZ) domain containing 2
25 RP9P 7p14.3 retinitis pigmentosa 9 pseudogene
26 FKBP9 7p11.1 FK506 binding protein 9, 63 kDa
27 NT5C3 7p14.3 5'-nucleotidase, cytosolic III
28 RP9 7p14.3 retinitis pigmentosa 9 (autosomal dominant)
29 BBS9 7p14 Bardet-Biedl syndrome 9
30 BMPER 7p14.3 BMP binding endothelial regulator
31 NPSR1 7p14.3 neuropeptide S receptor 1
32 AAA1 7p14.3 asthma-associated alternatively spliced gene 1
33 DPY19L1 7p14.3 dpy-19-like 1 (C. elegans)
34 DPY19L2P1 7p14.2 dpy-19-like 2 pseudogene 1 (C. elegans)
35 TBX20 7p15-p14 T-box 20
36 HERPUD2 7p14.2 HERPUD family member 2
37 SEPT7 7p14.3-p14.1 septin 7
38 EEPD1 7p14.2 endonuclease/exonuclease/phosphatase family domain containing 1
39 PP13004 7p14.2 hypothetical gene supported by AF447883
40 KIAA0895 7p14.2 KIAA0895 protein
41 ANLN 7p15-p14 anillin, actin binding protein
42 AOAH 7p14-p12 acyloxyacyl hydrolase (neutrophil)
43 NPM1P18 7p14.2 nucleophosmin 1 (nucleolar phosphoprotein B23, numatrin) pseudogene 18
44 ELMO1 7p14.2 engulfment and cell motility 1
45 GPR141 7p14.1 G protein-coupled receptor 141
46 TXNDC3 7p14.1 thioredoxin domain containing 3 (spermatozoa)
47 SFRP4 7p14.1 secreted frizzled-related protein 4
48 EPDR1 7p14.1 ependymin related protein 1 (zebrafish)  
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# Gene Position Full name
49 IRX3 16q12.2 iroquois homeobox 3
50 IRX5 16q11.2-q13 iroquois homeobox 5
51 IRX6 16q11.2-q13 iroquois homeobox 6
52 MMP2 16q13-q21 matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)
53 LPCAT2 16q12.2 lysophosphatidylcholine acyltransferase 2
54 CAPNS2 16q12.2 calpain, small subunit 2
55 SLC6A2 16q12.2 solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2
56 CES4 16q12.2 carboxylesterase 4-like
57 CES1 16q13-q22.1 carboxylesterase 1 (monocyte/macrophage serine esterase 1)
58 CES7 16q12.2 carboxylesterase 7
59 GNAO1 16q13 guanine nucleotide binding protein (G protein), alpha activating activity polypeptide O
60 AMFR 16q21 autocrine motility factor receptor
61 NUDT21 16q13 nudix (nucleoside diphosphate linked moiety X)-type motif 21
62 OGFOD1 16q13 2-oxoglutarate and iron-dependent oxygenase domain containing 1
63 BBS2 16q21 Bardet-Biedl syndrome 2
64 MT4 16q13 metallothionein 4
65 MT3 16q13 metallothionein 3
66 MT2A 16q13 metallothionein 2A
67 MT1L 16q13 metallothionein 1L (gene/pseudogene)
68 MT1E 16q13 metallothionein 1E
69 MT1M 16q13 metallothionein 1M
70 MT1JP 16q13 metallothionein 1J (pseudogene)
71 MT1A 16q13 metallothionein 1A
72 MT1DP 16q13 metallothionein 1D (pseudogene)
73 MT1CP 16q13 metallothionein 1C (pseudogene)
74 MT1B 16q13 metallothionein 1B
75 MT1F 16q13 metallothionein 1F
76 MT1G 16q13 metallothionein 1G
77 MT1H 16q13 metallothionein 1H
78 MT1IP 16q13 metallothionein 1I (pseudogene)
79 MT1X 16q13 metallothionein 1X
80 NUP93 16q13 nucleoporin 93kDa
81 SLC12A3 16q13 solute carrier family 12 (sodium/chloride transporters), member 3
82 HERPUD1 16q12.2-q13 homocysteine-inducible, endoplasmic reticul stress-inducible, ubiquitin-like domain 1
83 CETP 16q21 cholesteryl ester transfer protein, plasma
84 NLRC5 16q13 NLR family, CARD domain containing 5
85 CPNE2 16q13 copine II
86 NIP30 16q13 NEFA-interacting nuclear protein NIP30
87 RSPRY1 16q13 ring finger and SPRY domain containing 1
88 ARL2BP 16q13 ADP-ribosylation factor-like 2 binding protein
89 PLLP 16q13 plasma membrane proteolipid (plasmolipin)
90 CCL22 16q13 chemokine (C-C motif) ligand 22
91 CX3CL1 16q13 chemokine (C-X3-C motif) ligand 1
92 CCL17 16q13 chemokine (C-C motif) ligand 17
93 CIAPIN1 16q13-q21 cytokine induced apoptosis inhibitor 1
94 COQ9 16q13 coenzyme Q9 homolog (S. cerevisiae)
95 POLR2C 16q13-q21 polymerase (RNA) II (DNA directed) polypeptide C, 33kDa
96 DOK4 16q13 docking protein 4
97 CCDC102A 16q13 coiled-coil domain containing 102A
98 GPR114 16q13 G protein-coupled receptor 114
99 GPR56 16q12.2-q21 G protein-coupled receptor 56
100 GPR97 16q13 G protein-coupled receptor 97
101 CCDC135 16q13 coiled-coil domain containing 135
102 KATNB1 16q13 katanin p80 (WD repeat containing) subunit B 1  
191 
 
# Gene Position Full name
103 KIFC3 16q13-q21 kinesin family member C3
104 CNGB1 16q13 cyclic nucleotide gated channel beta 1
105 TEPP 16q13 testis/prostate/placenta-expressed protein
106 ZNF319 16q13 zinc finger protein 319
107 C16orf57 16q13 chromosome 16 open reading frame 57
108 MMP15 16q13-q21 matrix metallopeptidase 15 (membrane-inserted)
109 C16orf80 16q21 chromosome 16 open reading frame 80
110 CSNK2A2 16q21 casein kinase 2, alpha prime polypeptide
111 CCDC113 16q21 coiled-coil domain containing 113
112 Klkbl4 16q21 plasma kallikrein-like protein 4
113 GINS3 16q21 GINS complex subunit 3 (Psf3 homolog)
114 NDRG4 16q21-q22.1 NDRG family member 4
115 SETD6 16q21 SET domain containing 6
116 CNOT1 16q21 CCR4-NOT transcription complex, subunit 1
117 SNORA46 16q21 small nucleolar RNA, H/ACA box 46
118 SNORA50 16q21 small nucleolar RNA, H/ACA box 50
119 SLC38A7 16q21 amino acid transporter
120 GOT2 16q21 glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate aminotransferase 2)
121 CDH8 16q22.1 cadherin 8, type 2
122 ATF7IP2 16p13.13 activating transcription factor 7 interacting protein 2
123 EMP2 16p13.2 epithelial membrane protein 2
124 TEKT5 16p13.13 tektin 5
125 NUBP1 16p13.13 nucleotide binding protein 1 (MinD homolog, E. coli)
126 FAM18A 16p13.13 family with sequence similarity 18, member A
127 CIITA 16p13 class II, major histocompatibility complex, transactivator
128 DEXI 16p13.13 dexamethasone-induced transcript
129 CLEC16A 16p13.13 C-type lectin domain family 16, member A
130 SOCS1 16p13.13 suppressor of cytokine signaling 1
131 TNP2 16p13.13 transition protein 2 (during histone to protamine replacement)
132 PRM3 16p13.3 protamine 3
133 PRM2 16p13.2 protamine 2
134 PRM1 16p13.2 protamine 1
135 C16orf75 16p13.13 chromosome 16 open reading frame 75
136 LITAF 16p13.13 lipopolysaccharide-induced TNF factor
137 SNN 16p13 stannin
138 TXNDC11 16p13.13 thioredoxin domain containing 11
139 ZC3H7A 16p13-p12 zinc finger CCCH-type containing 7A
140 RSL1D1 16p13.13 ribosomal L1 domain containing 1
141 GSPT1 16p13.1 G1 to S phase transition 1
142 COX6CP1 16p12 cytochrome c oxidase subunit VIc pseudogene 1
143 TNFRSF17 16p13.1 tumor necrosis factor receptor superfamily, member 17
144 RUNDC2A 16p13.13 RUN domain containing 2A
145 SNX29 16p13.13-p13.12 sorting nexin 29
146 FLJ11151 16p13.12 hypothetical protein FLJ11151
147 SALL3 18q23 sal-like 3 (Drosophila)
148 ATP9B 18q23 ATPase, class II, type 9B
149 NFATC1 18q23 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1
150 CTDP1 18q23 carboxy-terminal domain, RNA polymerase II, polypeptide A phosphatase 1
151 KCNG2 18q22-q23 potassium voltage-gated channel, subfamily G, member 2
152 PQLC1 18q23 PQ loop repeat containing 1
153 LOC100131178 18q23 hypothetical protein LOC100131178
154 TXNL4A 18q23 thioredoxin-like 4A
155 C18orf22 18q23 chromosome 18 open reading frame 22
156 ADNP2 18q23 ADNP homeobox 2
157 PARD6G 18q23 par-6 partitioning defective 6 homolog gamma (C. elegans)  
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Appendix 3 Genotyping and homozygosity mapping of the Turkish family 
Homozygosity mapping was performed by the Gene Mapping Laboratory of Hacettepe 
University Medical Faculty in Turkey, using SNP genotyping data generated from Affymetrix 
GeneChip Human Mapping NspI 250K Arrays. Visual Genome Studio (VIGENOS) program 
(Hemosoft Inc, Ankara) developed by the Gene Mapping Laboratory allowed genome-wide 
haplotyping of SNP data. 
Because only one affected child (patient 5) was available for mapping, many more candidate loci 
were found compared to the mapping performed in the Jordanian family where three patients 
could be genotyped. The candidate loci found were as follow: 
- 2q22.2-q31.1 (~26.8Mb) 
- 4p13-q13.3 (~27.5 Mb) 
- 6p25.3-p25.2 (~2.9Mb) 
- 7q32.3-q35 (~16.3Mb) 
- 8p12-q11.23 (~16.8Mb) 
- 9p22.2-p21.3 (~4.8Mb) 
- 13q21.1-q22.1 (~16.3Mb) 
- 15q25.3-q26.1 (~5.6Mb) 
- 16p12.3-p12.1 (~4.7Mb) 
- 16p11.2-q23.1 (~47.4Mb) 






Detail of the 206 mismatches (positive strand) found following loci-capturing and re-sequencing 
of the genomic candidate region 16q12.2-q21. The 36 novel and homozygous polymorphisms are 




Position_End Mutation (Sequencing coverage)
1 52875672 52875673 C->A  (149:117:78.5%[F:92:61.7%|R:25:16.8%])
2 52876851 52876852 INS:-->C  (269:29:10.8%[F:3:1.1%|R:26:9.7%])
3 53524158 53524159 C->A  (94:35:37.2%[F:26:27.7%|R:9:9.6%]) IRX5
4 53918993 53918994 C->T  (205:143:69.8%[F:44:21.5%|R:99:48.3%])
5 53920042 53920043 C->G  (70:54:77.1%[F:52:74.3%|R:2:2.9%])
6 53920738 53920739 G->A  (131:107:81.7%[F:21:16.0%|R:86:65.6%])
7 54074267 54074268 G->A  (232:203:87.5%[F:196:84.5%|R:7:3.0%])
8 54077035 54077036 G->C  (343:240:70.0%[F:189:55.1%|R:51:14.9%])
9 54081205 54081206 T->C  (186:107:57.5%[F:80:43.0%|R:27:14.5%])
10 54084526 54084527 A->T  (59:50:84.7%[F:46:78.0%|R:4:6.8%])
11 54084613 54084614 G->A  (156:99:63.5%[F:74:47.4%|R:25:16.0%])
12 54088272 54088273 T->G  (107:29:27.1%[F:25:23.4%|R:4:3.7%])
13 54094227 54094228 C->T  (314:193:61.5%[F:120:38.2%|R:73:23.2%])
14 54100573 54100574 G->C  (17:14:82.4%[F:2:11.8%|R:12:70.6%])
15 54100822 54100823 G->T  (17:13:76.5%[F:2:11.8%|R:11:64.7%])
16 54117065 54117066 INS:-->A  (384:46:12.0%[F:2:0.5%|R:44:11.5%])
17 54119757 54119758 G->A  (81:56:69.1%[F:44:54.3%|R:12:14.8%])
18 54119966 54119967 G->A  (340:278:81.8%[F:72:21.2%|R:206:60.6%])
19 54248400 54248401 INS:-->G  (264:34:12.9%[F:17:6.4%|R:17:6.4%])
20 54276740 54276741 INS:-->G  (391:46:11.8%[F:10:2.6%|R:36:9.2%])
21 54285581 54285582 T->G  (177:80:45.2%[F:2:1.1%|R:78:44.1%])
22 54287624 54287625 A->C  (299:238:79.6%[F:143:47.8%|R:95:31.8%])
23 54317150 54317151 G->C  (46:30:65.2%[F:27:58.7%|R:3:6.5%])
24 54319659 54319660 INS:-->A  (302:40:13.2%[F:19:6.3%|R:21:7.0%])
25 54319700 54319701 G->A  (284:238:83.8%[F:29:10.2%|R:209:73.6%])
26 54331928 54331929 G->A  (242:164:67.8%[F:25:10.3%|R:139:57.4%])
27 54341547 54341548 A->G  (174:110:63.2%[F:25:14.4%|R:85:48.9%])
28 54352135 54352136 G->T  (198:131:66.2%[F:13:6.6%|R:118:59.6%])
29 54364795 54364796 T->A  (36:24:66.7%[F:22:61.1%|R:2:5.6%])
30 54368316 54368317 INS:-->C  (324:45:13.9%[F:5:1.5%|R:40:12.3%])
31 54377000 54377001 C->T  (153:109:71.2%[F:68:44.4%|R:41:26.8%])
32 54402109 54402110 G->T  (247:143:57.9%[F:25:10.1%|R:118:47.8%])
33 54402427 54402428 A->C  (430:248:57.7%[F:53:12.3%|R:195:45.3%])
34 54424542 54424543 A->C  (86:48:55.8%[F:5:5.8%|R:43:50.0%])
35 54437823 54437824 G->A  (515:295:57.3%[F:292:56.7%|R:3:0.6%])
36 54447898 54447899 G->C  (263:220:83.7%[F:12:4.6%|R:208:79.1%])
37 54451062 54451063 INS:-->A  (344:36:10.5%[F:4:1.2%|R:32:9.3%])
38 54452851 54452852 INS:-->G  (499:57:11.4%[F:41:8.2%|R:16:3.2%])
39 54463136 54463137 A->G  (598:454:75.9%[F:294:49.2%|R:160:26.8%])
40 54684471 54684472 INS:-->A  (74:11:14.9%[F:2:2.7%|R:9:12.2%])
41 54785465 54785466 T->G  (163:117:71.8%[F:103:63.2%|R:14:8.6%])
42 54785566 54785567 A->G  (170:137:80.6%[F:41:24.1%|R:96:56.5%])
43 54920225 54920226 T->C  (194:148:76.3%[F:38:19.6%|R:110:56.7%])
44 54932465 54932466 INS:-->C  (100:17:17.0%[F:2:2.0%|R:15:15.0%])







Position_End Mutation (Sequencing coverage)
46 54996514 54996515 A->G  (251:172:68.5%[F:58:23.1%|R:114:45.4%])
47 54999362 54999363 A->G  (439:354:80.6%[F:273:62.2%|R:81:18.5%])
48 54999566 54999567 C->T  (189:147:77.8%[F:13:6.9%|R:134:70.9%])
49 55029954 55029958 DEL:CCAC->----  (69:10:14.5%[F:3:4.3%|R:7:10.1%])
50 55043054 55043055 C->G  (181:80:44.2%[F:65:35.9%|R:15:8.3%])
51 55043295 55043296 G->A  (16:15:93.8%[F:2:12.5%|R:13:81.2%])
52 55061058 55061059 G->A  (18:13:72.2%[F:8:44.4%|R:5:27.8%])
53 55067639 55067640 INS:-->A  (576:85:14.8%[F:47:8.2%|R:38:6.6%])
54 55068443 55068444 INS:-->A  (20:13:65.0%[F:3:15.0%|R:10:50.0%])
55 55094242 55094243 INS:-->A  (363:43:11.8%[F:6:1.7%|R:37:10.2%])
56 55106001 55106002 C->T  (294:235:79.9%[F:138:46.9%|R:97:33.0%])
57 55159220 55159221 A->G  (311:163:52.4%[F:41:13.2%|R:122:39.2%])
58 55159222 55159223 T->C  (319:148:46.4%[F:39:12.2%|R:109:34.2%])
59 55209715 55209716 C->A  (311:224:72.0%[F:31:10.0%|R:193:62.1%])
60 55210044 55210045 INS:-->G  (406:48:11.8%[F:2:0.5%|R:46:11.3%])
61 55218114 55218115 INS:-->T  (846:124:14.7%[F:15:1.8%|R:109:12.9%])
62 55224149 55224150 INS:-->C  (186:37:19.9%[F:16:8.6%|R:21:11.3%])
63 55225114 55225115 C->T  (305:206:67.5%[F:106:34.8%|R:100:32.8%])
64 55227235 55227236 INS:-->C  (465:57:12.3%[F:38:8.2%|R:19:4.1%])
65 55228167 55228168 T->G  (278:178:64.0%[F:144:51.8%|R:34:12.2%])
66 55230183 55230184 INS:-->G  (757:91:12.0%[F:11:1.5%|R:80:10.6%])
67 55230643 55230644 A->G  (250:212:84.8%[F:180:72.0%|R:32:12.8%])
68 55230648 55230649 A->G  (233:161:69.1%[F:115:49.4%|R:46:19.7%])
69 55235134 55235135 C->T  (272:218:80.1%[F:99:36.4%|R:119:43.8%])
70 55243880 55243881 T->C  (47:31:66.0%[F:29:61.7%|R:2:4.3%])
71 55243971 55243972 G->T  (520:353:67.9%[F:110:21.2%|R:243:46.7%])
72 55244204 55244205 G->A  (67:23:34.3%[F:2:3.0%|R:21:31.3%])
73 55244218 55244219 INS:-->T  (127:14:11.0%[F:2:1.6%|R:12:9.4%])
74 55244352 55244353 A->G  (312:189:60.6%[F:125:40.1%|R:64:20.5%])
75 55254260 55254261 A->C  (174:127:73.0%[F:19:10.9%|R:108:62.1%])
76 55254286 55254287 T->C  (48:29:60.4%[F:6:12.5%|R:23:47.9%])
77 55254296 55254297 G->A  (52:27:51.9%[F:2:3.8%|R:25:48.1%])
78 55258382 55258383 INS:-->C  (631:67:10.6%[F:16:2.5%|R:51:8.1%])
79 55258419 55258420 T->A  (394:298:75.6%[F:60:15.2%|R:238:60.4%])
80 55261972 55261973 INS:-->C  (171:34:19.9%[F:18:10.5%|R:16:9.4%])
81 55262034 55262035 INS:-->G  (177:41:23.2%[F:2:1.1%|R:39:22.0%])
82 55268909 55268910 C->G  (14:14:100.0%[F:10:71.4%|R:4:28.6%])
83 55269058 55269059 C->T  (257:109:42.4%[F:72:28.0%|R:37:14.4%])
84 55396874 55396875 INS:-->T  (201:33:16.4%[F:22:10.9%|R:11:5.5%])
85 55412996 55412997 C->G  (310:234:75.5%[F:112:36.1%|R:122:39.4%])
86 55421898 55421899 C->T  (136:82:60.3%[F:67:49.3%|R:15:11.0%])
87 55422118 55422119 C->T  (117:95:81.2%[F:10:8.5%|R:85:72.6%])
88 55426200 55426201 A->G  (184:149:81.0%[F:32:17.4%|R:117:63.6%])
89 55456728 55456729 C->G  (162:134:82.7%[F:109:67.3%|R:25:15.4%]) SLC12A3
90 55462087 55462088 C->G  (403:320:79.4%[F:220:54.6%|R:100:24.8%])
91 55470919 55470920 C->T  (72:35:48.6%[F:24:33.3%|R:11:15.3%])
92 55475453 55475454 T->C  (108:84:77.8%[F:48:44.4%|R:36:33.3%])
93 55478300 55478301 INS:-->G  (74:12:16.2%[F:10:13.5%|R:2:2.7%])
94 55478469 55478470 C->T  (332:261:78.6%[F:73:22.0%|R:188:56.6%])






Position_End Mutation (Sequencing coverage)
96 55484328 55484329 T->C  (48:38:79.2%[F:32:66.7%|R:6:12.5%])
97 55486019 55486020 C->T  (550:371:67.5%[F:152:27.6%|R:219:39.8%])
98 55523511 55523512 G->A  (34:26:76.5%[F:8:23.5%|R:18:52.9%])
99 55530590 55530591 INS:-->T  (63:14:22.2%[F:9:14.3%|R:5:7.9%])
100 55561223 55561224 G->T  (76:44:57.9%[F:37:48.7%|R:7:9.2%])
101 55564690 55564691 INS:-->C  (110:14:12.7%[F:10:9.1%|R:4:3.6%])
102 55564951 55564952 G->A  (219:174:79.5%[F:37:16.9%|R:137:62.6%])
103 55564952 55564953 INS:-->A  (219:25:11.4%[F:3:1.4%|R:22:10.0%])
104 55573592 55573593 G->A  (526:417:79.3%[F:207:39.4%|R:210:39.9%])
105 55574974 55574975 G->A  (127:60:47.2%[F:53:41.7%|R:7:5.5%])
106 55574991 55574992 INS:-->C  (214:27:12.6%[F:19:8.9%|R:8:3.7%])
107 55619677 55619678 T->A  (255:220:86.3%[F:146:57.3%|R:74:29.0%])
108 55625095 55625096 A->T  (376:296:78.7%[F:107:28.5%|R:189:50.3%])
109 55627492 55627493 C->T  (168:128:76.2%[F:98:58.3%|R:30:17.9%])
110 55628614 55628615 A->G  (183:134:73.2%[F:87:47.5%|R:47:25.7%])
111 55628732 55628733 C->G  (103:31:30.1%[F:2:1.9%|R:29:28.2%])
112 55631183 55631184 G->C  (112:55:49.1%[F:13:11.6%|R:42:37.5%])
113 55638028 55638029 C->A  (197:146:74.1%[F:39:19.8%|R:107:54.3%])
114 55666153 55666154 INS:-->G  (195:25:12.8%[F:2:1.0%|R:23:11.8%])
115 55670596 55670597 INS:-->G  (358:51:14.2%[F:43:12.0%|R:8:2.2%])
116 55672482 55672483 C->T  (163:105:64.4%[F:43:26.4%|R:62:38.0%])
117 55672646 55672647 INS:-->G  (116:15:12.9%[F:12:10.3%|R:3:2.6%])
118 55673787 55673788 A->G  (326:215:66.0%[F:176:54.0%|R:39:12.0%])
119 55728733 55728734 C->G  (84:74:88.1%[F:2:2.4%|R:72:85.7%])
120 55737753 55737754 INS:-->G  (229:23:10.0%[F:8:3.5%|R:15:6.6%])
121 55755245 55755246 G->T  (388:307:79.1%[F:270:69.6%|R:37:9.5%])
122 55758623 55758624 INS:-->C  (565:88:15.6%[F:4:0.7%|R:84:14.9%])
123 55812863 55812864 T->C  (296:224:75.7%[F:8:2.7%|R:216:73.0%])
124 55822246 55822247 INS:-->A  (569:61:10.7%[F:5:0.9%|R:56:9.8%])
125 55950233 55950234 A->C  (284:227:79.9%[F:156:54.9%|R:71:25.0%])
126 56032367 56032368 INS:-->A  (172:18:10.5%[F:2:1.2%|R:16:9.3%])
127 56048221 56048222 G->A  (38:30:78.9%[F:28:73.7%|R:2:5.3%])
128 56057341 56057342 A->G  (357:298:83.5%[F:159:44.5%|R:139:38.9%])
129 56057402 56057403 T->C  (557:393:70.6%[F:114:20.5%|R:279:50.1%])
130 56060713 56060714 C->T  (227:170:74.9%[F:38:16.7%|R:132:58.1%])
131 56061273 56061274 G->A  (189:118:62.4%[F:81:42.9%|R:37:19.6%])
132 56066664 56066665 A->G  (151:106:70.2%[F:13:8.6%|R:93:61.6%])
133 56079503 56079504 T->A  (23:18:78.3%[F:16:69.6%|R:2:8.7%])
134 56079508 56079509 A->T  (16:13:81.2%[F:11:68.8%|R:2:12.5%])
135 56106897 56106898 INS:-->G  (120:12:10.0%[F:4:3.3%|R:8:6.7%])
136 56109469 56109470 INS:-->C  (105:12:11.4%[F:3:2.9%|R:9:8.6%])
137 56120304 56120305 G->A  (32:17:53.1%[F:3:9.4%|R:14:43.8%])
138 56166278 56166279 C->T  (134:91:67.9%[F:49:36.6%|R:42:31.3%])
139 56244555 56244556 INS:-->G  (74:10:13.5%[F:7:9.5%|R:3:4.1%])
140 56245561 56245562 INS:-->G  (118:20:16.9%[F:2:1.7%|R:18:15.3%])
141 56246885 56246886 C->G  (205:125:61.0%[F:116:56.6%|R:9:4.4%])
142 56247305 56247306 A->C  (377:259:68.7%[F:158:41.9%|R:101:26.8%])
143 56247383 56247384 T->C  (169:133:78.7%[F:20:11.8%|R:113:66.9%])
144 56250747 56250748 G->A  (55:37:67.3%[F:32:58.2%|R:5:9.1%])
145 56267786 56267787 INS:-->C  (331:38:11.5%[F:2:0.6%|R:36:10.9%])
146 56270750 56270751 C->T  (162:135:83.3%[F:3:1.9%|R:132:81.5%])
147 56279828 56279829 C->T  (549:291:53.0%[F:49:8.9%|R:242:44.1%])
148 56290388 56290389 G->A  (383:260:67.9%[F:56:14.6%|R:204:53.3%])






Position_End Mutation (Sequencing coverage)
150 56333218 56333219 INS:-->A  (230:23:10.0%[F:13:5.7%|R:10:4.3%]) KATNB1
151 56344211 56344212 C->T  (105:70:66.7%[F:52:49.5%|R:18:17.1%])
152 56344571 56344572 INS:-->G  (208:28:13.5%[F:2:1.0%|R:26:12.5%]) KATNB1
153 56348206 56348207 A->G  (74:44:59.5%[F:35:47.3%|R:9:12.2%])
154 56351236 56351237 INS:-->A  (135:16:11.9%[F:4:3.0%|R:12:8.9%])
155 56352388 56352389 A->T  (77:56:72.7%[F:37:48.1%|R:19:24.7%])
156 56352894 56352895 G->A  (211:145:68.7%[F:51:24.2%|R:94:44.5%])
157 56358424 56358425 INS:-->G  (243:36:14.8%[F:9:3.7%|R:27:11.1%])
158 56361411 56361412 A->G  (123:80:65.0%[F:16:13.0%|R:64:52.0%])
159 56362578 56362579 C->T  (45:37:82.2%[F:32:71.1%|R:5:11.1%])
160 56362676 56362677 A->G  (91:58:63.7%[F:18:19.8%|R:40:44.0%])
161 56363530 56363531 A->G  (30:20:66.7%[F:17:56.7%|R:3:10.0%])
162 56479346 56479347 INS:-->T  (486:51:10.5%[F:32:6.6%|R:19:3.9%])
163 56495356 56495357 G->C  (296:157:53.0%[F:22:7.4%|R:135:45.6%])
164 56495395 56495396 G->A  (246:73:29.7%[F:42:17.1%|R:31:12.6%])
165 56508894 56508895 T->G  (284:139:48.9%[F:49:17.3%|R:90:31.7%])
166 56511738 56511739 INS:-->G  (94:10:10.6%[F:8:8.5%|R:2:2.1%])
167 56511768 56511769 A->G  (157:89:56.7%[F:85:54.1%|R:4:2.5%])
168 56531740 56531741 G->A  (107:55:51.4%[F:29:27.1%|R:26:24.3%])
169 56541983 56541984 G->A  (287:199:69.3%[F:24:8.4%|R:175:61.0%])
170 56548817 56548818 C->T  (121:99:81.8%[F:15:12.4%|R:84:69.4%])
171 56554432 56554433 G->A  (251:194:77.3%[F:126:50.2%|R:68:27.1%])
172 56554460 56554461 C->T  (245:158:64.5%[F:59:24.1%|R:99:40.4%])
173 56555845 56555846 C->T  (90:60:66.7%[F:58:64.4%|R:2:2.2%])
174 56569245 56569246 INS:-->C  (425:46:10.8%[F:24:5.6%|R:22:5.2%])
175 56576592 56576593 INS:-->G  (228:28:12.3%[F:26:11.4%|R:2:0.9%])
176 56576896 56576897 G->A  (119:97:81.5%[F:80:67.2%|R:17:14.3%])
177 56588134 56588135 C->G  (191:42:22.0%[F:15:7.9%|R:27:14.1%])
178 56593847 56593848 G->A  (150:115:76.7%[F:99:66.0%|R:16:10.7%])
179 56593985 56593986 C->T  (293:231:78.8%[F:155:52.9%|R:76:25.9%])
180 56605631 56605632 INS:-->T  (64:19:29.7%[F:17:26.6%|R:2:3.1%])
181 56633583 56633584 INS:-->C  (162:19:11.7%[F:14:8.6%|R:5:3.1%])
182 56871066 56871067 T->G  (69:34:49.3%[F:4:5.8%|R:30:43.5%])
183 56876104 56876105 T->C  (688:580:84.3%[F:122:17.7%|R:458:66.6%])
184 56885146 56885147 A->G  (385:290:75.3%[F:111:28.8%|R:179:46.5%])
185 57095397 57095398 G->A  (77:55:71.4%[F:18:23.4%|R:37:48.1%])
186 57095747 57095748 INS:-->C  (253:31:12.3%[F:11:4.3%|R:20:7.9%])
187 57110029 57110030 INS:-->G  (354:40:11.3%[F:38:10.7%|R:2:0.6%])
188 57147058 57147059 INS:-->A  (162:18:11.1%[F:7:4.3%|R:11:6.8%])
189 57151788 57151789 INS:-->A  (407:52:12.8%[F:3:0.7%|R:49:12.0%])
190 57174484 57174485 T->C  (462:379:82.0%[F:344:74.5%|R:35:7.6%])
191 57257852 57257853 A->G  (54:31:57.4%[F:22:40.7%|R:9:16.7%])
192 57261466 57261467 A->G  (283:210:74.2%[F:204:72.1%|R:6:2.1%])
193 57271537 57271538 G->A  (137:89:65.0%[F:42:30.7%|R:47:34.3%])
194 57299612 57299613 INS:-->C  (677:86:12.7%[F:4:0.6%|R:82:12.1%])
195 57300954 57300955 A->C  (508:419:82.5%[F:187:36.8%|R:232:45.7%])
196 57315168 57315169 A->C  (234:153:65.4%[F:96:41.0%|R:57:24.4%])
197 57315183 57315184 A->G  (99:94:94.9%[F:44:44.4%|R:50:50.5%])
198 57325739 57325740 INS:-->G  (78:10:12.8%[F:5:6.4%|R:5:6.4%])
199 58950169 58950170 G->A  (27:13:48.1%[F:9:33.3%|R:4:14.8%])
200 58950736 58950737 C->T  (144:101:70.1%[F:21:14.6%|R:80:55.6%])
201 58950847 58950848 INS:-->G  (77:10:13.0%[F:2:2.6%|R:8:10.4%])
202 58950904 58950905 T->A  (42:25:59.5%[F:15:35.7%|R:10:23.8%])
203 59126756 59126757 A->G  (42:28:66.7%[F:25:59.5%|R:3:7.1%])
204 60161443 60161444 C->G  (161:70:43.5%[F:68:42.2%|R:2:1.2%])
205 60318794 60318795 INS:-->A  (301:43:14.3%[F:2:0.7%|R:41:13.6%])
206 60949109 60949110 G->A  (125:99:79.2%[F:69:55.2%|R:30:24.0%])  
197 
 




















Supplementary Figure 1 Craniofacial and digit anomalies in five probands diagnosed with Hamamy 
syndrome. (a-e)  Full face pictures of the 5 affected patients at different ages. (a’) Palm image of patient 1 
shows long fingers and ectopic finger creases. (a”) Hand X-ray of patient 1 reveals expansion of the 
medullary space resulting in widening of the hand metacarpal bones and phalanges. (b’) Hand picture of 
patient 2 shows long fingers with short index. (c’) Bilateral thumb deviation in patient 3. (e’) Image of 
patient 5’s hands reveals tapering fingers. (f) Dacryoscintillography (DSG) in patient 2, shows absence of 
lacrimal drainage system with tear flowing over left lateral cheek (red arrowhead). (g) Patient 2 coronal 
MRI T2 sequence shows both lacrimal sacs with left dilated sac (red arrowhead) not seen on DSG. (h) 
Patient 2 coronal MRI T2 sequence shows absence of both lacrimal glands (red arrowheads). (i) Patient 2 
coronal MRI scan shows symmetrical, normal size and signal intensities of both parotid glands (red 




Supplementary Figure 2 Amino-acid alignment of the homeodomain of all human IRX paralogs shows 
total conservation for both residues mutated (p.Ala150Pro and p.Asn166Lys). 
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Supplementary Figure 3 Irx5 knock down in Xenopus embryos partially phenocopies blood, heart and 
craniofacial disorders in IRX5 patients. (a) At stage 26, Irx5 MO-injected embryos show complete absence 
of Lmo2 (XL023e21) expression in their dorsal lateral plate where definitive hematopoiesis takes place (n = 
6/9). Lateral view, anterior to the left. (b) Marked down-regulation of Hba3 expression in primitive red 
blood cells of ventral blood islands is seen in Irx5 morphant embryos relative to controls at stage 32 (n = 
7/8). Lateral view, anterior is left. (c) At stage 28, impaired heart development in Irx5 morphant embryos is 
shown by altered Nkx2.5 expression in the first heart field (n = 10/14). (d) Decreased expression of the 
heart marker Gata5 is observed in stage 26 Irx5 morphant embryos relative to control embryos (n = 4/5). 
(e) The heart beat of Irx5-depleted embryos (red line) is reduced by 30% in comparison to that of control 
embryos (blue line). (f,g) Nrp2 and iXL069c09 mark defective migration of the cranial neural crest cells in 
the first branchial arch of Irx5 morphant embryos compared to controls (n = 10/16 and 13/20 respectively). 
Dashed red line outlines the eye vesicle and dashed black line the first branchial arch (BA). Red arrowhead 





Supplementary Figure 4 Gata3 reinforces Irx5-dependent repression of the SDF1 reporter in MS5, 293T 
and 10T1/2 cells. Data are presented as mean ± S.D. (error bars represented on top of charts). Statistical 






Supplementary Figure 5 Total body scan of technetium pertechnetate in patient 1 shows normal 
distribution of technetium in nasal mucosa (nm), salivary glands (sg), thyroid gland (tg), stomach (st), 
urinary bladder (bl) but with minimal uptake in both gonads (go). On the contrary, patient 2 shows 
decreased activity in submandibular and parotid glands compared to thyroid glands, larger than usual 
stomach, minimal uptake in bone cortex (most evident in femur bones with bowing of long bones) and, as 






Supplementary Figure 6 IRX5 transcriptional activity is modulated by the protein partners GATA3 and 
TRPS1. (a) GATA3 is co-immunoprecipitated by TRPS1 in the absence of IRX5 (lane 1). (b) Trps1 
potentiates the inhibitory role of Gata3 on the Irx5-mediated repression of the SDF1 reporter. (c) Wt Irx5 
together with Gata3 represses transcription of the GCMB reporter. Surprisingly, this inhibition is stronger 
when mutant Irx5N166K is co-expressed with Gata3, highlighting the possible neomorphic properties of this 
IRX5 missense mutant vis-à-vis its protein partners. Data are presented as mean ± S.D. (error bars 
represented on top of charts). Statistical significance was determined by one-tailed Student's t test (** p 
value < 0.005). 
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